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Abstract 
Breast cancer carries a lifetime risk of 1 in 8, making it the most common cancer 
affecting Australian women. Whilst the mortality rate associated with breast cancer has 
decreased by approximately 30% over the last 20 years, the most recent statistics show 
that breast cancer accounts for 28% of all new cancers diagnosed in women. It is 
therefore essential to find new regulators of breast cancer cell fate in order to be able to 
improve therapeutics, diagnostic tools and therefore the prognosis for patients 
presenting with breast cancer. 
The mammary gland is a complex organ that develops under the control of various 
hormones, regulatory genes and transcription factors. Elucidating the processes behind 
the mammopoiesis has shown to be crucial in increasing our understanding of how 
disruption of these tightly regulated systems leads to breast carcinogenesis.  
Recent studies have revealed a novel role for the transcription factor Runx2 in cell 
fate decisions in the mammary gland development during late pregnancy and lactation. 
Furthermore, it has been shown that Runx2 also regulates breast cancer cell fate in vitro 
and is able to delay breast cancer development and prolong survival in vivo. All three 
Runx genes form heterodimeric complexes with core-binding factor β (CBFβ), which 
ensures high affinity DNA binding, protein stability and therefore increased 
transcriptional efficiency of downstream targets. Modifying levels of CBFβ expression 
may create potential to investigate the effects of perturbing RUNX2 levels whilst 
compensating for the redundancy that exists between members of the Runx family.  
 There has been no previous data linking CBFβ with either mammary gland 
development or breast cancer. However, three recent whole-genome sequencing studies 
have identified CBFβ as a gene with recurrent mutations across an array of human 
breast cancer patients. More specifically, CBFβ was found to be mutated in 
approximately 5% of luminal breast cancers, making it one of the most highly mutated 
genes in human breast tumours. 
The overarching aim of this thesis is to determine the role of CBFβ in mammary 
gland cell fate specification and the mechanisms by which it controls normal mammary 
gland development and influence breast carcinogenesis and metastasis. 
This study has now examined CBFβ expression in the mammary gland for the first 
time and shows that it is differentially regulated through mammary gland development. 
 vi 
CBFβ expression is relatively high in virgin mice and decreases as the gland develops 
through to late pregnancy and early lactation with expression levels recovering at the 
time of involution. 
Mammary-specific deletion of CBFβ in an inducible mouse model clearly 
demonstrated an essential role for CBFβ in the early stages of mammary gland 
development. The CBFβ-/- glands presented with a significant decrease in ductal 
elongation that was attributed to a decrease in the proliferative capacity of the mammary 
epithelial cells.  
In the context of breast cancer, the knockdown and overexpression of CBFβ in 
human breast cancer cell lines demonstrated that CBFβ has a critical role in controlling 
breast cancer cell fate. These in vitro models revealed significant changes in the ability 
of breast cancer cells to control phenotypes consistent with metastasis, such as 
proliferation and migration in response to CBFβ expression levels.  
Furthermore, this thesis describes the first in vivo model capable of investigating the 
effects of CBFβ deletion on breast tumourigenesis and metastasis, demonstrating that 
deletion of CBFβ in the mouse mammary gland significantly delays tumour onset and 
increases overall survival in breast carcinogenesis whilst also reducing the incidence 
and severity of distal metastases. 
This thesis reports that RUNX2 and CBFβ expression are differentially regulated 
throughout mammary gland development and demonstrates a novel and exciting role for 
CBFβ as a new regulator of both mammary gland development and breast cancer 
progression and metastasis. 
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1. Introduction 
The mammary gland is an organ that develops predominantly post partum, under the 
influence of various regulatory genes and hormones associated with sexual development 
and reproduction. The established gland will undergo repeated cycles of proliferation, 
differentiation and apoptosis with each pregnancy as it transitions from its nulliparous 
state, through to a fully functional gland capable of lactation, before undergoing 
remodeling to once again resemble the mature nulliparous gland. These distinct stages 
enable the mammary gland to be the perfect platform in which to study cell fate 
decisions. It is often the dysregulation of the key regulators involved in these 
developmental processes that lead to disease progression, including cancer. The overall 
aim of this thesis is to examine the role of the Runx2/CBFβ transcriptional complex in 
the developing mammary gland and how changes in expression and regulation affects 
the pathogenicity and progression of breast cancer. 
 
Mammary Gland Development 
Overview 
The mammary gland is a complex organ that, unlike most other organs within the 
body, undergoes the majority of its development post-partum, making it quite a unique 
system. It was discovered in the early 1900s that the mammary gland primarily 
develops under the control of the ovarian hormones, estrogen and progesterone (Allen, 
1924; Halban, 1900) with prolactin becoming a key regulator during pregnancy as gland 
differentiates into its functional form (Brisken et al., 1999; Riddle, 1933; Topper & 
Freeman, 1980). There are many other growth factors, regulatory genes and 
transcription factors that control this multifaceted developmental process and the role of 
those regulators more directly related to this thesis will be described in due course. 
Development of the mammary gland can be compartmentalised into distinct stages 
that are inextricably linked to both sexual development and reproduction. Each phase of 
mammopoiesis is phenotypically unique, as shown in Figure 1.1. These stages have 
been coined embryonic, prepubertal, pubertal, pregnancy, lactation and involution 
(Hennighausen & Robinson, 2001).  
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Fig. 1.1.   Stages of mammary gland development 
Mammary gland development occurs in distinct and unique stages that are link to sexual and reproductive 
development. A) Following embryonic development, the mammary gland of the neonate consists of a 
rudimentary ductal tree within the fat pad. B) Pubertal growth is marked by the formation of terminal end 
buds (TEBs) that drive extensive proliferation and growth of the ductal network under the influence of 
estrogen. C) Once mature, the ductal network undergoes extensive side-branching during each estrous 
cycle under the influence of both estrogen and progesterone. D) During pregnancy, the gland under goes 
extensive differentiation and lobuloalveolar development under the influence of both progesterone and 
primarily prolactin E) During lactation milk is secreted from mature alveoli in response to suckling and 
oxytocin. F) Post weaning, the mammary gland undergoes controlled apoptosis and re-modeling until it 
resembles the nulliparous gland (Adapted from Henninghausen 2001). 
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The mammary gland consists of two major compartments, the epithelial ductal 
network and the stromal fat pad through which it protrudes. The mammary stroma is 
comprised of endothelium, fibroblasts, extracellular matrix proteins, immune cells and 
adipocytes (Hennighausen & Robinson, 2001). There are complex interactions and 
signalling networks between the epithelial and stromal cells, which help to define the 
functionality of the mammary gland throughout development (Nandi, 1958; Neville & 
Daniel, 1987). 
Much of what we know about the mechanisms behind mammary gland development 
has arisen from the detailed studies using mice where it is relatively simple to modify 
the genetic background of the animal through gene deletion and recombination 
approaches. Furthermore, the mouse mammary gland is very similar in architecture to 
the human breast and the importance of cross talk between the epithelium and stroma in 
both systems make the mouse a useful system in which to model human breast 
development and breast cancer (Plante et al., 2011; Sternlicht, 2006). 
Mammary gland development in mice begins around embryonic day 10 (e10) with 
the formation of the milk line, which develops into 5 pairs of placodes that will house a 
rudimentary ductal tree at the time of birth. It is the epithelial ductal network that 
branches throughout the mammary fat pad and undergoes high levels of proliferation 
during puberty. Following puberty the mammary gland undergoes repeated cycles of 
proliferation and differentiation under the influence of the female steroid hormones 
estrogen and progesterone. The cells then differentiate into alveolar buds during 
pregnancy before maturing into fully functional alveoli capable of lactation post partum. 
Involution is the final stage of the developmental cycle, whereby the gland undergoes 
controlled apoptosis and remodeling, returning to a mature pre-pregnancy like state 
(Hennighausen & Robinson, 2005). 
This brief summation of mammopoiesis will now be expanded upon to review the 
specific roles of the genes, hormones and growth factors that are critical for successful 
development and differentiation of the mammary gland. 
 
Structure of the Mammary Gland 
As mentioned above, two main cell types give rise to the mouse mammary gland: the 
epithelium that is derived from the ectoderm; and the surrounding stoma, which is 
derived from the mesoderm. The epithelial compartment is comprised of a branching 
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ductal network that does not fully begin to develop until puberty. Through the use of 
hormone therapy in ovariectomised, adrenalectomised and hypophysectomised mice, 
Nandi was able to show that estrogen is essential for ductal development during 
puberty, while prolactin is required later for the successful development of alveolar 
structures during pregnancy (Nandi, 1958). The epithelial ducts continue to branch 
through the stroma to form decreasingly smaller ductals that eventually form structures 
known as lobules. These lobules are made up of alveoli and it is this lobuloalveolar 
compartment that forms the functional aspect of the gland as it develops and expands 
with each pregnancy. The alveoli are also comprised of 2 main cell types: the luminal 
epithelial cells, which undergo differentiation during pregnancy in order to produce and 
secrete milk; and the basal or myoepithelial cells which form a contractile mesh-like 
network around the ductal tree and aid in the delivery of the milk from the ducts to the 
nipple in response to oxytocin (Hennighausen & Robinson, 2001, 2005).  
There are a host of hormones, genes, growth factors and transcription factors that 
controlled the developing mammary gland and it is becoming clearer that many of these 
are not solely confined to the mammary gland but are also important in the 
developmental regulation of other organs and tissues.  
 
Embryonic mammary gland development 
The mammary gland does not begin to form in the embryo until approximately day 
E10.5 with the formation of the milk line that run from the axilla to the groin along the 
rostro-caudal axis of the ventral body surface. By E11, the milk line is replaced by five 
pairs of mammary placodes, derived from the ectoderm (Balinksy, 1950; Turner & 
Gomez, 1933). These five placode pairs are placed where the eventual mammary glands 
will exist and form in an asynchronous order, beginning with the 3rd (thoracic), 4th 
(abdominal), 1st (cervical), 5th (inguinal) then finally the 2nd (upper thoracic) pair 
(Mailleux et al., 2002; Veltmaat et al., 2004). 
In an interesting example of cell fate regulation, each pair of mammary placodes 
require different developmental cues and signals in order to control not only the time at 
which they develop but also the place at which they develop along the milk line. Some 
of the genes that are essential for the timing and placement of mammary placodes 
include the ERBB2 ligand NRG3, FGF10 and its receptor FGFR2B and the 
transcription factors TBX3, LEF1 and Gli3. When these genes are deleted separately in 
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the embryo, only some of the placode pairs are absent or do not develop to the stage of 
bud formation (Foley et al., 2001). For example, deletion of LEF1 results in a failure to 
develop placodes 2 and 3 (Boras-Granic et al., 2006) whilst perturbed expression of 
NRG3 leads to loss of placode 3 as well as duplication of the 4th placodes (Howard et 
al., 2005). 
Many of the genes that control embryonic development of the mammary gland were 
identified when a genetic deletion or conditional knockout of a gene lead to an arrest of 
mammogenesis at a specific stage in mice (Robinson, 2004). 
By E15, the placodes have developed into epithelial buds that are surrounded by a 
mesenchymal cell layer. This development of the placode is controlled by and 
dependent on epithelial to mesenchymal signalling. This was first shown by Propper 
when he co-cultured non-mammary ectoderm with mammary mesenchyme in vitro and 
showed growth of epithelial buds (Propper, 1972). This phenomena was then confirmed 
when Cunha and colleagues cultured dorsal epidermis and mammary mesenchyme from 
E13 embryos and then xenografted the tissue on to lactating mice. In this instance, not 
only did the epithelial buds form but they also differentiated into lobuloalveolar cells 
capable of secreting milk protein such as casein and α-lactalbumin (Cunha et al., 1995). 
There are a multitude of genes and pathways that have been shown to regulate the 
epithelial to mesenchymal signalling that directs mammary gland development. It is 
thought that targeting these interactions may lead to therapeutics that are capable of 
transforming malignant cancer cells from undifferentiated proliferating masses back 
into differentiated populations (Cunha & Hom, 1996). 
One of the critical pathways in mammogenesis is the wingless-related MMTV 
integration site (WNT) signalling pathway and it has been found to be essential for 
initiation of milk line specification, successful placode development and also placode 
size (Chu et al., 2004; van Genderen et al., 1994; Veltmaat et al., 2004). WNT target 
genes Wnt10a, Wnt10b and Wnt6 can be first detected in the epithelial and 
mesenchymal cells of the milk line from approximately E10.25, with their signal 
intensifying in the placodes at E12.5 and expression is maintained as the buds develop 
until around E15.5 (Veltmaat et al., 2004). These target genes act through the canonical 
WNT/β-catenin signalling pathway to initiate placode development and drive mammary 
gland morphogenesis. When explants from developing embryos are cultured in WNT 
medium or lithium chloride (a WNT stimulator), formation of placodes is accelerated 
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and the resulting size is much larger (Chu et al., 2004). Conversely, in transgenic mice 
expressing Dick-kopf 1 (a WNT inhibitor) in the surface ectoderm, placode formation is 
completely inhibited (Chu et al., 2004). This control of mammogenesis through WNT 
signalling seems to be mediated through expression of the lymphoid enhancer-binding 
factor 1 (LEF1) transcription factor, a WNT/β-catenin downstream target. Deletion of 
LEF1 in mice leads to a complete abolishment of WNT signalling and mice that do not 
develop the correct number of mammary placodes (Andl et al., 2002; Boras-Granic et 
al., 2006; van Genderen et al., 1994). LEF1-/- mice are missing placode pairs 2 and 3 
with the remaining placodes developing into buds, which deteriorate and therefore mice 
that are born with no ducts or nipples, confirming the importance of WNT signalling in 
mammogenesis (Boras-Granic et al., 2006). 
In regards to mammary line specification, it has been shown that the fibroblast 
growth factor (FGF) family is also essential and acts in parallel to the WNT signalling 
pathway (Hens & Wysolmerski, 2005). FGF signals from the somites underlying the 
milk line are essential for the initiation and formation of mammary placodes (Mailleux 
et al., 2002). If the FGF ligand, Fgf10 or the receptor Fgfr2B are deleted in the embryo, 
the milk line does not form in the region where placodes two and three are supposed to 
form (Veltmaat et al., 2006). The 4th placode does form in these knock out mice but 
undergoes apoptosis by E12.5, indicating that a separate FGF family member must 
control the maintenance of the 4th gland though Fgfr2B, most likely Fgf7 due to its 
expression in the mesenchyme (Cunha & Hom, 1996; Mailleux et al., 2002). Several 
other FGF family members are also expressed in the formed mammary bud, including 
Fgf4, Fgf8, Fgf9 and Fgf17 whilst the receptors Fgfr1B and Fgfr2 are expressed in the 
placodes and surface ectoderm (Mailleux et al., 2002). 
The Homeobox genes have also been found to act as important regulators of cell fate 
in the mammary gland as well as several other systems, including the skeleton and the 
central nervous system (Visvader & Lindeman, 2003). The Msh Homeobox (Mxs) 
transcription factors are part of this family and are expressed in the mammary bud 
alongside LEF1 (Phippard et al., 1996). Msx1 and Msx2 are initially expressed in the 
placode (Phippard et al., 1996) before Msx1 expression is lost and the expression of 
Msx2 shifts into the surrounding mesenchyme (Satokata et al., 2000). Null mutations of 
both Msx1 and Msx2 lead to a failure in bud formation (Satokata et al., 2000). If Msx1 
alone is deleted, there is no effect on bud formation whereas specific mutation of Msx2 
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leads to an arrest of bud development at the sprouting stages around E16.5, proving a 
critical role of Msx2 in mammary branching morphogenesis (Satokata et al., 2000). 
Msx1 and Msx2 continue to be co-expressed in the post-natal mammary gland 
throughout virgin development and early pregnancy but expression is found to 
dramatically decrease in late pregnancy (Friedmann & Daniel, 1996; Phippard et al., 
1996). 
The T-box (TBX) family of proteins present another key regulatory family involved 
in embryonic mammary gland development that acts downstream, of both the WNT and 
FGF signalling pathways. More specifically, both Tbx2 and Tbx3 are expressed along 
the milk line from E10.5 before localising to the individual placodes as they are formed 
(Eblaghie et al., 2004; Jerome‐Majewska et al., 2005). It has been shown that Tbx3-/- 
embryos do not develop mammary buds and that they do not express Wnt10b or LEF1 
(Davenport et al., 2003). Tbx3 in conjunction with bone morphogenic protein 4 (BMP4) 
is also important for determining the dorso-ventral position of the buds through 
regulation of LEF1 (Cho et al., 2006). The region in the mesenchyme where Tbx3 is 
expressed determines the site of placode development whilst BMP4 expression localises 
to the area immediately ventral to the placode and acts to negatively regulate Tbx3, 
therefore enhancing LEF1 expression in the placode to stimulate development (Cho et 
al., 2006). 
Similarly to the WNT pathway, Hedgehog signalling is also crucial for the regulation 
of mammary cell fate specification. The GLI family zinc finger (GLI) proteins, which 
are either activators or repressors of Hedgehog signalling depending on the context 
(Aza-Blanc et al., 2000) are also expressed at E11, namely Gli2 and Gli3 (Hatsell & 
Cowin, 2006). In the context of mammogenesis, Gli3 is acting as a repressor of 
Hedgehog signalling which is evident by the loss of buds two and three when GLI is 
forced into its activator state. It can therefore be deduced that the repression on 
hedgehog signalling is required in order to maintain the identity of mammary epithelial 
cells (Gritli-Linde et al., 2007; Hatsell & Cowin, 2006). 
The final major family of proteins involved in placode development is the epidermal 
growth factor receptor (EGFR) family, primarily neuregulin 3 (NRG3) and its receptors 
v-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 2 and 4 (Erbb2 and 
Erbb4), which are expression in the milk line from E10.75 and confined to the epithelial 
placodes once they develop (Howard et al., 2005). When expression of NRG3 is not 
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localised to the placodes only one of the 3rd mammary buds will not develop, there is 
often duplication in the 4th pair and also Wnt10b and LEF1 expression is absent. This 
evidence points to NGR3 acting as mesenchymal signal upstream of WNT that is 
crucial to the positioning and number of mammary buds that are formed (Howard et al., 
2005). 
As well as placode and mammary bud formation, there is also a small degree of 
ductal growth and nipple formation that occurs during the embryonic phase of 
mammary gland development. Parathyroid hormone related protein (Pthrp) and 
parathyroid hormone related protein receptor 1 (Pthr1) are crucial to these processes as 
shown when mice that are null for these genes lead to ablation of LEF1 and β-catenin 
which are essential for mammary gland development (Foley et al., 2001; Wysolmerski 
et al., 1998). Furthermore, disruption of the Pthrp epithelial to mesenchymal signalling 
results in failure of both mammary bud and nipple formation. In this case the duct is 
unable to progress through the mesenchyme, the cells become more squamous and the 
cells lose the mammary specific keratin signals (Foley et al., 2001; Wysolmerski et al., 
1998). Conversely, if Pthrp is over-expressed in the epidermis, the mammary 
mesenchyme undergoes forced differentiation and the nipple is formed (Foley et al., 
2001). BMP4 acts downstream of Pthrp to mediated the cross talk between the epithelial 
bud and the surrounding mesenchyme (Hens et al., 2007). In order to stimulate ductal 
outgrowth, inhibit hair follicle formation and therefore allow nipple formation there is 
an increase in mesenchymal levels of bone morphogenic proteins (BMPs) in response to 
epithelial Pthrp signals (Robinson, 2007). 
RASGRF1 (Ras protein-specific guanine-releasing factor1) is also involved in the 
induction of the mammary mesenchyme and outgrowth of the ductal epithelium as it 
highly expressed in the most proliferative part of the mammary gland, the terminal end 
buds (Chakravarty et al., 2003). It has also been shown that RASGRF1 knockout mice 
have significantly smaller epithelial buds by E14.5 where the epithelial cells are highly 
disorganised and the mesenchymal cells do no express the appropriate steroid receptors 
(Heckman et al., 2007). 
In summary, it is evident that the control of mammary gland development during the 
embryonic stage is dependent on epithelial to mesenchymal signalling. 
 
Virgin mammary gland development 
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Ductal elongation and bifurcation 
The post-partum mammary epithelial ductal network undergoes allometric growth 
through the stromal fat pad from the nipple under the influence of the steroid hormone, 
estrogen throughout puberty. The engine that drives this growth are the terminal end 
buds (TEBs), which are situated at the tips of the growing ducts and enable ductal 
extension of the epithelium through the fat pad under the influence of both estrogen and 
growth hormone (Hinck & Silberstein, 2005). The presence of TEBs is the defining 
feature of a gland undergoing ductal extension (Williams & Daniel, 1983). TEBs are 
club-shaped masses made up of both proliferating and apoptosing cells that penetrate 
through the stromal fat pad and can undergo a process of bifurcation where two 
secondary ducts of equal size are formed (Silberstein, 2001). 
Ductal extension is driven by the proliferating cap cells at the distal tip of the TEB 
combined with several layers of proliferating cells underneath. It is this secondary layer 
of cells that undergo selective apoptosis in order to form the lumen of the epithelial duct 
(Silberstein, 2001). The processes of ductal elongation and bifurcation are primarily 
regulated by estrogen and growth hormone but there is also interaction with the 
surrounding stroma.  
Estrogen activity is regulated through binding interactions with its receptors ERα 
and ERβ, both of which are expressed in the mammary epithelium and stroma (Saji, 
2000). It has been shown that ERβ is not required for ductal elongation but rather is 
required for the differentiation events that take place during pregnancy (Förster et al., 
2002). However, when ERα is knocked out in the mammary stroma, ductal elongation 
fails but the same is not true if it is only knocked out in the epithelial compartment 
(Cunha et al., 1997). It is therefore evident that stromal ERα is crucial for outgrowth of 
the ductal tree. The adult animal requires both the stromal and epithelial expression of 
ERα in order to maintain the ductal network but this can also be achieved in the 
presence of stromal ERα only if doses of estrogen and progesterone are increased 
(Mueller, 2002).  
When estrogen binds to its receptor it results in translocation of the receptor to the 
nucleus, which leads to interactions with co-activators and finally gene transcription 
(McKenna et al., 1999). ERα knock out mice and null mutants for its co-activator, 
steroid receptor co-activator 3 both show failed ductal elongation in response to 
estrogen (Xu et al., 2000).  
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The other crucial hormone required during pubertal development of the mammary 
gland is growth hormone and also members of the insulin-like growth factor (IGF) 
family (Kleinberg, 1997). 
Growth hormone is mainly produced by the pituitary gland and its action is mediated 
through binding to its receptors, Ghr, located in both the mammary epithelium and 
stroma (Ilkbahar et al., 1999). Similar to ERα, only stromal Ghr is necessary for 
successful ductal elongation (Gallego et al., 2001; Walden et al., 1998) and these effects 
are mediated via induction of Igf1. Studies have shown that Igf1 is induced in the 
stroma by growth hormone (Ruan & Kleinberg, 1999; Ruan et al., 1992) and that Igf1 
can substitute for growth hormone and induce ductal elongation. Furthermore, null 
mutants of both Igf1 and Igfr lead to impaired outgrowth of the ductal network 
(Bonnette & Hadsell, 2001; Ruan & Kleinberg, 1999). It can therefore be deduced that 
the effects of growth hormone on TEB formation and ductal elongation are mediated by 
stromal Ghr induction of Igf1. 
Members of the epidermal growth factor (EGF) family are also important in 
mediating interactions between the epithelial and stromal cells in the mammary gland 
that are important for regulating ductal elongation. Similarly to the aforementioned 
hormones, it is primarily the binding of Egf to its stromal receptor, Egfr that is 
important of the regulation at this stage in mammopoiesis (Wiesen et al., 1999). Further 
to this, it has been shown that expression of a dominant negative form of Egfr in the 
mammary gland leads to failed outgrowth of the ducts (Xie et al., 1997). There are 
several ligands that are capable of binding to Egfr and therefore a multitude of binding 
combinations and dimerisations that will produce different signals and ultimately 
control different aspects of mammary gland development, from puberty through to 
lactation (Earp et al., 1995; Komurasaki et al., 1997; Pinkas-Kramarski et al., 1997). 
Another example of the role of EGF signalling importance in puberty is shown through 
the inactivation of one of these ligands, amphiregulain, resulting in a failure of ductal 
outgrowth similar to what is seen in the Egfr knockout model (Luetteke et al., 1999). 
GATA3 is another important regular of cell fate that has been found to be essential in 
mammary gland development. GATA3 is expressed as early as E12.5 and this 
expression increases during puberty and pregnancy but remains confined to the luminal 
cells of the mammary gland (Asselin-Labat et al., 2007; Kouros-Mehr et al., 2006; 
Ormandy et al., 2003). Studies have shown that K14cre-mediated deletion of GATA3 
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results in failure of placode development (Asselin-Labat et al., 2007), which is a similar 
phenotype to the LEF1, Msx1, and Msx2 knockout models (Hens & Wysolmerski, 
2005), indicating a potential transcriptional network that exists between GATA3 and 
LEF1 (Naylor & Ormandy, 2007).  It has also been shown that GATA3 is highly 
expressed in the TEBs as well as the nascent and adult ducts and that it plays a key role 
in maintaining luminal cell fate in the mammary gland. A lack of GATA3 in the luminal 
cells of the mammary ducts leads to failure of TEB formation during puberty and a 
subsequent disruption of ductal elongation in the adult gland (Kouros-Mehr et al., 
2006). GATA3 has now been established as a critical regulator of luminal cell 
differentiation within the epithelial hierarchy of the mammary gland (Asselin-Labat et 
al., 2007). This study has shown that a deficiency in GATA3 in the mammary gland 
leads an expansion of luminal progenitors and a subsequent arrest of differentiation, 
whilst induction of GATA3 in a stem cell enriched environment is able induce 
maturation of cells in the alveolar lineage (Asselin-Labat et al., 2007). 
 
Ductal side branching and alveolar bud formation 
During ductal elongation, the primary duct bifurcates into two new secondary ducts 
that are of equal size (Silberstein, 2001). Ductal side branching, which follows ductal 
bifurcation, is a slightly different process whereby a new ductal branch is formed at 90° 
from the mature duct (Wiseman & Werb, 2002). Side branching occurs during puberty 
and continues with each subsequent estrous cycle thereafter. This involves the 
mammary bud penetrating through the myoepithelial layer, the basement membrane and 
also the stroma and this occurs under both hormonal control and in response to 
epithelial to mesenchymal signalling (Wiseman & Werb, 2002). Similar to the TEBs, 
once the ductal side branches reach the end of the fat pad, the distal ends undergo 
differentiation to form alveolar buds (Hennighausen & Robinson, 1998).  The process 
of side branching also ensures that the ducts are far enough apart to allow for the 
formation of lobuloalveoli during late pregnancy and lactation (Silberstein, 2001).  
Estrogen is essential for mammary gland development during puberty and also into 
adulthood as well. ERα knock out mice are born infertile and the rudimentary ductal 
tree is found to be lacking terminal end buds. Furthermore, these mice will fail to 
undergo ductal outgrowth and will have reduced levels of progesterone receptor (PR) 
and prolactin receptor (PRLR) (Cunha et al., 1997; Korach et al., 1996). 
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Progesterone is the second ovarian hormone that begins to play a role in mammary 
gland development primarily after puberty and into pregnancy. Through the use of PR 
null mice and mammary transplantation, it is evident that progesterone is essential for 
both ductal side branching and formation of alveolar buds (Brisken et al., 1998; Lydon 
et al., 1995). There are two isoforms of PR, PrA and PrB, both of which are important 
in the regulation of mammary gland development (Graham & Clarke, 1997). 
Overexpression of PrA leads to a significant increase in ductal side branching 
(Shyamala et al., 1998) whilst mice that are transgenic for PrB present with reduced 
side branching and altered alveolar development (Shyamala et al., 2000). Other studies 
have shown that PrA null mice show no defect in ductal side branching, which indicates 
that PrB is the crucial isoform for mammopoiesis (Mulac-Jericevic et al., 2000). Tissue 
recombination and localisation studies have shown that epithelial rather than stromal PR 
is required for alveolar development (Brisken et al., 1998; Humphreys et al., 1997). 
There is evidence that stromal PR does play a role too, potentially through regulation of 
Wnt4 which acts downstream of PR and has been shown that Wnt4 is also essential for 
ductal side branching (Brisken et al., 2000).  
There are also several negative regulators of branching morphogenesis in the 
mammary gland that act to ensure this process is controlled and tightly regulated. The 
most common examples are Tgfβ1 and Sprouty2, both of which result in accelerated 
ductal branching when inactivated or deleted (Daniel, 1996; Ewan et al., 2002; Lu P, 
2005). 
It is evident that the control and regulation of the mammary gland between birth and 
adulthood are both multifaceted and complex and as a result there is still much to be 
elucidated regarding the hormones, genes and growth factors that play key roles in 
mammary cell fate. It is essential to fully understand the process of ductal extension and 
branching morphogenesis because almost 90% of human breast cancers arise from the 
mammary ducts. Therefore, the regulatory factors that control these processors may be 
potential therapeutic targets. 
 
Development of the mammary gland during pregnancy 
The previous sections have summarised the complex signalling networks that exist in 
the mammary gland from embryonic development through to adulthood, however the 
mammary gland itself is regarded as relatively quiescent in the virgin state. The 
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mammary gland does not become a fully functioning organ until the onset of pregnancy 
and its complete role does not become evident until after parturition when lactation 
commences. 
The early stages of pregnancy are similar to adolescence and involve mainly an 
increase in ductal side branching and alveolar bud formation. The alveolar buds then 
differentiate into alveoli, the precursor to the milk producing lobuloalveoli, the 
development of which are characteristic of mid-pregnancy. It is clear that the mammary 
gland has reached its functional endpoint when the lobuloalveolar cells begin to produce 
and eventually secrete milk proteins (Nandi, 1958; Topper & Freeman, 1980). 
While estrogen and progesterone are crucial for the regulation of mammopoiesis 
during puberty, mammary gland development during pregnancy is largely controlled by 
progesterone and the peptide hormone, prolactin.  
The importance of prolactin (Prl) became apparent in 1928 when Sticker & Grueuter 
injected pituitary peptides into artificially castrated animals and was able to induce 
lactation (Stricker & Grueter, 1928). It was later discovered that this peptide was in fact 
prolactin (Riddle, 1933) and these experiments demonstrated that mammary gland 
development was not purely under the control of the ovarian steroid hormones. The role 
of prolactin in mammary gland development was demonstrated following the generation 
of the Prl-/- mouse (Horseman et al., 1997). This model demonsrated that in the absence 
of prolactin, female mice were infertile and that mammary gland development was 
perturbed. Terminal end bud formation and ductal extension of the epithelial network 
appeared normal but the mature virgin gland did not develop alveolar buds, the 
precursors to lobuloalveoli (Horseman et al., 1997). 
The subsequent development of mice lacking the prolactin receptor further 
demonstrated the importance of prolactin in the regulation of almost all aspects of 
female reproduction including; ovulation rates, mammary gland development, fertility, 
embryonic implantation, lactation and behavioural aspects such as mating frequency 
and maternal behaviour (Ormandy et al., 1997). Prlr homozygous mutant mice are 
completely infertile due to failure of the embryo to implant in the uterus so the effects 
of prolactin on during pregnancy and lactation was observed using mice that were 
heterozygous for Prlr. In these mice, a failure of lactation in the first pregnancy was 
observed but following subsequent estrous cycles and pregnancies, the mice regained 
the ability to lactate (Ormandy et al., 1997). Given the widespread affects of PRLR 
reduction on female reproduction it was difficult to determine exact causation of this 
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lactational defect so a further study by Brisken and colleagues used these PRLR 
homozygous mutants to perform mammary gland transplants (Brisken et al., 1999). This 
study showed that mammary gland development is normal up until puberty when the 
mammary glands of Prlr knockout mice show a reduction in the frequency and 
complexity of ductal side branching and the persistence of atypical TEBs through to 
adulthood (Brisken et al., 1999). This defect in the side branching is also observed in 
prolactin knockout mice, indicating that Prl and Prlr are phenocopies of each other 
(Horseman et al., 1997). Brisken and colleagues determined that this phenotype does 
not occur when PRLR-/- epithelium is transplanted into wildtype mice, indicting that 
PRLR regulates this aspect of mammary gland development indirectly through 
endocrine factors (Brisken et al., 1999) such as progesterone, which has been previously 
shown to be essential for side-branching (Brisken et al., 1998). During pregnancy, 
transplanted glands showed that deletion of PRLR leads to a complete failure of 
lobuloalveolar development, confirmed by a lack of β-casein production. This revealed 
that prolactin acts directly on the mammary epithelial cells during pregnancy to ensure 
lobuloalveolar development and successful lactation (Brisken et al., 1999). 
 
Lobuloalveolar development 
Similarly to virgin development, signalling networks between stromal ECM proteins 
and the mammary epithelium act to direct both mammary gland development and 
epithelial cell function during pregnancy.  
Prolactin regulates the differentiation of alveolar cells into lobuloalveoli through 
binding its receptor (Prlr), which in turn activates the Janus-2 kinase JAK2/signal 
transducer and transactivator (STAT) signalling pathway (Hennighausen et al., 1997). 
Activation of Jak2 under the regulation of prolactin leads to the homodimeristaion and 
phosphorylation of both isoforms of Stat5 (Stat5a and Stat5b). There is a 96% 
homology between Stat5a and Stat5b but Stat5a appears to be the dominant isoform in 
the mammary gland as shown by the knock out mice being unable to lactate due to 
impaired lobuloalveolar development. The Sta5b knockout however, presents with a 
markedly reduced phenotype that can be rescued by forced Stat5a expression (Liu et al., 
1997; Udy et al., 1997). JAK/STAT signalling can also be induced by members of the 
EGF family and also growth hormone (Chapman et al., 1999). Phosphorylation of Stat5 
 24 
enables it to translocate to the nucleus and activate the subsequent genes that mediate 
proliferation and differentiation (Darnell, 1997; Ihle, 1996). 
Other regulators of both Stat5 and differentiation pathways include integrins, which 
are an important class of ECM receptors that regulate the cross talk between the ECM 
and hormone signalling pathways (Giancotti & Tarone, 2003; Katz & Streuli, 2007) 
allowing influence over cell fate decisions such as proliferation, migration, survival and 
differentiation (Streuli, 2009). Integrin signalling is essential for mediating cell matrix 
adhesion and epithelial function in several systems, including the mammary gland 
(Akhtar et al., 2009). In the mammary gland, β1-integrin is necessary for activating 
endocrine signalling pathways and also plays an important role in the pregnant 
mammary gland, as shown by impaired lobuloalveolar development in the β1-integrin 
chimeric mouse model (Naylor et al., 2005). In this study, deletion of β1 integrin 
specifically in the luminal mammary epithelium, led to impaired alveologenesis and 
lactation in vivo as well as a detachment of the luminal epithelial cells from the ECM, 
indicating a crucial role for β1-integrin in maintaining cell adhesion (Naylor et al., 
2005). These results were recapitulated is primary MEC cultures where ill-formed acini 
structures developed when grown in 3-D culture. This study highlighted the interaction 
between β1-intergrin and hormone signalling, as demonstrated by a lack of milk 
secretion in β1-integrin-/- luminal MECs upon stimulation with prolactin due to a lack of 
Stat5 integration into the nucleus (Naylor et al., 2005). Similarly it has been shown that 
deletion of integrin-linked kinase (ILK) in primary culture and in vivo leads to 
perturbation of differentiation in the pregnant mammary gland due to inhibiting the 
nuclear translocation of Stat5 (Akhtar et al., 2009). The integration of integrin signalling 
and prolactin is clearly essential for differentiation and milk synthesis in the mammary 
gland and it has been shown that Rac1 is key player in linking these two systems 
(Akhtar & Streuli, 2006). Dominant negative Rac1 inhibits Prl-induced production of β-
casein in mammary epithelial cells grown in 3-D culture whilst activation of Rac1 in β-
integrin null mammary epithelial cells is conversely able to rescue β-catenin levels. 
Therefore it is clear that Rac1 is an essential downstream target of integrins in regards 
to activation of PrlR/Stat5 signaling cascade (Akhtar & Streuli, 2006). This provides 
further evidence of the cooperation of hormonal and integrin signalling pathways in the 
regulation of mammary cell fate (Naylor et al., 2005; Naylor & Streuli, 2006). 
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It is evident that the hormonal control of mammary gland development is fairly well 
understood but the ensuing transcriptional regulation of genes involved in cell fate 
decisions is still under investigation. There are several key players in lobuloalveolar 
development, whose effects have been described through the use of knockout mouse 
models where a failure in development of these milk-producing cells is the primary 
phenotype. Cyclin D1 is one such regulator that is crucial for mediating cell cycle 
progression and is found to be essential for lobuloalveolar development, as shown by 
the impairments found in the knock out animal (Fantl et al., 1995; Sicinski et al., 1995). 
It is also true that an upregulation of Cyclin D1 found in the transgenic Msx1 mice also 
leads to disrupted lobuloalveolar formation due to inhibition of differentiation (Hu et 
al., 2001). This model also indicates that there is a potential role for the Homeobox 
protein Msx1 in lobuloalveolar formation. 
It has since been shown that the targeted deletion of the Hox genes, Hoxa9, Hoxb9 
and Hoxd9 also results in a defect in lobuloalveolar development, which ultimately 
leads to a failure in lactation (Chen & Capecchi, 1999). In addition, Hoxd10 has been 
found to play a role in the expansion of the alveolar buds in late pregnancy and deletion 
of this gene also leads to impairment in lactation due to insufficient lobules (Lewis, 
2000). 
Another important regulator of lobuloalveolar development is the CCAAT/enhancer 
binding protein β (C/EBPβ), which is responsible for transcriptionally regulating 
several genes, including those that regulated PR-mediated proliferation in the mammary 
gland. In addition, C/EBPβ-/- mice present with impaired ductal outgrowth, side 
branching and therefore subsequently limited lobuloalveolar development (Grimm et 
al., 2002; Robinson et al., 1998; Seagroves et al., 2000). It is therefore feasible that 
C/EBPβ is able to regulate mammary cell fate, on several levels, through regulation of 
downstream effectors such as the progesterone receptor. 
Regulators of mammary cell fate have become the focus of mammary gland biology 
in recent years due to their crucial role in development and the fact they are often 
perturbed in cancer. The ETS transcription factor ELF5 is one such example. ELF5 
expression in the mammary gland increases from early pregnancy before peaking mid-
way through gestation and remaining high through to early lactation (Zhou et al., 2005; 
Zhou et al., 1998). Due to embryonic lethality in ELF5-/- models, ELF5+/- mice have 
been used to show that this transcription factor is essential for the differentiation and 
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expansion of alveolar buds into lobuloalveoli (Zhou et al., 2005). ELF5+/- mice show 
normal ductal elongation and side branching through virgin development and enter the 
proliferative phase of alveolar morphogenesis but fail to produce milk proteins and 
lactate, leading to starvation of pups (Zhou et al., 2005). Recapitulation of this 
phenotype in mammary transplants using epithelium from these mice prove that ELF5 
regulation of lobuloalveolar development is epithelial cell autonomous (Naylor et al., 
2003; Zhou et al., 2005). These phenotypes are also observed in the PRLR+/- mice 
described earlier (Ormandy et al., 1997). The PRLR deficient mice showed a reduction 
in ELF5 expression but this was not reciprocated in the ELF5+/-, indicating that ELF5 is 
acting downstream of the prolactin signalling pathway (Zhou et al., 2005). 
Furthermore, it has been shown that overexpression of ELF5 in inducible transgenic 
mice results in a severe disruption of ductal morphogenesis as a result of forced alveolar 
differentiation and production of milk proteins in virgin mice (Oakes, 2008b). This 
study by Oakes and colleagues also found that ELF5 knockout mammary glands have 
an accumulation of CD61+ luminal progenitor cells whilst the glands overexpressing 
ELF5 showed a marked depletion in this cell population, indicating that ELF5 controls 
mammary alveolar cell fate through regulation of secretory alveolar precursor cell 
populations (Oakes, 2008b).  
Notch signalling is another crucial pathway involved in the mammary epithelial 
hierarchy and has been shown to regulated cell fate decisions in the. The Notch pathway 
has been implemented as an essential regulator of specification in many cell types 
(Schweisguth, 2004; Tanigaki et al., 2003) and has now been shown to be required for 
both mammary gland development and breast cancer (Gallahan et al., 1996; Jhappan et 
al., 1992; Kiaris et al., 2004; Kordon et al., 1995; Raafat et al., 2004). 
Notch signalling is mediated through receptor/ligand interactions that lead to 
cleavage of Notch and release of the active Notch intracellular domain (NICD). NICD 
interacts with downstream effectors to activate transcription (reviewed in (Bouras et al., 
2008)). One such effector is Recombining binding protein suppressor of hairless (RBPJ) 
that when down regulated in mammary stem cell (MaSC)-enriched environment, leads 
to increased stem cell activity and formation of aberrant end buds. Therefore it is 
evident that inappropriate Notch signalling leads to self-renewal and transformation of 
luminal progenitors (Bouras et al., 2008). Further evidence of Notch signalling luminal 
progenitors has been shown through the expression of downstream NICD effectors in 
luminal cell populations. Hey1 and Hey2 are expressed in the CD61+ luminal progenitor 
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populations whilst Hes6 is expressed in the CD61- mature luminal cells (Bouras et al., 
2008).  
It is clearly evident that Notch, as well as other signalling pathways are crucial for 
MaSCs regulation, luminal cell commitment and overall regulation of cell fate 
decisions. It is therefore crucial to identify novel regulators of mammary gland 
development because the factors capable of influencing cell fate hold the key to 
understanding the dysregulation of the mammary hierarchy that leads to breast cancer.  
 
Lactation 
Lactation is the functional end point of mammary gland development, involving the 
production of milk proteins and their subsequent secretion. Milk synthesis is stimulated 
and maintain by prolactin in the initial stages and then a secondary release of prolactin 
from the pituitary gland in response to suckling signals for continued milk production 
(Freeman et al., 2000). The secretion of milk is mediated by oxytocin which is released 
in response to suckling and causes the myoepithelial cells that surround the ducts to 
contract and expel the milk (Hennighausen & Robinson, 1998; Jones, 1967; Van 
Dongen, 1967). 
 
Apoptosis and involution 
Apoptosis is an important aspect of mammary gland development as it occurs after 
each estrous cycle where there is a reduction in the complexity of side branching and 
the alveolar buds from the previous cycle. More importantly, apoptosis is crucial for the 
stage of mammary gland development known as involution, which occurs after weaning 
when lactation has stopped (Wagner et al., 1997; Lund et a., 1996). 
Absence of suckling leads to inhibition of milk secretion and results in a loss of 
lobuloalveolar proliferation, followed by controlled apoptosis (Wagner et al., 1997). 
This is the beginning of the final phase of mammary gland development, known as 
involution. The second stage of involution requires the gland to undergo a process of 
remodeling until it resembles a nulliparous gland but with a higher degree of side 
branching (Lund et al., 1996). 
At the time of involution a number of genes that act as markers of cell death begin to 
increase in expression, primarily Bax and Tgfβ3 (Li et al., 1997; Nguyen & Pollard, 
2000). Overexpression of Tgfβ3 in the mammary gland is able to induce early 
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involution (Nguyen & Pollard, 2000) whilst knocking out Tgfβ will delay the onset of 
involution by preventing apoptosis (Nguyen & Pollard, 2000). 
Other molecules that are required for involution include those that are found to have 
apoptotic roles in other systems. Deletion of the tumour suppressor gene p53 leads to a 
delay in involution (Jerry et al., 1998), whilst deletion of the known death inducing 
molecules Fas and Fas ligand leads to a failure of apoptosis of mammary epithelial cells 
in response to weaning (Song et al., 2000).  
Members of the Stat family also play an essential role in the activation of involution, 
namely a loss of Stat5 and the activation of Stat3 (Chapman et al., 1999; Humphreys & 
Hennighausen, 1999). As reviewed earlier, Stat5 is crucial during lobuloalveolar 
development and milk production but acts to inhibit involution (Humphreys & 
Hennighausen, 1999). Stat3 however is an essential activator of involution as shown by 
the delay in regression of the mammary epithelial cells upon deletion of Stat3 
(Chapman et al., 1999). 
As seen throughout embryonic and virgin mammary gland development, interactions 
between the mammary epithelium and stroma are necessary throughout involution. 
Extracellular matrix (ECM) proteins such as the matrix metalloproteinases (MMPs) are 
recruited to assist in involution and work to remodel the mammary microenvironment 
by cleaving extracellular matrix and other scaffolding proteins (Wiseman & Werb, 
2002). Lysyl oxidase-like 2 (LOXL2), a member of the LOX family of ECM modifying 
enzymes, is also upregulated in the mammary gland during lactation and involution and 
has been shown to co-localise with MMP9 and tissue inhibitor metalloproteinase 1 
(TIMP1) (Barker et al., 2011). LOXL2 acts to remodel the mammary gland through 
regulation of TIMP1 and MMP9 activity and also through its action as actin cross-
linking ECM protein (Barker et al., 2011). 
 
Stems cell and the mammary gland 
The mammary gland is an organ that is capable of undergoing dramatic cyclical 
changes with each estrous cycle and pregnancy in response to an array of regulator 
genes, hormones and transcription factors. It is also evident that regulators of cell fate 
are crucial in mammopoiesis and furthermore, they provide clear links between 
development and disease. The ability of the gland to essentially be able to self-renew 
during and after each estrous cycle and pregnancy has been attributed to the mammary 
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stem cells (MaSCs) that exist in, not only the developing gland, but the adult gland as 
well (Daniel et al., 1968; Hoshino & Gardner, 1967; Smith & Medina, 1988). MaSCs 
are essential for organogenesis and homeostasis and fall into two lineages, luminal and 
myoepithelial (basal). The luminal lineage gives rise to the ductal cells that line the 
epithelial ducts and establish the secretory alveolar components capable of milk 
production, and the luminal cells that line the epithelial ducts (Visvader, 2009) (Fig. 
1.2). 
The initial in vivo experiments showing the these stem cell phenotypes of the breast 
were established by De Ome and colleagues in 1959 where donor epithelium is 
transplanted into the cleared fat pad of a recipient mouse and the ensuing result is a 
completely reconstituted mammary gland capable of differentiation under the influences 
of pregnancy (De Ome et al, 1959). It has since been shown that these transplants can 
be performed using both explants and also cell suspension of dissociated mammary 
glands (Daniel et al., 1968; Hoshino & Gardner, 1967; Smith, 1996). Furthermore, 
explants from various regions of the ductal network have all shown full reconstitution 
of a mammary gland through up to seven generations, which is evidence that persistent 
and long-lived stem cells exist throughout the entire adult mammary ductal network 
(Daniel & Young, 1971; Smith & Medina, 1988).  
  
 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2.   Mammary stem cell hierarchy 
The regenerative capabilities of the mammary gland can be attributed to the existence of the mammary 
stem cell hierarchy. Luminal and basal are the two main lineages that arise from a common multi-potent 
progenitor. The luminal lineage gives rise to the ductal and secretory alveolar cells whilst the basal 
progenitors give rise to the contractile myoepithelial cells. In red are the major transcription factors 
involved in the regulation of stem cell populations and in blue are the breast cancer subtypes that arise 
from each stem cell population (Adapted from Visvader 2009). 
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The regulation of MaSCs is controlled by a number of major signalling pathways and 
transcription factors including Hedgehog, WNT, GATA3, Notch (Liu et al., 2005) and 
more recently Runx2 (Owens et al., 2014), which have been described in previous 
sections. The principal concept behind the heterogeneity of breast cancer is known as 
the “cell of origin” theory and states that breast cancers arise from different mammary 
epithelial subtypes. Therefore, a better understanding of the properties of these different 
subtypes will further our knowledge about the heterogeneity of breast cancer (Visvader, 
2009) (Fig. 1.2).  
More recently, techniques have been developed that allow the formation of single 
cell suspensions of mammary epithelial cells (MECs), which can be analysed using 
fluorescent-activated cell sorting (FACS). The populations of stem cells are sorted using 
specific cell surface markers (Shackleton et al., 2006; Sleeman et al., 2005; Stingl et al., 
2006). For example, MECs enriched in the CD49fhi, CD29hi, CD24+, Sca- subset and 
when transplanted, generate an extensive ductal network and a whole gland that is 
capable of forming alveolar components that produce milk (Shackleton et al., 2006; 
Sleeman et al., 2005; Stingl et al., 2006). FACS-sorting of MECs allows linage tracing 
of stem cells involved in both mammopoiesis and breast cancer and indicate the 
potential to identify the “cell of origin” of a particular breast tumour, which would 
allow a more in-depth perspective in regards to treatment options. 
There has been ongoing debate in the field as to whether bipotent or unipotent 
MaSCs are responsible for the coordination of the extensive ductal branching during 
both estrous and pregnancy and the subsequent maintenance of the mature gland (van 
Amerongen et al., 2012; Van Keymeulen et al., 2011). A recent study has shown 
through extensive lineage tracing experiments, that bipotent MaSCs exist and that these 
are responsible for producing long-lived progenitor cells (Rios et al., 2014). This study 
was also able to determine that bipotent MaSCs exist in extensive clonal domains of the 
mammary epithelium and actively work to control physiological processes in the gland 
rather than lay dormant until injury or transplantation requires them to function, as was 
previously thought (Rios et al., 2014). 
Research into MaSCs has been critical to increasing our knowledge of how the gland 
is able to undergo repeated and drastic changes and it provides us with the potential to 
understand how aberrations in the regulation of such processes lead to disease 
progression and cancer. Cell fate mapping will ultimately be needed in order to 
elucidate the complex cell hierarchy that exists within the mammary gland. 
 32 
 
Summary 
It is abundantly clear that that the process of mammary gland development involves 
a complex signalling network of hormones, growth factor ligands and their receptors 
and transcription factors. Whilst many of these pathways and functions have been 
elucidated, we are still yet to unravel the complete story behind mammary gland 
development. It is essential to fully understand the developmental regulation of the 
mammary gland in order to be able to comprehend how perturbation of these signalling 
networks leads to disease progression.  
 
Breast Carcinogenesis 
Overview 
The primary structures within the breast are the lobules that produce milk and the 
ducts that transport the milk to the nipple. A network of connective, lymphatic and fatty 
tissue surrounds both of these structures. Breast cancer is able to form in both the 
lobules and the ducts and is found to be the point of origin for 10-15% and 50-75% of 
breast cancers respectively (Youk et al., 2009). If the cancer remains within these 
structures it is classified as in situ carcinoma however if it spreads into the surrounding 
breast tissue, it is known as invasive carcinoma. 
Breast cancer is a heterogeneous disease that has a good prognosis in the initial phase 
but this changes dramatically if the cancer has spread to distal organs. The molecular 
subtyping of breast cancer has played a significant role in both the successful treatment 
of patients and the development of new therapic targets. The five major subtypes of 
breast cancer are Luminal A, Luminal B, Basal/Triple Negative (TNBC), “Normal-like” 
and HER2 type (Perou et al., 2000) and are characterised in regards to their hormone 
receptor status, specifically the expression of the estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2).  
The Luminal A and B subtypes are defined as being positive for both ER and PR, 
while Luminal B is also positive for HER2. These are the most prevalent types of breast 
cancer diagnosed, accounting for a combined total of 60% of all cases. These tumours 
form in the luminal cells lining the ducts in the mammary gland and have the highest 
survival rates and the best prognoses when compared to other subtypes due to the 
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effectiveness of hormonal therapy.  Basal breast cancers, including triple negative 
cancers, are associated with a poor patient prognosis and more aggressive tumours that 
arise from the basal cells of the mammary ducts. Basal breast cancers often carry 
mutations in both the P53 and the BRCA genes whilst the TNBCs are also negative for 
all three main hormone receptors, which, combined with a lack of targeted therapeutic 
options, leads to significantly lower survival rates and increased rates of recurrence 
when compared to ER/PR+ luminal breast cancers (Dent et al., 2007). HER2 type breast 
cancers lack both ER and PR expression and also have a mutation in the P53 gene, but 
can be treated with trastuzumab because the majority of these tumours are HER2+. 
These tumours are still associated with poor prognosis and do have high recurrence 
rates, compared to luminal breast cancers. “Normal-like” breast cancers have, as the 
name suggests, similar hormone receptor status to normal breast cells but have a similar 
prognosis to basal breast cancers. 
There is a high degree of tumour heterogeneity that exists in breast cancers, meaning 
that that there will be tumour cells that do not fit the classification of the diagnosed 
subtype and as such may evade therapeutics and result in relapses or metastasis. In order 
to improve the clinical outcomes of breast cancer we need to fully understand the 
reasons behind tumour heterogeneity and the cells type from which breast cancers 
originate. There is also an crucial need to identify novel regulators of mammary cell fate 
that act to direct breast cancer phenotypes such as increased proliferative, migratory and 
invasive capacities. 
 
Prevalence of breast cancer 
More than 1,300,000 people across the world suffer from breast cancer each year 
making it one of the most common forms of cancer and despite advances in detection 
methods and therapeutics approximately 450,000 will die due to this disease each year 
(CGAN 2012).  
The most recent statistics for breast cancer in Australia show that whilst the risk of 
developing the disease before 85 is 1 in 8, the survival rate has significantly increased 
over the last 20 years. In New South Wales alone, there were 4,606 cases of breast 
cancer diagnosed in 2009, accounting for 27.4% of all new cancers diagnosed in women 
and 28.8% cancers diagnosed in women overall. In the same year 13,668 patients were 
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diagnosed across the country, making it the most the common cancer detected in 
Australian women and the third most common cancer overall.  
In terms of breast cancer mortality, in Australia it was found to be the second leading 
cause of cancer-related death in women with 2,840 patients succumbing to the disease 
in 2010, which equated to 15.3% of all cancer related death in women. 
Whilst the incidence of breast cancer in Australia is high, the prognosis for patients 
presenting with localised disease is extremely good and they have a 97% five-year 
survival rate. Unfortunately, for patients presenting with distal metastasis, this five-year 
survival rate is greatly reduced to only 40%, and more dramatically so in regards to 
long-term survival in which the survival rate is only 5-10%. These poor statistics 
highlight importance of elucidating the mechanism behind breast cancer progression 
and investigate new key regulators of breast cancer cell fate. 
 
Breast Cancer Metastasis 
Overview 
As stated above, the survival rates for breast cancer, both short term and long term, 
are severely reduced in patients who present with distal metastasis. Over 90% of all 
breast cancer-related deaths can be attributed to metastasis, most commonly detected in 
the liver, lung and bone.  
Even though improvement in treatment options and early detection methods have 
significantly increased the survival rates for primary breast cancer over the last two 
decades, the poor statistics associated with the metastatic phase of the disease have 
remained largely unchanged for 25 years.  For this reason, it is integral that research in 
to the mechanism behind which breast cancer cells are able to travel to and colonise 
these secondary sites continues.  
Metastasis is a multistage process whereby cancer cells acquire the ability to escape 
the primary tumour environment and colonise a secondary organ (Steeg, 2006). There 
are six main phenotypes that cancer cells exhibit that enable them to become metastatic 
and these “hallmarks” of cancer have been outlined by Hanahan and Weinberg 
(Hanahan & Weinberg, 2000, 2011) and are summarized in Figure 1.3.   
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Fig. 1.3.  Hallmark of cancer 
The six major functional capabilities cancer cells acquire in order to grow, spread and colonise secondary 
organs are found in the center, surrounded by the more recent additions in red (adapted from Hanahan & 
Weinberg 2011). 
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In order to metastasise, the primary cancer cell must be able to invade the local 
environment before undergoing intravasation and extravasation, a process by which 
they enter the blood stream in order to circulate around the body before exiting the 
blood vessel and finally establishing a new colony in a distal organ (Steeg, 2006). In 
breast cancer where tumours are comprised of epithelial cells, these cells need to 
undergo a transformation in order to become more aggressive by losing such traits as 
cell adhesion and apical-planar cell polarity and gaining traits such a apoptotic 
resistance and motility, this process is collectively known as the epithelial-mesenchymal 
transition (EMT) (Kalluri & Weinberg, 2009).  
There are numerous genes involved in the progression of breast cancer from a 
primary tumour to metastatic disease. One of the initial steps is to evade detection by 
the immune system and to do this breast cancer cells secrete compounds such as Fas 
death receptor ligand, which tricks the immune cells into destroying each other instead 
of the cancer cells (Mann et al., 1999). Once “invisible” the cancer cells have to be able 
to detach in order to metastasise and do this by altering expression of genes that regulate 
cell adhesion such as selectins (Krause & Turner, 1999), integrins (Kumar, 1998), 
lectins (Raz & Lotan, 1987) and cadherins (Perl et al., 1998) (Akimoto et al., 1999). In 
order to cross basement membranes and separate tissue, breast cancer cells upregulate 
proteolytic enzymes such as metalloproteinases (MMPs), serine proteinases and 
cathepsins (Andreasen et al., 1997; Brew et al., 2000; Chambers & Matrisian, 1997; 
Koblinski et al., 2000; Nelson et al., 2000) as well as genes that increase cell motility 
such as autotaxin and hepatocyte growth factor (Lamszus et al., 1997; Stracke et al., 
1997). The organotropism of breast cancer metastasis is potentially aided by the 
upregulation of specific chemoattractants and receptors (Müller et al., 2001). As 
previously mentioned, breast cancer preferentially metastasises to the bone and this 
process has been reviewed below. 
 
Breast cancer bone metastasis and the “vicious cycle” 
Bone metastasis is one of the most painful and unfortunately most common 
outcomes of advanced breast cancer. Almost 70% of patients who are diagnosed with 
metastatic breast cancer present with bone lesions. This preference of breast cancer cells 
to metastasise to the bone contributes to the high morbidity and mortality associated 
with breast cancer (Coleman & Rubens, 1987; McNeil, 1984).  
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Bone metastases that arise from breast cancer are osteolytic and this resorption of 
bone leads to severe complications such as hypercalcemia, long bone fractures, spinal 
cord compression and osteoporosis (Coleman & Rubens, 1987). Current treatments for 
bone metastasis are considered to be palliative rather than curative, aiming at reducing 
pain and improving quality of life. These treatments include radiation therapy and 
occasionally surgery to reduce tumour size and slow tumour growth and also the 
administration of bisphosphonates, which treat the ensuing osteoporosis and slow 
tumour growth by preventing bone resorption (Lipton et al., 2000; Paterson et al., 
1993). 
Paget’s “seed and soil” theory postulates that the bone microenvironment acts a 
fertile “soil” factor that attracts the breast cancer cells and then provides a suitable 
environment where the cancer cells are able to thrive and proliferate (Paget, 1889). It is 
therefore pertinent to investigate the mechanisms of genes and pathways that regulate 
both bone development and homeostasis and also mammary gland development. The 
most prominent example is receptor activator of NF-κB (RANK) and it’s ligand 
RANKL. RANKL is an essential regulator of osteoclastogenesis in the bone (Lacey et 
al., 1998) whilst it is also crucial in the mammary gland for lobuloalveolar development 
as it controls epithelial cell proliferation and apoptosis along with RANK (Fata et al., 
2000). Due to having essential functions in both bone and mammary development, it is 
evident that RANK/RANKL may be acting as a “soil” factor in what is known as the 
“vicious cycle” of breast cancer bone metastasis. 
The “vicious cycle” bone destruction hypothesis states that tumour cells activate and 
perturb bone cell function by secreting growth factors resulting in bone destruction 
which in turn leads to the secretion and release of subsequent growth factors that 
support the growth of the tumour cells (Roodman & Dougall, 2008; Steeg, 2006). When 
breast cancer cells colonise the bone it results in secretion of tumour growth factors 
such as OPN, IL-6, IL-8, IL-11, PTHrP, TGF-β and MMPs, which in turn activate 
osteoblasts that will secrete RANKL and OPG. This causes a shift in the balance of 
osteoblastogenesis and osteoclastogenesis and eventually leads to excess osteoclasts and 
therefore bone destruction (Roodman & Dougall, 2008; Steeg, 2006). To complete the 
cycle, the damaged bone release osteoblast-activating growth factors such as BMPs, 
TGF-β, IGF and FGFs which aid tumour growth and exacerbate the excessive osteolysis 
(Roodman & Dougall, 2008; Steeg, 2006). 
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Another potential key player in this cycle is the osteogenic transcription factor, 
Runx2. Runx2 is known as a master regulator of bone development and homeostasis 
due to its regulation of cell fate and lineage determination in the bone (Ali et al., 2008) 
(Young et al., 2007a; Young et al., 2007b). Runx2 both directly regulates and is 
regulated by many of the genes and growth factors involved in bone metastasis 
including OPN, TGF-β, collagenase-3, BSP, MMP13 and RANKL (Steeg, 2006) 
(Roodman & Dougall, 2008). Runx2 is also considered to be a master regulator of 
osteoclastogenesis because it regulates both RANKL expression and osteoblast 
differentiation (Enomoto et al., 2003). It is clear that Runx2 controls cell fate in the 
bone through a number of regulatory functions and therefore dysregulation in Runx2 
expression would lead disruption of the balance of bone resorption and formation, thus 
leading to bone lesions. 
Furthermore, a recent study by our lab has indicated that Runx2 may be a novel 
regulator of both mammary gland development and breast cancer cell fate (Owens et al., 
2014). This new evidence may provide the tangible link between these two seemingly 
disparate systems and may lead development of novel therapies against breast cancer 
bone metastasis. 
 
Summary 
Breast cancer, in its primary form, is a disease with a good prognosis and an ever-
increasing array of treatment options. However, the complex mechanisms by which 
breast cancers are able to metastasise, and location to which they preferentially 
colonise, often lead to poor prognosis, reduced quality of life and eventual death for the 
patient. It is important that we continue to investigate the missing pieces of the puzzle in 
order to find ways to treat and circumvent the unrelenting process that is breast cancer 
metastasis by studying both the cancer itself and also the regulatory factors involved in 
the formation and function of the health mammary gland. This will allow the tools to 
design improved diagnostic, prognostic and treatment options for people suffering from 
breast cancer.  
Our lab has recently identified Runx2 as a potential link between breast cancer and 
bone metastasis, however the fetal lethal phenotypes of Runx2-/- mice and the potential 
redundancy that exists in the Runx family have presented difficulties regarding full 
elucidation of the role of Runx2 in the breast. This thesis suggests that investigation into 
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the binding partner, CBFβ, may not only negate these issues but provide the field with 
an exciting and novel regulator of mammary gland development and breast 
carcinogenesis. 
 
CBF Complex 
The Core Binding Factor (CBF) complex is essential for the successful regulation of 
developmental processes (Kundu et al., 2002; Yoshida, 2002) and also stem cell 
homeostasis (Kurosaka et al., 2011; Okuda et al., 1996; Wang et al., 1996). In addition, 
this complex plays key roles in the aetiology of several diseases, namely leukaemias 
(Blyth et al., 2005; Speck & Gilliland, 2002).  
The CBF complex is a heterodimeric transcription factor that is made up of a DNA 
binding subunit, CBFα, and the non-DNA binding subunit, CBFβ (E Ogawa, 1993b; 
Ogawa et al., 1993a; Wang et al., 1993). The CBFα subunit is encoded by the genes in 
both mice and humans Runx1, Runx2 and Runx3 (Bae et al., 1995; E Ogawa, 1993b; 
Levanon et al., 1994; Miyoshi et al., 1991). These Runx genes are differentially 
expressed across tissue types (Levanon & Groner, 2004) whilst the non-DNA binding 
subunit on the other hand is only encoded by one gene in humans, CBFβ, and it is 
ubiquitously expressed across most tissue types (Adya et al., 2000; Hajra & Collins, 
1995; Ogawa et al., 1993a; Wang et al., 1993). 
The CBF complex can both activate or repress transcription of key regulators of 
growth, survival and differentiation pathways (Blyth et al., 2005) and its most widely 
known for its role in both osteogenesis and hematopoiesis (Huang et al., 1999; Nagata 
et al., 1999) (Fig. .4). Aberrations in the CBF complex during osteogenesis leads to 
disorders such as cleidocranial dysplasia and similarly, translocation events during 
haematopoiesis implicate CBF in a large percentage of acute human leukaemias (Huang 
et al., 1999; Nagata et al., 1999). 
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Fig. 1.4.  The CBF complex 
All members of the Runx family form heterodimeric complexes with the same co-transcription factor, 
CBFβ. This complex can both activate and repress transcription of key regulators of growth, survival and 
differentiation pathways depending on context (adapted from Blyth 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 41 
There is new evidence that the CBF complex, primarily via Runx2, plays an 
important role in the developing mammary gland and potentially breast cancer 
(McDonald et al., 2014; Owens et al., 2014). Our lab has recently shown a novel role 
for Runx2 in lobuloalveolar development through regulation of progenitor cell 
populations We have also shown a potential role for Runx2 in the regulation of breast 
cancer cell fate (Owens et al., 2014). This novel Runx2 data will be reviewed 
throughout this thesis and furthermore, how it lead to the discovery of CBFβ as a key 
player in both mammary development and breast carcinogenesis. 
 
Runx2 
Runx gene family 
The Runx family is made up of three closely related yet phenotypically diverse 
transcription factors which are primarily known for their critical roles in tissue 
development and haematopoietic lineages (Coffman, 2003).  
Runx genes 1, 2 and 3 are essential for the regulation of cell fate processes in both a 
lineage and stage specific context. All members of this family are integral to decisive 
processes whereby a cell will either continue to proliferate or exit the cell cycle or 
alternatively, whether it continues along the self-renewal pathway or undergoes 
functional differentiation. The Runx genes have also been implicated in several diseases 
involving skeletal and neurological defects as well as several types of cancer, such as 
leukaemia, bone and gastric cancer (Reviewed in (Blyth et al., 2005)). 
Runx 1, 2 and 3 have highly conserved and essential roles in important 
developmental processes such as haematopoiesis, osteogenesis and neurogenesis 
respectively (Reviewed in (Blyth et al., 2005)). In terms of disease progression, Runx1 
has a well-defined role in acute myeloid leukaemia (Okuda et al., 1996) whilst Runx2 
has severe implications in bone development and related conditions such as 
cleidocranial dysplasia (Otto et al., 1997). Runx3 on the other hand has been implicated 
in gastric and other epithelial cancers (Li et al., 2002).  
It is a well-understood paradigm that aberrant expression or dysregulation of genes 
involved in critical developmental processes often leads to disease progression and 
cancers. Due to this reasoning, there has been a significant increase of interest of the 
Runx genes in recent years, not only because of their role in development but also due 
to their somewhat paradoxical roles in cancer, whereby they are capable on acting as 
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both tumour repressors or oncogenes depending on context (Reviewed in (Blyth et al., 
2005)).  
Genes that are implicated in cancer generally fall either into the category of 
oncogenes or tumour suppressors, the Runx genes however refuse to conform to this 
model (Reviewed in (Blyth et al., 2005)). Runx1 and Runx3 in particular highlight the 
tumour suppressor function of this family, promoting gene deletion, dominant negative 
function, hypermethylation events and inactivating mutations in some cancers including 
both haematological and gastric cancers (Li et al., 2002; Osato et al., 1999; Song et al., 
1999; Tanaka et al., 1995). There is also evidence of the dominant oncogenic function 
of all three Runx genes, principally in lymphomas where Runx genes are often targeted 
for viral insertion (Kim et al., 2003; Li et al., 1999; Stewart et al., 1997). 
Runx1 is found to be the most targeted gene in leukaemias with over 30 
translocations that fall into 3 main classes of fusion proteins; RUNX1-ETO, RUNX1-
EVI1 and RUNX1-TEL. These fusion proteins act as a dominant negative across several 
subtypes of leukaemias including AML, B-ALL and ALL (Gamou et al., 1998; Golub et 
al., 1995; Roulston et al., 1998; Shurtleff et al., 1995; Slovak et al., 2002) (Romana et 
al., 1995) (Fears et al., 1996). RUNX1 also forms another fusion protein with CBFβ and 
MYH11, which also presents with dominant negative functions and significantly 
increases the binding affinity of Runx2 to its cofactors (Adya et al., 1998; Lutterbach et 
al., 1999). 
Runx3 on the other hand is found to be highly methylated in epithelial cancers such 
as gastric cancer which provides strong evidence for Runx3, like Runx1, to be acting in 
a tumour suppressor-like capacity (Goel et al., 2004; Kim et al., 2004; Ku et al., 2004) 
(Li et al., 2004). This theory is supported by the fact that mice that are null for Runx3 
developed epithelial hyperplasia, particularly in the gastric tract (Li et al., 2002). 
Runx2 differs from its family members as it acts predominantly as an oncogene 
when expression is perturbed. This is evidenced by its amplification in several cancers, 
primarily osteosarcoma but also leukaemia and more recently, both primary and 
secondary prostate and breast cancers (Forus et al., 1995; Selvamurugan et al., 2004) 
(Barnes et al., 2003; Lau et al., 2004; McDonald et al., 2014; Owens et al., 2014; Yang 
et al., 2001; Yeung et al., 2002). 
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Runx2 as a master regulator of bone development and homeostasis 
Runx2 is one of the most critical transcription factors involved in skeletal 
morphogenesis and osteoblast differentiation (Komori, 2011). Its primary known 
function is as a master regulator of osteoblast differentiation and bone development and 
homeostasis (Komori et al., 1997; Otto et al., 1997).  
Deletion of Runx2 in the mouse leads to a severe inhibition of bone development 
through an ablation of the osteoblast population and impaired bone mineralisation 
(Komori et al., 1997; Otto et al., 1997) whilst a haploinsufficiency in humans results in 
the autosomal dominant skeletal condition known as cleidocranial dysplasia (Mundlos 
et al., 1997). In regards to the role of Runx2 in cancer, numerous studies show that 
Runx2 is amplified in in several cancers, especially osteosarcomas, indicating a 
primarily oncogenic role (Forus et al., 1995; Lau et al., 2004). This oncogenic 
phenotype is reiterated by cell culture studies which have shown that the overexpression 
of Runx2 in both endothelial and osteoblastic cells drives the cells towards a more 
metastatic phenotype a where cell migration, invasion, survival and angiogenesis are 
enhanced (Fujita et al., 2004; Sun et al., 2001; Sun et al., 2004; Zelzer et al., 2001). 
It is evident from these studies that Runx2 is integral to the normal development of 
the skeletal system and that its dysregulation has severe implications on the aetiology of 
disease. This paradigm has shaped the course of this thesis in the context of the 
mammopoiesis and breast carcinogenesis. 
 
Runx2 and mammary gland development 
As stated previously, Runx2 is best known for its role as a master regulator of bone 
development and homeostasis, but in recent years the role Runx2 plays in non-osseous 
tissue has become an increasing point of intrigue (Reviewed in (Ferrari et al., 2013)).  
Recent studies by our lab and others have shown a novel role for this osteogenic 
transcription factor in both mammary gland development and carcinogenesis (Blyth et 
al., 2010; Owens et al., 2014; Pratap et al., 2011; Shore, 2005). 
The first evidence of a relationship between Runx2 and the mammary gland was 
established when Otto and colleagues (Otto et al., 1997) discovered it was expressed in 
the nascent mammary gland through β-galactosidase staining of the CBFα1-/- embryos 
that housed the LacZ reporter gene (Otto et al., 1997). It was later shown that Runx2 is 
particularly highly expressed in the terminal end buds, which are the driving force 
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behind extending the ductal network through the mammary fat pad (Kendrick et al., 
2008; Kouros-Mehr et al., 2006) confirmed the role of Runx2 in the mammary gland 
when they found that it was expressed specifically in the basal/myoepithelial sub-
population (Kendrick et al., 2008). This was an interesting discovery as it was 
previously shown that mammary stems cells exist in the basal/myoepithelial sub-
population (Shackleton et al., 2006; Stingl et al., 2006). 
Not only is there now evidence that Runx2 is expressed in the mammary gland, there 
have also been several studies reported in recent years that have focused on the role this 
transcription factor is playing in mammopoiesis. 
It has now been shown that the expression of Runx2 in the mammary gland 
fluctuates over the course of development, indicating critical involvement (Blyth et al., 
2010; Owens et al., 2014) and it is required for regulation of genes that are essential for 
mammary function (Inman & Shore, 2003).  
It has been shown that Runx2 regulates genes that are essential for mammary gland 
function in both primary mammary epithelial cells and in HC11 cells, which are derived 
from the lactating mouse mammary gland (Inman et al., 2005; Inman & Shore, 2003). 
Inman & Shore found that Runx2 is not only expressed in HC11 cells but that it binds 
directly to the osteopontin (OPN) promoter (Inman & Shore, 2003). OPN is an 
extracellular matrix protein that acts to stimulate cell migration, invasion adhesion and 
protection against apoptosis and is a known target gene of Runx2 in osteoblasts 
(reviewed in (Shore, 2005)). OPN is also expressed in the mammary gland and is 
important for lactation. Transgenic mice that expressed OPN anti-sense RNA that are 
deficient in OPN are found to show a deficiency in lactation due to an absence of 
mammary alveolar structures and reduced synthesis of both β-catenin and whey acidic 
milk protein (WAP). 
The binding interaction between Runx2 and the OPN promoter is required for 
activation of OPN in mammary epithelial cells (Inman & Shore, 2003). Furthermore it 
has been shown, through transient transfections, that dominant negative Runx proteins 
can inhibit the actions of both OPN and its promoter in mouse mammary epithelial cells 
(Inman & Shore, 2003). These findings were pivotal in this field because it was the first 
indication that Runx2 is able to regulate gene transcription in normal mammary cells 
where most of the previous data had indicated it role more inline with cancer due to 
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Runx2 transcripts being discovered in the MDA-MB-231 and MCF7 breast cancer cell 
lines (Selvamurugan & Partridge, 2000; Shore, 2005).  
Our lab has recently confirmed that Runx2 is differentially expressed across 
development of the mouse mammary gland. Runx2 expression is relatively high in 
virgin glands and throughout early pregnancy but then levels are significantly reduced 
during late pregnancy and into early lactation before returning to virgin-like levels 
during involution of the gland (McDonald et al., 2014; Owens et al., 2014). Our lab 
went on to produce two different Runx2 knockout mouse models in order to examine 
the role of Runx2 throughout mammopoiesis for the first time in vivo. Two approaches 
were used, a whole body knockout combined with mammary transplantation and a 
mammary gland specific Runx2 knockout. The Runx2-/- transplantation model showed 
no difference in the ability of the gland to undergo ductal extension whilst the 
mammary-specific knockout displayed only transient delay of ductal morphogenesis 
during puberty or in early to mid pregnancy. This indicates that Runx2 may not be 
essential for development of the ductal epithelium. This study did not investigate the 
effects of Runx2 deletion during the early stages of puberty; therefore there is a need to 
determine if there is a role for Runx2 during ductal extension in order to fully 
comprehend the role of Runx2 in mammopoiesis. There was however a severe 
impairment of lobuloalveolar development noticed during late-mid pregnancy, which 
continued into early lactation in both knockout models (Owens et al., 2014). These 
alveoli had no discernable lumen but were found to be correctly polarized and capable 
of lactation. We then showed, through lineage analysis that a loss of Runx2 during mid 
to late pregnancy results in a shift in the balance of luminal progenitors to alveolar 
progenitors in the pregnant mammary glands of both mouse models. This increase of 
alveolar progenitors explains the impaired development in the lumens of Runx2 
knockout mice and suggests Runx2 plays a role in mammary progenitor cell 
specification (Owens et al., 2014). Another study showed a similar inhibition of 
lobuloalveolar development in a Runx2 overexpressing transgenic mouse rather than a 
knockout model (McDonald et al., 2014). However, the transgenic mouse used in this 
study was reported to have supraphysiological overexpression of Runx2 (McDonald et 
al., 2014) complicating the interpretation of this data.  
It is evident from the conflicting data that there is a need for further investigation 
into the role of Runx2 and the entire CBF complex in mammary gland development.  
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Runx2 in breast cancer 
Breast cancer has a good prognosis and survival rate in the localised phase of the 
disease but the survival rate drops dramatically if the cancer is able to metastasise. 
There is certainly a dual purpose for many genes that are involved in both mammary 
gland development and breast cancer including RANK, RANKL, vitamin D, bone sialo 
protein and osteopontin (Martin & Gillespie, 2001) and current evidence has confirmed 
that Runx2 is not only essential for regulating gene transcription in the developing 
mammary gland, but it also a key regulator of breast cancer cell fate (Ferrari et al., 
2013; Owens et al., 2014) . 
It is widely known that breast cancers will preferentially metastasise to bone (Juan 
Juan et al., 2005; Yoneda & Hiraga, 2005) but the mechanism behind this has remained 
a key question in breast cancer research. Many genes involved in mammary gland 
development are also involved in bone homeostasis, such as those listed below and it is 
believed that Runx2 could be the missing link that drives breast cancer to bone and 
allows the cancer cells to maintain this colonisation as it is known to regulate these 
“bone” genes that are also found in metastatic breast cancer (Martin & Gillespie, 2001) 
(Blyth et al., 2005; Shore, 2005).  
It has been shown that, when compared to normal mammary epithelial cells, Runx2 
is upregulated in several breast cancer cell lines (Lau et al., 2006). The involvement of 
Runx2 in breast cancer was further evidenced when Nagaraja et al identified, through a 
comparative screen, it as being on of the most regulated genes in invasive breast cancers 
versus non-invasive breast cancers (Nagaraja et al., 2006). 
Several studies have used the highly invasive MDA-MB-231 cell lines to assess the 
function of Runx2 in terms of its ability to increase the invasiveness of human breast 
cancer cells (Ferrari et al., 2013; Owens et al., 2014; Pratap et al., 2011; Shore, 2005). 
More specifically, down regulating Runx2 in MDA-MB-231 cells leads to a reduction 
in the invasive capacity of the cells in vitro. Furthermore, when these cells are injected 
into mice, there is a reduction in subsequent osteolytic disease and tumour growth in 
vivo (Barnes, 2004; Javed, 2005; Mendoza-Villanueva et al., 2010; Pratap, 2009).  
Converse studies have also shown that forcing Runx2 expression in the less 
aggressive breast cancer cell line, MCF7, leads to a distinct epithelial to mesenchymal 
transition (Chimge et al., 2011) and the cells also become more invasive (Pratap, 2006 ). 
Similarly, ectopic expression of Runx2 in the “normal” breast cell line, MCF10A 
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induces cancer-like phenotypes when grown in 3D (Pratap, 2009). Our lab has also 
shown that forced expression of Runx2 in MCF-10A cells leads to an upregulation of 
Cyclin D1 and N-Cadherin as well as a decrease in E-Cadherin, further evidencing that 
the cells undergo EMT when exposed to ectopic levels of Runx2 (Owens et al., 2014). 
We also went on to show that Runx2 over-expression in the normal mouse mammary 
epithelial HC11 cells lead to a perturbation in differentiation which resulted in a 
transition of these epithelial cells to a more “cancer-like” phenotype with increased E-
Cadherin and phosphor-FAK levels and an increased ability to migrate compared to 
control cells (Owens et al., 2014). 
 Current evidence suggests that Runx2 is able to enhance the metastatic potential of 
breast cancer cells through the regulation of target genes that known key players in the 
metastatic cascade  (Reviewed in (Pratap, 2006 )). These target genes include vascular 
endothelial growth factor (VEGF) which requires Runx2 for activation and is essential 
for tumour vascularisation (Zelzer et al., 2001) and bone matrix protein such as bone 
sialo protein (BSP) and osteopontin (OPN) which are required for recruiting cancer 
cells to the bone and increasing resorptive activity respectively (Natasha et al., 2006) 
(Ohyama et al., 2004). As stated previously, Runx2 is known to regulate OPN in the 
developing mammary gland, through binding of the OPN receptor, (Inman & Shore, 
2003) and also in cancers, including some melanomas and colorectal cancers 
(Riminucci et al., 2003; Wai et al., 2006). Barnes et al confirmed the role of Runx2 in 
metastatic cancer by showing that inhibition Runx2 expression in MDA-MB-231 cells 
leads to decreased expression in both OPN and BSP which suggests that Runx2 may be 
driving breast cancer cells to preferentially metastasise to bone by enhancing both bone 
targeting and adhesion genes (Barnes, 2004). 
Runx2 also directly regulates genes that are associated with the ability of breast 
cancer cells to escape the primary tumour and colonise a secondary site, such as the 
matrix metalloproteinases (MMPs), in particular MMP9 and MMP13 (Pratap et al., 
2005) (Selvamurugan et al., 2004). Studies have shown that suppressing Runx2 in 
MDA-MB-231 cells causes a decrease in OPN, MMP9 and MMP13 expression which 
in turn leads to decreased invasive capability of the cells (Mendoza-Villanueva et al., 
2010; Mendoza-Villanueva et al., 2011; Pratap et al., 2005). 
Runx2 also has a known oncogenic role in the T-cell lineage and has been shown by 
our lab and others to be upregulated in human breast cancer cell lines, correlating with 
invasiveness so it is an enticing candidate for a potential prognostic marker in human 
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breast cancer (McDonald et al., 2014). One study has attempted to examine the 
expression of Runx2 in human breast cancer TMAs but due to a limited sample number 
they were unable to draw concrete conclusions linking Runx2 expression to overall 
survival, tumour size or grade or lymph node status. This study does however show that 
Runx2 expression is associated with ER/PR/HER2 negative breast cancers and could 
possibly distinguish patient prognosis within this specific subtype (McDonald et al., 
2014). 
To date, all of the data describing the role of Runx2 in breast cancer has been 
collected using either cell lines or tissue sections. In order to further examine the role 
Runx2 plays in breast tumourigenesis, our lab generated the first in vivo model capable 
of discerning the function of this essential transcription factor. We crossed the Runx2-/- 
mouse on to the MMTV-PyMT luminal breast cancer mouse model and transplanted 
mammary epithelium from these mice into immunocompromised recipients. This was 
the first in vivo model to look into the role Runx2 plays in breast tumourigenesis and it 
showed that a lack of Runx2 in the mammary gland lead to an increase in both tumour 
latency and an increase in overall survival of the mice (Owens et al., 2014). We also 
report a down regulation of Cyclin D1 accompanied reduced Runx2 expression, 
indicating a reduction in the proliferative capacity of the Runx2-/- tumour cells. 
Unfortunately this model did not examine metastases due to the fact that the recipient 
mice are immunocompromised, and a functioning immune system is required for 
metastasis (Olkhanud et al., 2009). While a transplantation approach was required due 
to the embryonic lethality that occurs in Runx2 knockout mice, it is clear that there is a 
need for a model in which the metastatic potential of tumour cells can be observed in 
vivo. This is one of the issues that has been addressed in this thesis. 
 
Summary 
It is clear that the Runx genes are extremely important in both the normal 
development and disease progression of several systems including haematopoiesis, 
neurogenesis, osteogenesis and now the mammary gland.  
Runx2 has long been a prime suspect in breast cancer, particularly in regards to 
metastasis, and now recent studies have outlined a novel role for Runx2 in 
mammopoiesis as well. It is also understood that the Runx genes act as one part of the 
CBF complex, however there is no data describing the role its binding partner, CBFβ, 
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may be playing in either mammary gland development or breast carcinogenesis. Given 
the critical role that Runx2 in these systems coupled with the limitations of working in a 
system where there is potential for redundancy and fetal lethal phenotypes, there is a 
clear need for further investigation and establishment of models that address these 
issues. The results of this thesis show that the investigation of the role of CBFβ is not 
only able to circumvent these issues but has also uncovered an exciting and novel role 
for this gene in mammary gland development and breast cancer.  
 
CBFβ  
The role of the Runx genes as critical regulators of cell fate in both developmental 
processes and cancer is well established but they are not able to execute this role in 
isolation.  
Whilst the Runx genes determine tissue specificity, CBFβ is the transcriptional co-
activator that increases the stability and the DNA binding affinity of the complex by 
triggering structural changes (Ito, 2008; Tahirov et al., 2001; Zhang et al., 2003). Not 
only does the binding of CBFβ alter the confirmation of the complex to make to 
increase DNA binding affinity but studies also suggest that this structural shift may also 
provide protection to the Runx proteins from proteolytic degradation (Huang et al., 
2001; Huang et al., 1999). 
 
CBFβ  in development 
The heterodimeric binding of Runx proteins and CBFβ is able to bind co-factors that 
able to either activate or repress transcription of key regulators of growth, survival and 
differentiation pathways (Tanaka et al., 1995). More specifically, CBFβ has found to be 
integral in the control of haematopoiesis and skeletal development through the 
regulation of stem cell proliferation and differentiation (Kurosaka et al., 2011). 
It was originally thought that the function of CBFβ was purely to increase the DNA 
binding affinity of the Runx genes (Wang et al., 1996) but it has since been discovered 
that CBFβ collaborates with the Runx genes in order to successfully regulate 
transcription (Davis et al., 2010). It has now been shown that CBFβ null mice show the 
same embryonic lethality at day 11.5 as Runx1 null mice due severe haemorrhaging as a 
result of defective haematopoiesis in the fetal liver. Interestingly, over expression of 
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Runx genes in the CBFβ null mice leads to only a partial rescue of the phenotypes 
reported (Okuda et al., 1996; Wang et al., 1996). This indicates that there are functions 
of CBFβ and Runx2 that are independent of each other. Furthermore, CBFβ null mice 
present with a delayed bone formation phenotype, where the fontanelles and sutures of 
the skull remain open and the clavicles are hypoplastic. These phenotypes are similar to 
Runx2 null mice and have shown that it is possible to rescue the CBFβ null mice in a 
haematopoietic-specific context (Kundu et al., 2002; Yoshida, 2002). This data also 
indicates that CBFβ is able to enhance the transcriptional effectiveness of the Runx 
genes in order to control developmental processes (Davis et al., 2010). In the context of 
skeletal development it has been shown that CBFβ is necessary for the efficient DNA 
binding of Runx2 and therefore the subsequent Runx2-dependent transcriptional 
activation (Yoshida, 2002). A more recent study from the same lab has now shown that 
CBFβ is also able to stabilise all Runx proteins through induction of structural changes, 
which in turn leads to enhanced transcriptional activation of downstream target genes 
(Qin et al., 2014).  
 
CBFβ  in the mammary gland 
There is currently no data regarding the role of CBFβ in the developing mammary 
gland, or in the mammary gland at all. We do know however that it is a crucial 
transcription factor in development of other systems such as haematopoiesis and 
osteogenesis (Kundu et al., 2002; Yoshida, 2002) in conjunction with Runx proteins 
through the regulation of stem cell homeostasis (Okuda et al., 1996; Wang et al., 1996) 
(Kurosaka et al., 2011). 
It has now been shown that Runx2 plays an integral role in the development of the 
mammary gland (Owens et al., 2014) and when this is coupled with the fact that CBFβ 
is critical for enhancing the DNA binding affinity and overall stabilisation of the Runx 
genes (Ito, 2008; Tahirov et al., 2001; Zhang et al., 2003), it is evident that CBFβ may 
also be playing a key role in mammopoiesis. 
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CBFβ  in cancer 
It is well known that the CBF complex is capable of binding co-factors that able to 
either activate or repress transcription of key regulators of growth, survival and 
differentiation pathways (Tanaka et al., 1995) and many of these targets are now known 
to be compromised in cancer, including those which involved in reprogramming cell 
fate (Blyth et al., 2010). 
The first cases of CBF perturbation were described in acute myeloid leukaemias 
(AML) where it was shown that both Runx1 and CBFβ are the targets of the most 
common chromosomal translocations found in AML (Look, 1997). CBFβ has also been 
found to form fusion proteins through inversion events in mye-lomonocytic (M4Eo) 
leukaemias, for example CBFβ-MYH11, which affects the binding of the CBF complex 
in a dominant negative fashion (Adya et al., 1998; Lutterbach et al., 1999). There is 
further evidence of the oncogenic properties of CBFβ as it has also been implemented 
in both human B-cell acute lymphoblastic leukaemia and also granulocytic sarcoma 
where expression is upregulated along with Runx1 (Mallo et al., 2007; Niini et al., 
2000). 
Whilst CBFβ is primarily known for its role in leukaemias, there has been a growing 
interest in its involvement in solid tumours, a role that is yet to be fully elucidated 
(Davis et al., 2010). Recent publications have provided evidence that CBFβ may play a 
role in prostate and ovarian cancers (Davis et al., 2010), may be involved in breast 
cancer invasion in vitro (Mendoza-Villanueva et al., 2011) and is found to be down 
regulated in gastric cancer along side Runx1 and Runx3 (Sakakura et al., 2005). 
 
CBFβ  in breast cancer 
As previously mentioned, many genes that are involved in developmental systems 
are often perturbed in disease progression. This thesis essentially aims to examine this 
concept in regards to the mammary gland and breast cancer. Evidence has been 
provided by several studies and has indicated a potential role of Runx2 in both 
mammopoiesis and breast carcinogenesis. 
With the exception of a single in vitro study focusing on a single breast cancer cell 
line, there has been no data suggesting a role for CBFβ, the non-DNA binding partner 
of Runx2 in breast cancer. During the course of this thesis, three separate whole 
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genome/exon sequencing studies sought to identify genes that are significantly mutated 
in human breast cancers. These studies examined 77, 103 and 510 human breast 
tumours and identified 18, 6 and 23 significantly mutated genes respectively (Banerji et 
al., 2012; CGAN, 2012; Ellis et al., 2012). From three independent studies, only five 
genes were found to be commonly mutated, GATA3, PIK3CA, MAP2KI, TP53 and 
CBFβ. The first four genes in this list have known key players with well-documented 
roles in breast cancer, CBFβ on the other hand is the outlier of the group as it has no 
previous ties to breast cancer (Banerji et al., 2012; CGAN, 2012; Ellis et al., 2012). 
Even more remarkably, CBFβ was found to be mutated in approximately 5% of all 
luminal tumours, making it one of the most frequently mutated genes in human breast 
cancer (CGAN, 2012). 
The outcome of this study highlights that whilst we have identified many of the 
regulatory factors that are crucial for the development of breast cancer, there are clearly 
still essential elements that are yet to be examined. The fact that CBFβ is involved in 
regulation of cell fate processes in both development and cancer makes it a tantalising 
new key player in breast carcinogenesis. The aim of this thesis is to investigate this 
potential novel role for CBFβ. 
A previously stated, there has been almost a complete lack of published data linking 
CBFβ to breast cancer other than the whole genome/exon sequencing results. As part of 
their research into the role of Runx2 in breast cancer metastasis, Mendoza-Villanueva et 
al found that CBFβ was expressed in the aggressive MDA-MB-231 cell line (Mendoza-
Villanueva et al., 2010), which is consistent with previous data showing higher levels of 
CBFβ mRNA in cancer cell lines compared to normal breast cells (Lau et al., 2006). 
CBFβ expression was also found in cell lines for osteosarcoma (UMR-106), HeLa cells 
and also MCF7 cells, which shows CBFβ is present in both metastatic and non-
metastatic cancer cell lines. Interestingly, when the nuclear fraction of the cell lysate 
was examined, it was found that CBFβ was only present in the nucleus of cells that also 
expressed Runx2. Therefore CBFβ was present in both the MDA-MB-231s and the 
UMR-106 cells but not in the Runx2 negative HeLa and MCF7 cells (Mendoza-
Villanueva et al., 2010). 
Mendoza-Villanueva et al examines the potential involvement of both CBFβ and 
Runx2 for the invasive potential of MDA-MB-231 cells by using siRNA and shRNA 
against both genes. The results showed that deletion of either gene led to a decrease in 
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the invasive potential of the breast cancer cell (Mendoza-Villanueva et al., 2010). 
Mendoza and colleagues then investigated the effects of CBFβ knockdown on a subset 
of Runx2 target genes that are involved in cell invasion, it was observed that CBFβ 
expression was required for expression of some but not all of these targets. The 
downstream targets that were tested were the matrix metalloproteases MMP9 and 
MMP13, osteopontin (OPN), Galectin-3 and osteocalcin (OC) and it was found that a 
down regulation of CBFβ led to a decrease in the expression of all these genes except 
for Galectin-3. This indicates that the functions of Runx2 and CBFβ are not mutually 
exclusive and together with the sequencing data, highlight a potentially novel and 
exciting role of CBFβ in breast cancer (Mendoza-Villanueva et al., 2010; Mendoza-
Villanueva et al., 2011). Furthermore, chromatin precipitation (ChIP) was performed to 
see if the DNA binding interactions of CBFβ with the promoters of both OPN and 
Galectin-3 and it was discovered that CBFβ is recruited to both of the promoters but is 
not essential for Galectin-3 activation (Mendoza-Villanueva et al., 2010). 
A reduced level of CBFβ in MDA-MB-231 cells leads to a reduction in not only 
genes required for invasion but the invasive capacity of the cells as well. This invasive 
defect and also the expression levels of both MMP13 and OPN can be rescued by the 
restoration of CBFβ expression, which proves that CBFβ is a positive regulator of 
metastasis in breast cancer cells (Mendoza-Villanueva et al., 2010). 
An additional study from this group used a microarray to identify the genes which 
were common as well as differentially regulated between MDA-MB-231 cells with 
either Runx2 or CBFβ knocked down using siRNA. The results showed that out of 
38,500 genes in the array they identifies 357 and 340 genes in the Runx2 and CBFβ 
respectively that were differentially expressed between MDA-MB-231 transfected with 
Runx2 or CBFβ siRNA and those transfected with non-specific siRNA (Mendoza-
Villanueva et al., 2011). They found that there was no significant change in Runx2 
expression in the CBFβ knockdown cells or in Runx2 expression in CBFβ knockdown 
cells, indicating that the changes in the 161 genes that were common to both sets were 
not due to downstream changes in just one of these transcription factors. Further 
analysis found that Runx2/CBFβ regulate some of the genes that play a role in 
mediating the activation of osteoclasts and the inhibition of osteoblasts, namely IL-11, 
CSF-2 and SOST (Mendoza-Villanueva et al., 2011). 
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This work has helped to provide some insight into the potential links between breast 
cancer and bone metastasis. However, this data has been accumulated using in vitro 
techniques and focuses on one breast cancer cell line. It is essential to see how CBFβ 
mediates metastatic phenotypes in, not only additional cell lines, but also in an in vivo 
context.  
  
Summary 
Transcription factors, regulatory genes and hormones act to influence cell fate and 
are essential for mammary gland development. It is pertinent to fully elucidate the 
mechanism of cell fate regulation in the mammary gland to be able to understand the 
implication of their dysregulation in breast cancer. 
The role of the CBF complex in its entirety is undoubtedly crucial for development 
of numerous systems, including neurogenesis, haematopoiesis and osteogenesis. All 
members of this complex have been shown to influence cell fate decisions and hence 
dysregulation or aberrant expression of either CBFβ or the Runx genes has severe 
implications in terms of disease, including several cancers. Recent studies have now 
identified CBFβ as one of the most frequently mutated genes in human breast tumours 
which fits with other published data stating that the functions of the Runx proteins and 
CBFβ in breast cancer are not always mutually exclusive. With this in mind, we can 
start to explore the role of CBFβ as a novel regulator of cell fate in the in the developing 
mammary gland and examine the implication of this role in the context of breast 
carcinogenesis. 
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Aims of this Thesis 
The overall aim of this project is to examine a potential role for CBFβ as a regulator 
of mammary cell fate specification and determine if it plays a role in the regulation of 
normal mammary gland development and can influence breast carcinogenesis and 
metastasis. 
The mammary gland is a dynamic organ that undergoes dramatic cyclical changes 
under the influence of female hormones and given the complexity of this system it is 
clear that there may be more transcription factors involved then is currently known. 
Runx2, one of the binding partners of CBFβ, has recently has been implicated in the 
mammopoiesis and given that we know CBFβ is integral to the functions of all Runx 
proteins, this thesis aims to provide insight into the role CBFβ itself may have in 
mammary gland development. Chapter 3 therefore specifically examines the effects of 
CBFβ deletion during mammopoiesis through the use of two independent inducible and 
conditional mouse models as well as through analysis of protein and mRNA levels 
through the developmental time course of the gland.  
Furthermore, we aim to elucidate the role CBFβ is playing in human breast cancer. 
Breast cancer is a heterogeneous disease with good prognosis in the primary phase of 
the disease but a high morbidity and mortality rate in the metastatic phase, due in the 
most part to the preference of breast cancer cells to colonise the bone. This is a 
mechanism that still evades us but it is thought that Runx2 plays a role due to its 
involvement in both osteogenesis and now mammopoiesis. Although closely linked, it 
has already been suggested that the functions of Runx2 and CBFβ may not be mutually 
exclusive so there is potential for a novel role CFBβ in its own right. Recent sequencing 
studies have now identified CBFβ, for the first time, as one of the most frequently and 
significantly mutated genes in human breast tumours. Chapter 4 therefore aims to 
examine the expression patterns of CBFβ in human breast cancer cell lines then 
determine how the augmentation of CBFβ expression affects the growth and phenotype 
of these cells. In addition, we aim to provide insight into the potential mechanism 
behind CBFβ regulation of breast cancer through microarray analysis of breast cancer 
cells with altered levels of CBFβ expression. 
As mentioned previously, it is the metastatic phase of breast cancer that has poor 
prognosis and survival rates and unfortunately, this is the area of research that poses the 
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most questions. Chapter 5 is therefore dedicated to studying the outcomes of deleting 
CBFβ in an in vivo model of breast carcinogenesis and metastasis. We will investigate if 
deletion of CFBβ affects tumour latency, overall survival of the animals and also on the 
incidence and severity of metastasis.  
Overall, it is evident from the literature that there is definite potential for CBFβ to be 
deemed an important player and key regulator in both the developing mammary gland 
and also in breast carcinogenesis and it is the definitive aim of this thesis to reveal this 
novel function of CBFβ. 
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2. Materials and Methods 
In Vivo Techniques 
Mice 
The development of CBFβ floxed mice (Naoe et al., 2007), CreERT2 transgenic 
mice (Ruzankina et al., 2007), BLG-Cre transgenic mice (Selbert et al 1998), Polyoma 
Middle T (PyMT) transgenic mice (Lin et al., 2003) and Rag1-/- mice (Mombaerts et al., 
1992) have been previously described. FVBN mice were used for time mating 
experiments and were purchased from the Animal Research Centre (ARC) Perth, 
Australia. Rag1-/- mice of the C57BL/6J strain were purchased from ARC, Perth, 
Australia. The CBFβ floxed, CreERT2 and BLG-Cre mice used in these studies were of 
the mixed background 129/C57. The PyMT mice in these studies were of the FVBN 
background. Mice were housed in the Bosch Rodent Facility at the University of 
Sydney in accordance with ethics approvals K00/6-11/3/5545. All animals were housed 
with food and water ad libitum at 22°C and 80% relative humidity with a 12-hour 
day/night cycle. 
 
Time mating 
Time mating is a technique used to assess changes in the mouse mammary gland 
across all stages of development. Breeding pairs were set up and then mammary glands 
were harvested at representative time points from virgin development, pregnancy, 
lactation and involution. The stage of the estrous cycle was determined through staining 
of a vaginal smear using the Shandon Kwik DiffTM Stain (Thermo Scientific, Australia). 
Early stages of pregnancy were confirmed after post-mortem examination of the uterus. 
For the purpose of this thesis, the 4th mammary glands were harvested from mice at the 
following developmental stages: virgin (estrous); 4 days post coitus (d.p.c); 7 d.p.c; 12 
d.p.c; 18 d.p.c; the 2nd day of lactation; and the 5th day of involution. Both of the 
inguinal 4th mammary glands were harvested, one was used for protein and RNA 
analysis and the second was used for whole mount analysis. 
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Mammary epithelium transplants 
Mammary epithelium transplants were performed as previously described (De Ome, 
1959). Succinctly, the procedure involved excising a 1mm3 (approximately) piece of 
mammary gland epithelium from between the nipple and lymph node of the 4th 
mammary gland from 12-week-old donors. The 3rd mammary gland was also taken from 
the donor and stained with carmine to be used as a histological reference. The donor 
mammary gland tissue was transplanted into the 4th mammary fat pad of 3-week-old 
Rag1-/- animal once it was cleared of all endogenous epithelium. The epithelium was 
cleared from the recipient fat pad by cauterisation of the lymph node, nipple and the 
bridge between the 4th and 5th mammary gland. This section of the mammary gland is 
then removed which left the remaining fat pad that the ductal tree had yet to penetrate. 
The transplanted epithelium forms a new association with the host stroma as it grows 
out in to the recipient fat pad. Transplanted gland were examined by whole mount 
analysis which confirmed the formation of a new functional mammary gland that had be 
derived from the transplanted epithelium and not the endogenous gland. Ductal 
structures arising from endogenous epithelium originate from the side of the gland 
whilst ductal outgrowth from transplanted epithelium originates from the centre (Lewis 
et al., 1999). 
 
Tamoxifen injections to activate Cre expression 
In order to drive Cre expression and activate deletion of CBFβ in the 
CBFβf/fcreERT2 line, the mice were injected with a Tamoxifen solution. The 
Tamoxifen powder (Sigma) was added to corn oil (Sigma) and incubated in the dark for 
three hours at 37°C until dissolved and filter sterilised to make a 20mg/mL stock 
solution. Mice were administered with a 50µL intra-peritoneal injection of 1mg of 
Tamoxifen over three consecutive days. 
 
Tumour measurement and harvesting 
In the PyMT tumourigenesis study, mice were examined three times a week for 
tumour development, weight and overall health. Once mammary tumours were 
palpable, digital calipers were used measure the minor and major axis of each mammary 
tumour to determine the volume, which has been found to have a good correlation to the 
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weight of the tumour in grams (Attia & Weiss, 1966). Mice were euthanised when the 
tumour burden reached the ethical endpoint, which was when the combined tumour 
burden reached 10% of the animal’s weight. After the mice were euthanised, tumours 
and organs were collected for histological analysis and the remaining mammary glands 
were collected for whole mount analysis. 
 
Organ and tumour harvesting  
In the PyMT tumourigenesis study, mice were examined post-mortem for signs of 
metastasis and any organs found to be affected were surgically removed and placed in 
10% neutral buffered formalin (NBF) for 4 hours before being transferred to 70% 
ethanol and then processed for histological analysis. 
 
In Vitro Techniques 
Cell culture 
All cell lines were obtained from the American Type Culture Collection (Rockville, 
MD) through the Garvan Institute of Medical Research (Sydney, Australia). All cell 
lines were cultured in a humidified incubator at 37°C with 5% carbon dioxide. MDA-
MB-231 and Hs578T cells were cultured in Roswell Park Memorial Institute 1640 
medium (RPMI-1640, Gibco) with 10% fetal bovine serum (Bovogen) and PlatE cells 
were culture in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) with 10% fetal 
bovine serum. 
 
siRNA transfection 
Two different and specific human CBFβ siRNAs (On-TARGETplus CBFβ siRNAs) 
and a negative control (On-TARGETplus RISC-free siRNA) were purchased from 
Dharmacon (USA). MDA-MB-231 cells were seeded at 1x105 cells/mL in 6-well plates 
to ensure they were 30-40% confluent 24 hours later. The cells were transfected with a 
final concentration of 5nM CBFβ or RISC-free siRNA diluted in Opti-MEM (Gibco). 
The transfection reagent, Lipofectamine 2000 (Invitrogen) was added to the diluted 
siRNA and incubated for 20 minutes at room temperature before being added to the 
cells. Each transfection was conducted in triplicate and cells were incubated for 48 
hours before the cells were harvested.  
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Retroviral synthesis 
Retroviral constructs to knockdown and overexpress CBFβ were generated as part of 
this thesis. In order to synthesise retrovirus, PlatE cells were seeded at 8x106 cells/15cm 
dish and left to grow for 24 hours at 37°C. The following day, 180µL of Fugene6 
(Promega) to 5mL of serum-free media and incubated at room temperature for 5 
minutes before the addition of 60µg of vector DNA and a further 20 minutes of 
incubation. The majority of growth media was removed from the cells and replaced 
with the 5mL Fugene/media/DNA solution and incubated overnight at 37°C. The media 
was changed the next day and then cells left to incubate overnight before the viral 
supernatant harvested and filter sterilised (0.45µm) the following day. The filtered virus 
was then aliquoted, frozen in liquid nitrogen and stored at -80°C until use. 
 
Retroviral infection of human breast cancer cells 
Human breast cancer cells were plated at 2x105 cells/10cm dish and left to incubate 
overnight at 37°C before the majority of media was removed and they were infected 
with a mixture of 1mL retrovirus, 3mL growth media and 4µL polybrene (8mg/mL 
stock) and incubated at 37°C. After 6 hours incubation, a further 6mL of growth media 
was added and the cells left to incubate overnight at 37°C. The process for infection was 
repeated for a second time before the cells populations were sorted by FACS sorting. 
 
Proliferation assays 
In order to assess the rate of proliferation, cells were seeded at a low density in 6-
well plates. Cells were counted over a 96 hour period at 3-8 time points a day as the 
cells moved through the exponential growth phase. MDA-MB-231 cells expressing 
CBFβ or non-specific shRNA were initially seeded at 2x104 cells/mL and Hs78T cells 
containing the CBFβ overexpression construct or empty vector were seeded at 5x103 
cells/mL. 
 
Migration assays 
Migration assays were performed using the xCelligence DP system (Roche) by 
measuring increasing electrical impedance as cells migrated across electrodes towards a 
chemoattractant, in this case fetal bovine serum. MDA-MB-231 cells expressing CBFβ 
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or non-specific shRNA were initially seeded at 4x104 cells/well and Hs78T cells 
containing the CBFβ overexpression construct or empty vector were seeded at 1x104 
cells/well. 
 
Cloning of CBFβ  shRNA retroviral constructs  
Primer design 
 Sense and anti-sense shRNA primers were designed based on the siRNA sequences 
and were made to include both the hairpin an additional MLU1 restriction enzyme that 
was used to confirm the identity of the insert. The sense primers used can be found in 
the table below: 
  
Annealing and ligation 
The CBFβ shRNA sense and anti-sense primers were annealed in a 1:1 ratio in the 
following reaction: 30 seconds at 95°C, 2 minutes at 72°C, 2 minutes at 37°C and then 
2 minutes at 25°C before storage at -20°C.The annealed oligos were then ligated into 
the linearised pSiren-retroQ-ZsGreen vetor. The amount of vector and insert DNA was 
calculated using the following formula: 
 
((ng vector x insert size)/vector size) x molar ratio of insert to vector 
 
Ligation reactions were performed using 1:1 and 1:3 vector:insert ratios containing: 
50ng of vector, the appropriate amount of insert, 1 unit of T4 DNA ligase (Promega), 2x 
DNA ligase buffer in a 10µL reaction. Ligation reactions were incubated at room 
temperature for three hours. 
 
Transformation 
The plasmid DNA was transformed into the competent DH5α E. coli strain, which 
were thawed on ice. Approximately 15ng of the ligated DNA was mixed gently with 
100µL of bacteria then incubated on ice for 30 minutes. The mixture was then heated to 
hCBFβ5shRNA GATCCGCCGAGAGTATGTCGACTTATTCAAGAGATAAGTCGACATACTCTCGGTTTTTTACGCGTG 
hCBFβ6shRNA GATCCGCAATTAGGTGGTGGTGATTTCAAGAGAATCACCACCACCTAAATTGTTTTTTACGCGTG 
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42°C for 1 minute to heat shock the cells, before being place immediately on ice for a 
further 2 mintues. 500µL of Luria Bertani (LB) medium was added and incubated on an 
orbital shaker for 1 hour at 37°C and 220 rpm. The entire mixture was then plated onto 
selective LB plates containing 50µg/mL of ampicillin and incubated overnight at 37°C. 
 
DNA isolation and sequencing 
Several colonies were picked from the selective LB plates and the plasmid DNA was 
then purified using the Wizard Plus SV Miniprep DNA Purification System (Promega) 
according to the manufacturer’s instructions. The purified DNA was sent for sequencing 
at the ACRF facility at the Garvan Institute according to their recommendations and 
requirements. Once sequences were confirmed, Endo-free Maxipreps (Qiagen) were 
performed and plasmids were eventually used to generate MDA-MB-231 cells that 
stably expressed CBFβ shRNA. 
 
Cloning of CBFβ  overexpression retroviral vector 
A CBFβ human cDNA ORF clone was ordered from Origen (NM_022845) and the 
insert was excised form the pCMV6-Entry vector is arrived in through restriction 
enzyme digests using AsiS1 and Fse1. The CBFβ insert was then ligated (as per 
previous description) into the linearised pRetroX-IRES-DsRedExpress retroviral vector. 
A diagnostic digest was performed using the restriction enzyme PshA1 before the 
construct was sent for sequencing. Once the sequence was confirmed, this retroviral 
vector was used to generate Hs578T cells that stably overexpressed CBFβ. 
 
Histological Analysis 
Mammary gland whole mounts 
Mammary gland whole mounts were generated by spreading the gland over a 
charged glass slide and were fixed immediately in 10% NBF solution (Sigma) for a 
minimum of 4 hours or overnight. The glands were then defatted through three changes 
of acetone before carmine alum staining overnight (0.2% carmine, 0.5% aluminum 
sulfate). The whole mount was then dehydrated using a graded ethanol series and then 
treated with Histolene (Thermofisher) for 60 minutes and then stored in methyl 
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salicylate. Metamorph software was used to determine the extent of ductal elongation in 
whole mounted mammary glands. 
 
Haemotoxylin and eosin staining 
Five micron sections of mammary glands and lungs were incubated for 5 minutes in 
two changes of Histolene (Thermofisher). Sections were then rehydrated before a 2 
minute incubation in Harris Haemotoxylin (Thermofisher), washed with water, 
dehydrated and stained for 30 seconds in Eosin (Thermofisher). Sections were then 
incubated in 95% ethanol and two changes of 100% ethanol before two final changes of 
Histolene before coverslips were mounted.  
 
Immunohistochemistry 
IHC for CBFβ and Ki-67 was performed on 5µm sections of mammary gland that 
were de-waxed as per standard protocol before antigen retrieval using S1699 buffer 
(DAKO) in a 95°C water bath for 20 minutes. A 5% hydrogen peroxide (DAKO) in 
methanol solution was used as an enzyme block for both Ki-67 and CBFβ and an 
additional protein block (DAKO) was used in the CBFβ IHC only. Sections were 
incubated in primary antibodies (anti-Ki-67 (Rb) from Thermofisher (LBVRM-9106-S) 
and anti-CBFβ (Rb) from Abcam (ab133600)) at room temperature for 60 minutes and 
the Envision rabbit/mouse secondary (DAKO) for 30 minutes. Counterstaining and was 
performed according to standard protocol before coverslips were mounted. 
 
RNA Analysis 
RNA extraction 
TriZol reagent (Life Techonologies) was used, according to the manufacturer’s 
instructions, to extract RNA from the 4th mouse mammary glands that were frozen in 
liquid nitrogen and stored at -80°C prior to use. 
 
cDNA synthesis 
RNA samples were DNase treated using the RQ1 DNase kit (Promega) before cDNA 
synthesis was performed using Multiscribe reverse transcriptase (Life Technologies) 
according to the manufacturer’s instructions.  
 64 
 
 
 
Quantitative RT-PCR 
RT-qPCR was performed on the Rotogene 3000 (Roche) using TaqMan® probes 
(Applied Biosciences) and the TaqMan® Universal Master Mix (Life Technologies). 
Thermal cycling conditions include an initial UNG activation step for 2 minutes at 
50°C, followed by 10 minutes at 95°C, then 40 cycles at 95°C for 15 seconds with an 
annealing temperature of 60°C. The following probes were used: CBFβ 
(Hs00903431_g1), Runx2 (Hs00231692_m1), SatB1 (Hs00161515_m1), MMP9 
(Hs00957562_m1), MMP13 (Hs00233992_m1), BgLap1 (Hs01587814_g1), Pthlp 
(Hs00174969_m1), Rankl (Hs00243522_m1) and β-actin (Hs99999903_m1). 
 
Microarray Analysis 
RNA extraction for microarray analysis was performed using the RNeasy Mini Kit 
from Qiagen according to the manufacturer’s instructions. For each sample, 1 µg of 
RNA at a concentration of 50ng/µl was submitted for microarray analysis. The quality 
of the RNA was assessed on the Nanodrop and Aglient Bioanalyzer 2100. Probe 
labeling and hybridisation on to the Affymetrix GeneChip PrimeView Human Gene 
Expression Array was performed at the Ramaciotti Centre for Gene Function Analysis 
(UNSW, Australia). Microarrays were normalised using the RMA method of 
normalisation through the use of Garvan GenePattern NormalizeAffymetrix3prime 
(version 2.1). Hierarchical clustering was performed to validate the results using GENE-
E software (version 3.0.230, Broad Institute, Inc). Differentially expressed genes were 
detected using Garvan GenePattern LimmaGP (v20.0) using the positive false discovery 
rate (FDR) multiple hypothesis test correction. Gene set enrichment analysis (GSEA) 
was run in pre-ranked mode using Garvan GenePattern GSEApreranked module 
(version 3.2) and GSEA (version 2.0.13). The GSEA data was visualised using 
Cytoscape software (version 3.2.0). 
 
Protein Analysis 
Protein extraction 
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Protein was extracted from mouse mammary tissue using the TriZol reagent 
according to the manufacturer’s instructions, with the exception that the protein pellet 
was dissolved in 4M urea and 1% SDS.  Protein was extraction from cell lines using 
NET lysis buffer supplemented with protease inhibitor (Roche), 1mM sodium 
orthovanadate and 10mM sodium fluoride. The cell lysate was incubated at 4°C for 30 
minutes, centrifuged and then the supernatant was used for protein analysis. 
Quantification of protein was performed using the Bradford reagent (Bio-Rad) 
according to the manufacturer’s instructions. 
 
Western blotting 
Protein samples were denatured in laemmli sample buffer (Bio-Rad) supplemented 
with β-mercaptoethanol by heating to 95°C and then separated on 12% SDS-PAGE gels 
depending on the molecular weight of the protein being examined. Proteins were 
transferred on to PVDF membrane (Bio-Rad) and blocked for 2-3 hours at room 
temperature or overnight at 4°C in a solution containing 5% skim milk, 10mM Tris pH 
7.6, 150mM NaCl and 0.2% v/v Tween-20. Membranes were incubated in one of the 
following primary antibodies for 1-2 hours at room temperature or 4°C overnight: α-
CBFβ (Abcam), α-CBFβ (kindly provided by Ichiro Taniuchi, RIKEN, Japan), α-
Runx2 (Cell Signaling Technology), α-cytokeratin 18 (Sapphire Biosciences), α-Cre 
(Covance) or α-β-actin (Sigma). Membranes were washed a minimum of three times 
for 10-15 minutes between antibody incubations in TBS/Tween (10mM Tris pH 7.6, 
150mM NaCl, 0.2% v/v Tween-20). Specific binding was detected using Horseradish 
Peroxidase conjugated secondary antibodies (VWR) and Western Clarity 
chemiluminescence reagent (Bio-Rad) using the Bio-Rad ChemiDoc instrument. 
 
Statistical Analysis 
All statistical analysis was performed using GraphPad Prism 5 software. 
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3. A novel role for CBFβ  in mammary gland development 
Introduction 
Regulatory genes and hormones such as estrogen, progesterone, ERBB2, WNT and 
Notch have been implicated in the developmental processes of the mammary gland. It is 
these key players that then act on a smaller sub-set of transcription factors, which in 
turn regulate cell fate decisions such as whether or not a cell undergoes proliferation, 
differentiation or apoptosis (Hennighausen & Robinson, 2005). Investigation into the 
role of these factors that regulate mammary gland cell fate has been fundamental in 
increasing our current understanding of the processes that control the development of 
this complex organ and by extension, the implications of their dysregulation in regards 
to breast cancer. 
The mammary gland is an incredibly dynamic organ that undergoes dramatic cyclical 
changes under the influence of female hormones (Hennighausen & Robinson, 2005). 
Several transcription factors, including Gata3, Elf5, Stat5A, ER and PR have been 
identified as essential regulators of mammary gland development and their roles have 
been studied in detail (Kouros-Mehr et al., 2006; Kouros‐Mehr & Werb, 2006; Naylor 
& Ormandy, 2007; Oakes, 2008b; Siegel & Muller, 2010). Given the complexity of this 
developmental system, much of which is yet to be fully understood, it is clear that there 
may be more transcription factors involved. 
The Runx family of transcription factors have become an increasingly intriguing 
point of interest due to their critical involvement in both developmental processes and 
disease progression. The Runx genes are well known as essential regulators of cell fate, 
with lineage and stage specific roles. The importance of Runx2 in the regulation of cell-
fate and lineage-maintenance of non-osseous tissue has been highlighted by recent 
studies, particularly its potential role in mammary gland development (Blyth et al., 
2005; Ferrari et al., 2013; McDonald et al., 2014; Owens et al., 2014; Shore, 2005).  
Our lab recently demonstrated that Runx2 is expressed in the mammary ductal 
epithelium and that expression is differentially regulated throughout mammopoiesis 
(Owens et al., 2014). Furthermore, we have shown that Runx2 controls lobuloalveolar 
development in vivo through regulation of luminal progenitors during alveolar 
development (Owens et al., 2014). Another recent study reports that overexpression of 
Runx2 also results in perturbed lobuloalveolar development (McDonald et al., 2014). 
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This is an intriguing conundrum and indicates that further work is required to determine 
the mechanism of Runx2 function in the mammary gland. 
Whilst the Runx genes are critical for the regulation of cell fate and essential for 
normal development, they require a binding partner in order to carry out transcriptional 
regulation. All members of the Runx family form heterodimeric complexes with the 
same non-DNA binding transcriptional co-activator, core-binding factor β (CBFβ) (Ito, 
2008). The binding of CBFβ to the Runx genes causes a structural change that increases 
the DNA-binding affinity of the entire complex (Tahirov et al., 2001; Zhang et al., 
2003). It is this combined CBF complex that can bind co-factors capable of both 
activating and repressing transcription of key regulators of growth, survival and 
differentiation pathways (Tanaka et al., 1995).  
It has been shown in other developmental systems such as osteogenesis and 
haematopoiesis that CBFβ is essential for the regulation of stem cell differentiation and 
proliferation (Kurosaka et al., 2011). Furthermore, there is now evidence that CBFβ is 
able to boost the transcriptional effectiveness of the Runx genes and their downstream 
targets by both enhancing their DNA-binding efficiency and structural stability, 
allowing for successful regulation of cell fate in multiple systems (Davis et al., 2010; 
Qin et al., 2014; Yoshida, 2002).  
Given the novel role recently discovered for Runx2 in the mammary gland and the 
knowledge that CBFβ is able to enhance Runx2 function and DNA-binding affinity, 
possibly through stem cell control, there is a strong indication that CBFβ may be 
essential to the developing mammary gland and potentially in its own right.  
 The aim of this chapter was to examine, for the first time, the potential role of CBFβ 
in mammary gland development.   
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Results 
CBFβ  is developmentally regulated in the mammary gland 
Several studies have demonstrated that whilst there is a close relationship between 
the Runx genes and CBFβ, their functions are not always mutually exclusive, 
(Mendoza-Villanueva et al., 2011; Okuda et al., 1996; Wang et al., 1996). We have 
previously shown that Runx2 is differentially regulated throughout mammary gland 
development at both the protein and mRNA levels, and plays an essential role in the 
regulation of mammopoiesis (Owens et al., 2014). This study aimed to explore whether 
CBFβ expression was also differentially regulated throughout mammary gland 
development and whether CBFβ was required for normal mammary gland development 
and epithelial cell function.  
To investigate the potential role of CBFβ during mammopoiesis, expression levels of 
CBFβ were measured throughout all stages of development. Analysis of mRNA from 
the mouse mammary gland showed that CBFβ expression levels decreased in late 
pregnancy through to early lactation, before increasing again during involution as the 
glands returns to a virgin-like state (Fig.3.1.A). This expression pattern mirrors that of 
Runx2 and is a strong indication that CBFβ is involved in mammary gland 
development. 
 
CBFβ  expression is restricted to the mammary epithelial cells 
It has been shown that Runx2 is expressed in the basal or myoepithelial cell sub-
populations in the mammary gland where the mammary stem cells are thought to reside 
(Kendrick et al., 2008). This is a further indication that Runx2 plays a critical role in the 
mammary gland, perhaps at the stem cell level. Since we have now shown that CBFβ is 
also developmentally regulated in the mammary gland in conjunction with Runx2, we 
performed IHC for CBFβ and have shown that CBFβ expression in the mammary gland 
is also restricted to the luminal and myoepithelial cells of the mammary epithelium (Fig. 
3.1.B).  
This data therefore provides further evidence that CBFβ is involved in mammary 
gland development and that it may potentially be involved in regulation of stem cell 
populations, similar to its function in haematopoiesis and skeletal development 
(Kurosaka et al., 2011).   
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Fig. 3.1.  CBFβ  is expressed in mammary epithelial cells and is developmentally regulated 
during mammopoiesis.  
CBFβ expression in the mammary gland is exclusively found in the luminal and myoepithelial cells 
layers of the epithelial ductal network. Furthermore CBFβ is developmentally regulated throughout 
mammary gland development, whereby expression levels are decreased in late pregnancy through to early 
lactation. A) mRNA expression of CBFβ across a mammary gland development series relative to the 
virgin gland and normalised to β-actin as shown by RT-qPCR (P = pregnancy, L = lactation, I = 
involution). Error bars represent SEM (N=3). B) Immunohistochemistry staining showing exclusive 
localisation of CBFβ to the epithelium of the virgin mammary gland.  
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CBFβ  expression is required in the early stages of mammary gland development for 
successful outgrowth of the ductal epithelium 
Given that CBFβ is differentially regulated throughout mammopoiesis and 
expression is confined to the mammary epithelium, we next sought to investigate the 
potential role of CBFβ in mammary gland development. In order to achieve this, we 
generated a CBFβ knockout mouse by crossing CBFβ floxed (CBFβf/f) mice (Naoe et 
al., 2007) with CreERT2tg/+ mice (Ruzankina et al., 2007) resulting in 
CBFβf/+;CreERT2tg/+. These mice were then backcrossed to CBFβf/f mice to produce 
either CBFβf/fCreER+/+ or CBFβf/fCreERtg/+ mice. Crossing the CBFβf/f mice with the 
CreERT2tg/+ mice resulted in an inducible model where Cre expression is activated in 
the presence of Tamoxifen, resulting in the subsequent deletion of CBFβ ubiquitously 
throughout the mouse.  
In order to investigate the temporal and spatial effects of CBFβ in the developing 
mammary gland, mammary epithelium from CBFβf/fCreER+/+ and CBFβf/fCreERtg/+ 
mice was transplanted into the opposite inguinal fat-pads, cleared of endogenous 
epithelium, of 3-week-old immunocompromised Rag1-/- mice. Mammary 
transplantation enables reconstitution of a mammary gland with epithelium derived 
from the donor gland which interacts with the host stroma as the ductal network extends 
throughout the recipient fat pad (De Ome, 1959). These mice were subsequently 
injected with Tamoxifen four days post transplant for three consecutive days to activate 
Cre-mediated deletion of CBFβ from the epithelium of the transplanted mammary 
glands.  
Mice were sacrificed six weeks post transplantation surgery and the transplanted 
glands were harvested and whole mounted for carmine staining and histological 
analysis. In order to confirm that mammopoiesis progressed normally in the Rag1-/- 
recipient mice, an endogenous 3rd mammary was also collected as a control.  
At six weeks post transplant, CBFβf/fCreERtg/+ glands showed a significant reduction 
in the development of the ductal tree when compared to the CBFβf/fCreER+/+ gland 
from the same mouse (Fig. 3.2. A). The majority of CBFβf/fCreERtg/+ glands showed a 
50% reduction in epithelial ductal outgrowth compared to the CBFβf/fCreER+/+glands, 
as shown by image analysis using Metamorph software (Fig. 3.2. B). 
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This result clearly demonstrates that deletion of CBFβ at the onset of post-natal 
mammary gland development leads to a marked reduction in the successful outgrowth 
of the ductal network. This in vivo data has demonstrated for the time that CBFβ plays a 
critical role in mammary gland development.  
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Fig. 3.2.  Spatial and temporal deletion of CBFβ  in the mammary gland leads to reduced 
ductal elongation in virgin mice. 
Deletion of CBFβ expression in the mammary gland leads to a reduction in outgrowth of the ductal tree 
through the fat pad. A) Representative whole mount images of virgin mammary glands 6 weeks post 
transplant showing delayed ductal elongation in the CBFβf/fCreERtg/+ glands when compared to the 
CBFβf/fCreER+/+ glands (N=6). These mice were injected with Tamoxifen 4 days post transplant in order 
to activate Cre-induced deletion of CBFβ in the mammary gland. B) Representative images of the binary 
mask generated in order to analysis ductal extension in CBFβf/fCreERtg/+ and CBFβf/fCreER+/+ glands. C) 
Histograms quantifying the percentage of the fat pad that is filled with ductal epithelium in the 
CBFβf/fCreERtg/+ glands compared to the CBFβf/fCreER+/+ glands in five individual animals.   
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Characterisation of CBFβ  deletion in the CBFβcreER mouse model 
Our novel mouse model of mammary-specific CBFβ deletion has shown an 
undisputable role for CBFβ in this mammary gland development. In order to confirm 
that the phenotype observed was due to a lack of CBFβ in the mammary gland, western 
blotting for CBFβ was performed on protein from the transplanted CBFβf/fCreERtg/+ and 
CBFβf/fCreER+/+ glands. Western blot analysis for CBFβ showed a clear deletion of 
CBFβ in the CBFβf/fCreERtg/+ glands compared to the CBFβf/fCreER+/+ glands (Fig. 3.3. 
A).  
 
CBFβ  is required for the proliferation of mammary epithelial cells during ductal 
elongation 
CBFβ has been shown to regulate both skeletal and haematopoietic development 
through the regulation of both stem cell proliferation and differentiation (Kurosaka et 
al., 2011).  
The virgin gland undergoes high levels of proliferation during the process of ductal 
extension (Hennighausen & Robinson, 2005), which corresponds to the stage of 
mammary gland development where we observe a defect in the CBFβf/fCreERtg/+ 
glands. In order to examine whether this phenotype was due to a defect in proliferation, 
we stained 6-week-old CBFβf/fCreERtg/+ and CBFβf/fCreER+/+ transplanted mammary 
glands for Ki-67, a marker of cell proliferation and quantified the percentage of Ki-67 
positive cells between the two genotypes.  
There are significantly less Ki-67 positive cells in the CBFβf/fCreERtg/+ glands 
compared to the CBFβf/fCreER+/+ glands as seen in Figure 3.3.B. Quantification of cell 
counts confirmed a marked decrease Ki-67 staining in the CBFβf/fCreERtg/+ glands (p = 
0.003) with a total of 53.5% (± 4.8) Ki67 positive cells in the CBFβf/fCreER+/+ glands 
and only 18.9% (± 5.1) Ki67 positive cells in the CBFβf/fCreERtg/+ glands (Fig. 3.3.C).  
This data demonstrates a novel role for CBFβ in the regulation of mammary 
epithelial cell proliferation during ductal elongation. 
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Fig. 3.3.  CBFβ  regulates mammary epithelial cell proliferation during ductal elongation 
CBFβ deletion leads to a decrease proliferation of mammary epithelial cells during ductal elongation. A) 
Western blot for CBFβ confirming CBFβ knockout in the CBFβf/fCreERtg/+ glands compared to the 
CBFβf/fCreER+/+glands, loaded to the epithelial marker cytokeratin 18. B) IHC staining showing a 
reduction in the proliferative marker Ki-67 in the CBFβf/fCreERtg/+ glands compared to the 
CBFβf/fCreER+/+ 6-week-old transplanted glands (N=6). C) Histogram quantitating a significant increase 
in Ki-67 positive cells in CBFβf/fCreERtg/+ compared to the CBFβf/fCreER+/+ 6-week-old transplanted 
glands (p = 0.003, students unpaired t-test). Error bars represent SEM.  
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Ductal elongation is not affected in 14-week-old CBFβ f/fCreERtg/+ mammary glands  
In order to determine if the stunted ductal outgrowth observed in the 6-week-old 
CBFβf/fCreERtg/+ transplanted glands was due to a delay in epithelial outgrowth or if 
proliferation was being completely blocked, transplanted glands were left to develop for 
a further 8 weeks.  
Mammary glands collected 14 weeks post transplant and showed no difference 
between the CBFβf/fCreERtg/+ and CBFβf/fCreERtg/+ glands in regards to ductal 
elongation and outgrowth, as seen in the whole mount images in Figure 3.4. This result 
indicates that deletion of CBFβ results in a delay in ductal extension of the mammary 
epithelium but does not lead to a permanent arrest.  
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Fig. 3.4.  14-week-old CBFβ f/fCreERtg/+ mammary glands show no delay in ductal 
elongation. 
Representative whole mount images of virgin CBFβf/fCreERtg/+ mammary glands 14 weeks post 
transplant showing a recovery in ductal outgrowth (N=10). These mice were injected with Tamoxifen 4 
days post transplant in order to activate Cre-mediated deletion of CBFβ in the mammary gland.   
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CBFβ  deletion does not perturb lobuloalveolar development in CBFβ f/fCreERtg/+ 
mice 
We have now shown that CBFβ plays a critical role in the early development of the 
mammary gland, a phenotype that is recovered as the gland reaches maturity. We have 
determined that this is due to a reduction in the number of proliferating mammary 
epithelial cells in the CBFβf/fCreERtg/+ glands, leading to a significant delay in the 
elongation of the ductal network.  
The second important aspect of cell fate that CBFβ is known to regulate in other 
developmental systems is differentiation (Kurosaka et al., 2011). The highest levels of 
differentiation occur in the mammary gland during pregnancy, when lobuloalveolar 
development occurs and the functional alveoli are formed (Hennighausen & Robinson, 
2005).   
In order to investigate whether CBFβ plays a role in the regulation of differentiation 
in the mammary gland, we examined CBFβf/fCreERtg/+ transplanted glands at both mid 
and late pregnancy time points. Mammary glands were harvested at both 12 and 18 days 
post coitus (d.p.c). Whole mount analysis showed that neither alveolar bud formation or 
lobuloalveolar development was affected in the CBFβf/fCreERtg/+ glands compared with 
CBFβf/fCreER+/+ glands (Fig. 3.5). This data indicates that CBFβ is an important 
regulator of proliferation but not differentiation in the developing mammary gland.  
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Fig. 3.5.  CBFβ  does not regulate alveolar bud formation or lobuloalveolar development in 
CBFβ f/fCreERtg/+mice. 
Whole mount images of CBFβf/fCreERtg/+ and CBFβf/fCreER+/+mammary glands at mid and late 
pregnancy showing a recovery of the phenotype seen in the 6-week-virgin glands on no defects in 
alveolar bud formation or lobuloalveolar development.   
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CBFβ  does not regulate virgin development in CBFβ f/fBLGCretg/+ mice 
In order to further investigate the role of CBFβ in mammopoiesis we generated a 
second CBFβ knockout mouse model by crossing the CBFβf/f mouse (Naoe et al., 2007) 
on to a BLG-Cretg/+ mouse (Selbert & Bentley, 1998). The resulting CBFβf/+;BLG-
Cretg/+ mice were then backcrossed on to the CBFβf/f mice to generate both 
CBFβf/fBLGCretg/+ and CBFβf/fBLGCre+/+ mice. Crossing the CBFβf/f mice with the 
BLGCretg/+ mice resulted in a mammary epithelium-specific, constitutive CBFβ 
knockout model where Cre-mediated deletion of CBFβ is driven off the beta 
lactoglobulin (BLG) promoter, which is expressed mostly highly during pregnancy and 
lactation.  
To further examine the effects of CBFβ deletion on virgin development, 
CBFβf/fBLGCretg/+ and CBFβf/fBLGCre+/+ mammary glands were collected at 5, 7 and 9 
weeks of age, representing pre-pubescent, pubescent and mature virgin glands 
respectively.  
Whole mount analysis of the glands at each time point showed no differences in the 
ductal outgrowth, terminal end bud formation or side branching of the ductal network in 
either the CBFβf/fBLGCretg/+ or CBFβf/fBLGCre+/+ mice (Fig 3.6).  
This data indicates that CBFβ is not required to regulate virgin mammary 
development and morphogenesis in CBFβf/fBLGCretg/+ mice.  
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Fig. 3.6.  Late onset CBFβ  deletion does not affect development of the virgin mammary 
gland. 
Images of whole mounted images virgin mammary glands from CBFβBLG mice showing no change in 
morphology at 5, 7 and 9 weeks of age (N=3 for CBFβf/fBLGCre+/+ and CBFβf/fBLGCretg/+ at each time 
point).   
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CBFβ  is not required for lobuloalveolar development or alveologenesis  
To examine whether CBFβ deletion in CBFβf/fBLGCretg/+ mice affected 
development during pregnancy, we harvested glands from CBFβf/fBLGCretg/+ and 
CBFβf/fBLGCre+/+ mice at the key developmental stages of mid pregnancy and early 
lactation, where CBFβ is deleted in the majority of mammary epithelial cells in this 
model (Selbert & Bentley, 1998). 
Whole mount analysis of CBFβf/fBLGCretg/+ and CBFβf/fBLGCre+/+ mammary 
glands at day 12 d.p.c and at the first day of lactation show no difference in morphology 
(Fig. 3.7.A). As per the virgin CBFβf/fBLGCretg/+ mice, ductal elongation and side 
branching also remains unchanged under BLGCre-mediated deletion of CBFβ. In 
addition, there is also no change in lobuloalveolar development during pregnancy or 
alveoli formation in the lactating glands.  
This data indicates that CBFβ is not required for regulating differentiation during 
pregnancy and lactation. 
 
Characterisation of CBFβ  deletion in the CBFβBLG mouse model 
To confirm that CBFβ was deleted in the CBFβf/fBLGCretg/+ mice, mammary glands 
were collected for protein expression analysis by western blotting. There was clearly a 
significant reduction of CBFβ protein expression in the CBFβf/fBLGCretg/+ glands when 
compared to the glands from CBFβf/fBLGCre+/+ mice, as shown in Figure 3.7.B. 
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Fig. 3.7.  Constitutive CBFβ  deletion does not effect development of the pregnant 
mammary gland. 
A) Whole mount analysis of CBFβf/fBLGCretg/+ mammary glands at key stages of pregnancy shows no 
change in morphology between the CBFβf/fBLGCretg/+ and CBFβf/fBLGCre+/+ glands (N=3 for each 
genotype). B) Analysis of CBFβ protein levels, normalised to cytokeratin 18, confirming CBFβ knockout 
in the CBFβf/fBLGCretg/+ mouse line (p = 0.01, student’s unpaired t-test).    
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Discussion 
The mammary gland is a complex and dynamic organ that undergoes cyclical rounds 
of proliferation and differentiation under the influence of female hormones 
(Hennighausen & Robinson, 2001), making it an excellent system in which to study 
regulators of cell fate. There are a number of elements of mammary gland development 
that are well understood, such as placode development and placement in the embryonic 
mammary gland or the signals required to induce lactation. There are however, many 
aspects of virgin development and development during pregnancy that are yet to be 
fully elucidated.  
It is well understood that, as part of the CBF complex, CBFβ is crucial for the 
regulation of cell fate in haematopoiesis and skeletal development (Coffman, 2003; 
Huang et al., 1999; Nagata et al., 1999). This however, is the first study to show a role 
for the CBFβ in the mammary gland. Given the importance of the binding process of 
CBFβ to the Runx genes, we hypothesised that this role for CBFβ would be in either a 
dependent or supportive context.  
We observed that CBFβ expression levels follow the same differentially regulated 
pattern as Runx2 throughout mammary developmental which is intriguing as it has been 
shown in other systems that expression of the Runx genes is tissue-specific whilst CBFβ 
is more ubiquitously expressed (Adya et al., 2000; Hajra & Collins, 1995; Ogawa et al., 
1993a; Wang et al., 1993). Therefore, it was exciting to see that CBFβ levels are 
differentially expressed in the mammary gland in conjunction with Runx2 even though 
unpublished data from our lab shows that Runx and Runx3 levels stay consistent. This 
is a clear indication that CBFβ is plays a key role in this developmental process.  
The decrease in CBFβ expression in the mammary gland during pregnancy was not 
as dramatic as the observed decrease in Runx2 expression (unpublished data), which 
may provide an explanation for the apparent lack of lobuloalveolar defect in both the 
CBFβf/fCreERtg/+ and the CBFβf/fBLGCretg/+ mammary glands during pregnancy and 
lactation. Rather we observe a proliferative defect in the pubertal CBFβf/fCreERtg/+ 
glands at a time point where expression levels of CBFβ are constitutively higher in 
wildtype mammary glands.  
Whilst our lab has not examined the effects of Runx2 deletion at the onset of 
mammary gland development, there appears to be no discernable effect on Runx2 
deletion in virgin mammary glands, rather major defects during lobuloalveolar 
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development (Owens et al., 2014). Runx2 deletion may not affect the onset of 
mammary gland development because CBFβ expression would remain unchanged and 
therefore it would still act to stabilise Runx1 and Runx3 proteins in the same way it has 
been shown to stabilise Runx2 during skeletal development (Qin et al., 2014; Yoshida, 
2002). This would lead to a protective effect and would allow Runx1 and 3 to 
compensate for Runx2 function, resulting in normal virgin development. Alternatively, 
Runx1 or Runx3 may be regulating early mammary gland development, which would 
also explain the phenotypic differences observed between the Runx2 and CBFβ 
knockout mouse models. This hypothesis could be tested via generation of Runx1 and 
Runx3 mammary-specific mouse models. 
The evidence our lab has produced demonstrating a novel role for Runx2 in the 
mammary gland has formed the basis for this thesis. This study has shown a crucial role 
for Runx2 in lobuloalveolar development during pregnancy through regulation of the 
luminal stem cell populations (Owens et al., 2014). 
Interestingly, a separate study has shown a similar lobuloalveolar defect through the 
use of a Runx2 transgenic mouse rather than a knockout model (McDonald et al., 2014). 
As described by the authors, the levels of Runx2 are expressed at supraphysiological 
levels in the transgenic mouse (McDonald et al., 2014) and as such, the validity of these 
results may be compromised. This Runx2 overexpression study also shows a delay in 
ductal elongation in the developing virgin gland (McDonald et al., 2014) and whilst our 
lab did not examine earlier time points in the Runx2 knockout mouse, the delayed 
ductal extension observed in the CBFβf/fCreERtg/+ glands is clear. Traditionally, the 
roles of genes and transcription factors involved in mammary gland development have 
been described through targeted deletion in vivo (reviewed in (Robinson, 2004; 
Visvader & Lindeman, 2003)). This is the approach used by our group in both the 
Runx2 and CBFβ studies as it allows greater control over temporal and spatial 
expression levels than the transgenic model used by McDonald and colleagues 
(McDonald et al., 2014). However, the discrepancies observed, particularly in regards to 
Runx2 function, indicate that further investigation is required to discern the mechanism 
by which the CBF complex regulates mammary cell fate. 
Both Runx2 studies do demonstrate that the decreased levels of Runx2 observed 
throughout normal mammary gland development indicates that Runx2 down regulation 
is required in order to induce differentiation (McDonald et al., 2014; Owens et al., 
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2014). It has been shown that forcing Runx2 expression at this time (both in vivo and in 
vitro) leads to poorly differentiated lobuloalveolar structures (McDonald et al., 2014) 
and results in HC11 cells that are no longer able to differentiate and produce milk 
proteins (Owens et al., 2014). These studies show that the overexpression of Runx2 
leads to changes in the mammary epithelium that are consistent with tumourigenesis, an 
area that will be discussed in the following chapters. It is therefore clear that Runx2 is 
essential for the control cell fate decisions in the mammary gland. 
Whilst there is virtually no previous data describing a role for CBFβ in the 
developing mammary gland, there have been suggestions by studies investigating breast 
cancer, that CBFβ is not just playing a supportive role to Runx2 but may have 
independent functions as well (Mendoza-Villanueva et al., 2010). The stark difference 
in the phenotypes observed in CBFβ-/- and Runx2-/- mammary glands supports this 
hypothesis. 
Previous studies in other developmental models such as haematopoiesis and skeletal 
development indicate that CBFβ is an important regulatory element in a range of 
developmental processes (Qin et al., 2014; Tanaka et al., 1995; Yoshida, 2002).  The 
common hypothesis formed from these studies is that CBFβ is controlling the function 
of Runx proteins through regulating the proliferation and differentiation of stem cell 
populations (Kurosaka et al., 2011). This thesis, for the first time, has detected CBFβ 
expression in the mammary gland and shows that it is expressed in both the luminal and 
also in myoepithelial cells of the mammary gland, which is where is Runx2 is expressed 
and also where mammary stem cells are derived from (Kendrick et al., 2008; Molyneux 
et al., 2010; Owens et al., 2014; Rios et al., 2014). This supports the hypothesis that 
CBFβ may be involved in the control of mammary stem cell populations.  
The in vivo data from this chapter demonstrates a significant delay in ductal 
elongation of the developing mammary gland due to decreased numbers of proliferating 
mammary epithelial cells in CBFβf/fCreERtg/+ mammary glands. This defect however, is 
only observed in virgin mice when CBFβ is deleted from the onset of post-natal 
mammary gland development. In this model, CreERT2-mediated deletion of CBFβ 
targets all cells, including stem and progenitor cells. In contrast in BLG mice CBFβ 
deletion is restricted to more differentiated luminal populations.  
Given the phenotypes observed in these in vivo models of CBFβ deletion, our data 
indicates a potential and novel role for CBFβ as a potential regulator of mammary 
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progenitor/stem cell populations. This is a hypothesis supported by previous published 
data describing roles for both CBFβ and the Runx genes in stem cell regulation in other 
developmental systems (Kurosaka et al., 2011).  
In order to confirm the effects of CBFβ on the proliferative capacity of mammary 
gland stem cells, it would be interesting to perform additional mammary transplants 
using the CBFβf/fCreERtg/+ mice and then use flow cytometry analysis on total cell 
populations to see if there is a shift in progenitor populations in the CBFβf/fCreERtg/+ 
glands compared to the CBFβf/fCreER+/+ glands.  
In regards to the effects of CBFβ deletion on mammary gland during pregnancy, no 
effect was seen in either CBFβ-/- mouse model. There was no difference in the ability of 
the ductal tree to undergo successful lobuloalveolar development during pregnancy or 
alveoli formation during lactation. This indicates that CBFβ is not required for 
regulating differentiation in the mammary gland during pregnancy or lactation.  
This is the first study to show that CBFβ is both present and essential for the 
development of the mammary gland and highlights a novel and exciting role for this 
transcription factor. 
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4. CBFβ  plays an important regulatory role in breast cancer cells and 
can drive metastatic phenotypes such as proliferation and migration 
Introduction 
Our lab has now shown that Runx2 plays a definitive role in lobuloalveolar 
development via regulation of luminal progenitor cells populations (Owens et al., 2014). 
Data from this thesis has also determined that CBFβ also plays a role in mammary 
gland development, through regulating the proliferation of mammary epithelial cells 
during ductal elongation. The importance of this novel role for CBFβ in mammary 
gland development is the potential implication for CBFβ in breast cancer. It is a well-
understood paradigm that regulatory genes and transcription factors that are involved in 
development and cell fate regulation are often perturbed in cancer. 
Most genes that are implicated in cancer can be easily defined as either oncogenes or 
tumour suppressors however, this is not the case for the Runx genes and CBFβ, which 
have been shown to function as either in a context-dependent manner (Blyth et al., 
2005). Runx2 is found to be amplified in several cancers, especially osteosarcoma, and 
therefore is primarily considered to be an oncogene (Forus et al., 1995; Lau et al., 
2004). When Runx2 is overexpressed in endothelial cells and osteoblasts it leads to 
enhanced cell migration, survival, invasion and angiogenesis, all of which are indicative 
of oncogenic transformation (Fujita et al., 2004; Sun et al., 2001; Sun et al., 2004; 
Zelzer et al., 2001).  
Our lab has now shown that overexpressing Runx2 in the MCF10a normal breast 
cells leads to induction of epithelial to mesenchymal transition (EMT), characterised by 
increased expression of N-Cadherin and Cyclin D1, loss of E-Cadherin expression and a 
distinct shift in the morphology of the cell from a cobblestone epithelial shape to a more 
fibroblastic shape consistent with breast cancer cells. Similarly, forced expression of 
Runx2 in the HC11 mouse mammary epithelial cells leads to an increase in both the 
proliferative and migrational capacity of the cells, classic hallmarks of cancer (Owens et 
al., 2014). We and others have also shown that reducing Runx2 expression in the 
aggressive MDA-MB-231 cells breast cancer cell line leads to decreased migration and 
invasion (Mendoza-Villanueva et al., 2010; Mendoza-Villanueva et al., 2011; Owens et 
al., 2014). This collective data demonstrates a novel for Runx2 as a regulator of breast 
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cancer cell fate and also highlights that there are many aspects of breast cancer that 
require further investigation. 
The focus of this thesis is to determine whether CBFβ also plays a role in breast 
cancer, although to date there has been very little data suggesting a causal relationship 
between the two. As part of their research into the role of Runx2 in breast cancer 
metastasis, Mendoza-Villanueva et al found that CBFβ was expressed in the aggressive 
MDA-MB-231 and found evidence to suggest a potential role for CBFβ in the invasive 
potential of these cells (Mendoza-Villanueva et al., 2010). This study indicates that 
CBFβ may be involved in breast cancer but further investigation is clearly needed. 
Recent whole genome/exon signaling sequencing, aiming to find genetic alterations, 
has recently found that only 5 genes were found to be commonly mutated; GATA3, 
PIK3CA, MAP3KI, TP53 and CBFβ. The first four genes are known key players in 
breast cancer, however as previously stated, there has been very little data associating 
CBFβ with breast cancer these studies present an enticing new link (Banerji et al., 2012; 
CGAN, 2012; Ellis et al., 2012). In addition, CBFβ was identified as one of the most 
frequently mutated genes, being mutated in approximately 5% of all luminal breast 
cancers (CGAN, 2012). This data suggests that CBFβ may play a critical role in breast 
cancer and further investigation is needed in order to elucidate this potential new 
function.  
The aim of this chapter therefore, is to explore the role of CBFβ in human breast 
cancer in the context of an in vitro model.  
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Results 
CBFβ  is expressed across all sub-types of human breast cancer 
Until recently, very little has been known about the role of CBFβ in the context of 
breast cancer, as such we examined the expression levels of CBFβ across a panel of 
human breast cancer cell lines in order to determine whether CBFβ expression 
correlated with a particular subtype. This panel included multiple cell lines from each of 
the following breast cancer subtypes; Luminal, Basal A, Basal B and also cell lines that 
represented a normal breast cell population.  
The mRNA expression analysis shows that CBFβ expression does not distinctly 
associate with a particular breast cancer (Fig. 4.1.A). Similarly, CBFβ expression also 
does not increase with invasiveness or correlate with estrogen receptor status as shown 
in Figures 4.1.B and C respectively. 
Our lab has previously shown that Runx2, unlike its binding partner CBFβ, has 
distinct expression patterns in relation to subtype and estrogen receptor status (Fig. 
4.1.D). Runx2 levels are higher in the more aggressive basal A and B subtypes lower in 
the luminal cancers that are associated with better prognosis. Runx2 levels also increase 
with invasiveness and are higher in cell lines that are estrogen receptor negative. This 
indicates that CBFβ is it always present but potentially only directly affected when 
Runx2 is activated.  
In addition to performing CBFβ expression analysis in breast cancer cell lines, we 
have also shown through immunohistochemistry that CBFβ is expressed in a range of 
human breast tumours (Fig. 4.1.E). The data is the first evidence of CBFβ expression in 
the human breast and is a clear indication that CBFβ may be playing an important role 
in breast cancer. 
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Fig. 4.1.  Expression of CBFβ in human breast cancer cell lines 
A) mRNA expression of CBFβ, relative to MCF10a cells and normalised to GAPDH,  across a panel of 
human breast cancer cell lines as shown by RT-qPCR. Error bars represent SEM (N=3). B) mRNA 
analysis shows that CBFβ expression does not correlate with invasiveness. C) mRNA analysis shows that 
CBFβ expression does not correlate with estrogen receptor status. D) mRNA analysis shows that Runx2 
is significantly upregulated in the aggressive basal breast cancer subtype (p = 0.02, Student’s t-test) and 
that Runx2 expression also correlates with ER negative breast cancers using a panel of human breast 
cancer cell lines. E) Immunohistochemistry was used to show that CBFβ is expressed in a range human 
breast tumours from the Royal Brisbane & Women’s Hospital breast cancer cohort (Supplied by Peter 
Simpson).  
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CBFβ  regulates the expression of crucial downstream targets involved in cancer 
progression 
A previous study in human breast cancer cells showed that knocking down CBFβ 
expression in MDA-MB-231 cells lead to a subsequent reduction of several downstream 
targets of the Runx2-CBFβ complex (Mendoza-Villanueva et al., 2010). We have now 
shown that CBFβ is expressed across all breast cancer subtypes and that expression 
varies between individual cell lines.  
Based on this comparative analysis we selected two cell lines in which to study the 
function of CBFβ; one that has high levels of CBFβ expression and one that has low 
expression. We chose to focus on the highly metastatic MDA-MB-231 cells, which 
have high levels of both Runx2 and CBFβ and also another basal breast cancer cell line, 
Hs578T cells which have high Runx2 expression but low expression of CBFβ. 
CBFβ expression was transiently knocked down in the MDA-MB-231 cells using 
two individual siRNAs against CBFβ, achieving over 90% decrease in expression (p 
<0.0001 for both siRNAs) as shown by western blotting and RTqPCR (Fig. 4.2.A). 
Similarly, two siRNAs were used to knockdown the protein and mRNA levels of Runx2 
by 50% (p = 0.001, p <0.0001) (Fig. 4.2.B). Non-specific siRNAs were used as negative 
controls for both CBFβ and Runx2. 
Expression analysis of key downstream targets of the Runx2/CBFβ complex when 
the levels of either CBFβ or Runx2 were significantly down regulated was undertaken 
using RT-qPCR. The genes examined were MMP9, MMP13, RankL, SatB1, BgLap1 
and PTHrP. This cohort includes gene that are involved in the maintenance and 
development of the mammary gland (PTHrP); genes that control bone metabolism and 
homeostasis (SatB1 and BgLap1); and also genes that contribute to breast cancer 
growth and disease progression (MMP9, MMP13 and SatB1) (Duffy et al., 2000; Pratap 
et al., 2005; Pratap, 2006 ; Shore, 2005).  
Knocking down the expression of CBFβ or Runx2 in MDA-MB-231s reduces the 
expression of these keys target genes, however Runx2 levels are unaffected when CBFβ 
is knocked down and the same is true for CBFβ expression levels when Runx2 is 
knocked down (Figure 4.2.C). Mendoza-Villanueva and colleagues have also observed 
this pattern of expression (Mendoza-Villanueva et al., 2010) and it indicates that any 
downstream effects are not due to a reduction in expression of the entire Runx2/CBFβ 
 95 
complex but that these co-transcription factors also have critical an individual roles in 
breast cancer.  
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Fig. 4.2.  Deletion of CBFβ in MDA-MD-231 breast cancer cells by siRNA results in down 
regulation of key downstream targets 
A) Western blot and RT-qPCR showing a 90% knockdown of CBFβ protein and mRNA levels in MDA-
MB-231 cells transfected with CBFβ siRNA (CBFβ5 & CBFβ6 p <0.0001, Student’s unpaired t-test). 
Error bars represent SEM. B) RT-qPCR showing a 50% knockdown of Runx2 protein and mRNA levels 
in MDA-MB-231 cells transfected with Runx2 siRNA (Runx2A p <0.0001; Runx2B p <0.0001, 
Student’s unpaired t-test). Error bars represent SEM. C) RT-qPCR data showing down regulation of key 
downstream targets of Runx2/CBFβ in MDA-MB-231 cells as a result of CBFβ siRNA knockdown. 
Expression of BgLap1, MMP9 and MMP13 is significantly decreased (p <0.05, Student’s t-test) Error 
bars represent SEM.  
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Down regulation of CBFβ  reduces the metastatic potential of human breast cancer 
cells  
It has been shown that Runx2 regulates several genes that are implicated in the 
metastatic potential of breast cancer cells (Pratap et al., 2005; Pratap, 2006 ; Shore, 
2005) and whilst there is some evidence to suggest that CBFβ is potentially required for 
invasion of breast cancer cells (Mendoza-Villanueva et al., 2010), our aim is to further 
characterise the role for CBFβ in breast cancer cell fate.  
After validation, the CBFβ siRNA sequences were used to generate CBFβ shRNA 
constructs. MDA-MB-231 breast cancer cells were retrovirally infected with these 
constructs in order to generate three stable cohorts; two expressing different CBFβ 
shRNAs and one expressing a luciferase shRNA as a control. Validation of shRNA-
mediated knockdown of CBFβ in the MDA-MB-231 cells was shown through western 
blotting and RT-qPCR as seen in Figure 4.3.A and B respectively. 
In order to determine whether CBFβ is able to regulate the growth rate of breast 
cancer cells, the proliferation rate of these MDA-MB-231 cohorts was assessed using 
proliferation assays. The results of these assays showed that the two cell lines 
expressing the CBFβ shRNA underwent proliferation at a significantly slower rate than 
the cells expressing the non-specific luciferase as shown by the graph in Figure 4.3.C (p 
<0.001). 
Migration assays were performed using the xCelligence DP system to ascertain 
whether reducing CBFβ expression in MDA-MB-231 cells also affected the ability of 
the cells to migrate towards a chemoattractant. The data obtained showed, once again, 
that in the two cell lines containing CBFβ shRNA migration was significantly impaired 
compared to the luciferase shRNA control (p <0.01) (Fig. 4.4).  
The collective data from the proliferation and migration assays indicates a critical 
role for CBFβ as a regulator of breast cancer cell fate, not only complemented but also 
furthering previously described results from Mendoza-Villanueva and colleagues 
(Mendoza-Villanueva et al., 2010).  
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Fig. 4.3.  Down regulation of CBFβ in MDA-MB-231 breast cancer cells leads to a reduction 
in cell proliferative capacity  
A) Western blot showing successful knockdown of CBFβ via stable shRNA integration into MDA-MB-
231 cells. B) RT-qPCR results showing knock down of CBFβ mRNA levels in MDA-MB-231 cell (N=3, 
p = 0.032, Student’s unpaired t-test). Error bars represent SEM. C) Results from proliferation assays 
using MDA-MB-231 cells stably expressing CBFβ shRNA showing significantly decreased proliferation 
with a non-specific shRNA used as a control. A two-way ANOVA of N=3 assays resulted in the 
following: Time: F (8,162.5) = 83.48, p < 0.0001; Treatment: F (2,32.51) = 7.57, p = 0.0006; Interaction: 
F (16, 51.05) = 5.24, p < 0.0001. Error bars represent SEM.  
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Fig. 4.4.  Down regulation of CBFβ in MDA-MB-231 breast cancer cells leads to a reduction 
in cell migratory capacity  
Results from migration assays using MDA-MB-231 cells stably expressing CBFβ shRNA showing 
significantly decreased migration with a non-specific shRNA used as a control. A two-way ANOVA of 
N=3 assays resulted the following: Time: F (95, 127.6) = 61.08, p < 0.0001; Treatment: F (92, 10.53) = 
21.88, p < 0.01; Interaction: F (190, 8.293) = 7.94, p < 0.0001. Error bars represent SEM.  
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Overexpression of CBFβ  increases the metastatic potential of human breast cancer 
cells  
We have now shown that knocking down CBFβ expression in MDA-MB-231 cells 
leads to a significant decrease in the ability of these cells to proliferate and migrate. 
There is currently no published data documenting the effects of CBFβ overexpression 
on breast cancer cell fate. In order to investigate this, we developed a CBFβ 
overexpression construct and retrovirally infected Hs578T breast cancer cells, which 
has constitutively low levels of CBFβ. Hs578T cells expressing the vector-only 
construct were used as a control. The overexpression of CBFβ compared to the vector 
only in the Hs578T cells was confirmed by both western blot and RT-qPCR analysis 
(Figures 4.5.A and B respectively).  
In order to examine the effects of CBFβ overexpression on the growth rate of 
Hs578T cells, proliferation assays were performed using cells expressing either the 
CBFβ or vector-only construct. Overexpression of CBFβ led to an increase in the rate of 
proliferation when compared to the control cell line (p <0.05) (Fig. 4.5.C). 
Migration assays were performed using the xCelligence DP system to determine if 
overexpressing CBFβ in Hs78T cells had any affect on the ability of the cells to migrate 
towards a chemoattractant. The results of these experiments showed that there was a 
substantial increase in the ability of the Hs578T cells overexpressing CBFβ to migrate 
when compared to the cells containing only the empty vector. 
These results show a clear and novel role for CBFβ in the regulation of breast cancer 
cell fate, specifically in terms of proliferation and migration. As these two phenotypes 
are classic characteristics of breast cancer pathogenesis, it can be deduced that CBFβ 
also has a potential and important role in breast cancer metastasis.  
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Fig. 4.5.  Overexpression of CBFβ in Hs578T breast cancer cells leads to an increase in cell 
proliferative capacity.  
A) Western blot showing successful overexpression of CBFβ via stable integration into Hs578T cells. B) 
RT-qPCR results showing increased CBFβ mRNA levels in Hs578T cells (N=3, p = 0.001, Student’s 
unpaired t-test). Error bars represent SEM C) Results from proliferation assays using Hs578T cells stably 
overexpressing CBFβ showing significantly increased proliferation compared to a vector only control. A 
two-way ANOVA from N=3 assays resulted in the following: Time: F (8, 61.46) = 73.47, p < 0.0001; 
Treatment: F (1, 20.70) = 13.43, p = 0.0104; Interaction: F (8, 4.785) = 5.72, p = 0.0006. Error bars 
represent SEM.  
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Fig. 4.6.  Overexpression of CBFβ in Hs-578T breast cancer cells leads to an increase in cell 
migratory capacity. 
Results from migration assays using Hs578T cells stably overexpressing CBFβ showing increased 
migration compared to a vector only control (N=4). Error bars represent SEM.  
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CBFβ  affects the regulation of genes involved in mammary gland development and 
breast cancer 
The results described in this chapter demonstrate that perturbation of CBFβ 
expression leads to altered metastatic phenotypes in breast cancer cells, clearly 
indicating that CBFβ is able to regulate breast cancer cell fate. 
In order to elucidate a potential mechanism by which CBFβ may be able to control 
proliferation and migration of breast cancer cells, we performed microarray analysis on 
mRNA lysates from MDA-MB-231 cells containing CBFβ shRNA, Hs578T cells 
overexpressing CBFβ and their respective controls, using the GeneChip PrimeView 
Human Gene Expression Array (N=3 for each sample). Hierarchical clustering and gene 
expression profiling was performed to confirm that the levels of CBFβ were reduced in 
the MDA-MB-231 cells and increased in the Hs587T cells compared to their respective 
control groups (Figure 4.7.A and B). Gene expression profiling for the Hs578T cells did 
not show a clear increase in CBFβ expression levels even though cluster analysis 
showed clear separation of the two groups. This was mostly likely do to the probes not 
being specific enough, therefore independent RT-qPCR validation was performed and 
clearly confirmed significant overexpression of CBFβ in the Hs578T cells compared to 
the control group. CBFβ expression was clearly decreased in MDA-MB-231 cells 
expressing CBFβ shRNA but initial cluster analysis identified one of the luciferase 
shRNA samples as an outlier and it was therefore been removed from subsequent 
analyses.  
Further analysis was performed using Garvan GenePattern LimmaGP (v20.0) in 
order to determine the number of differentially expressed genes in each experimental 
group. When CBFβ was overexpressed in Hs587T cells, a total of 725 of the 20548 
genes in the array were significantly regulated by CBFβ (with an q-value < 0.05). Of 
these 725 genes, we found that 451 were significantly up regulated and 275 were 
significantly down regulated (Figure 4.7.C). In the opposing experimental conditions 
where CBFβ expression was knocked down in the MDA-MB-231 cells, we found that 
of the 20548 genes in the array 58 were significantly regulated by CBFβ (q-value < 
0.05), with 29 genes significantly up regulated and 29 genes significantly down 
regulated (Figure 4.7.C). This data is evidence that CBFβ is responsible for 
differentially regulating genes in human breast cancer cells.  
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Fig. 4.7.  Validation of experimental designs for microarray analysis and evidence that 
CBFβ  differentially regulates gene expression in human breast cancer cells. 
A) Expression profile for Hs578T cells containing the CBFβ or vector only construct indicates that the 
probes used in the array were not specific enough to detect an increase in CBFβ expression. Therefore 
RT-qPCR was used as further validation (N=3 for experimental group and control group). B) Expression 
profile for MDA-MB-231 cells expressing CBFβ or luciferase shRNA shows reduced CBFβ expression 
in the experimental group, as confirmed by RT-qPCR analysis. (N=3 for experimental group and N=2 for 
control group). C) Table summarising the number of genes found to be differentially regulated by CBFβ. 
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Once the array was validated and it was clear that CBFβ was regulating genes 
involved breast cancer, the top fifty genes were collated for both the Hs578T CBFβ 
overexpression and MDA-MB-231 CBFβ knock down data sets. These results reveals 
that CBFβ regulates several genes are important for both mammary gland development 
as well as genes that have been implicated in breast cancer, including: components of 
both the WNT and Hedgehog signalling pathways; insulin, epidermal and fibroblastic 
growth factors; and ECM components (Figure 4.8.A & B). It is therefore clear that 
CBFβ regulates multiple aspects of breast development and carcinogenesis. 
Interestingly, there was minimal correlation between the differentially regulated 
genes identified in the CBFβ overexpression samples when compared with the samples 
where CBFβ expression was knocked down. This dissimilarity is highlighted in Figure 
4.9 where the data has been summarised to show that, of the 8 genes common to both 
studies, 7 were found to be oppositely regulated genes, 1 commonly upregulated and 
there were no genes that were commonly down regulated.   
Comparisons were also made between data from this array and from a previous 
microarray undertaken by our lab, where MCF10a cells overexpressing Runx2 were 
compared to MCF10a containing the empty pMIG vector. Two separate comparisons 
were made; between the CBFβ and Runx2 overexpression data and also between the 
CBFβ knock down study and the Runx2 overexpression data. These analyses also 
showed little correlation in differential gene expression with 10 commonly regulated 
genes between the two overexpression studies and only 1 gene in the Runx2 
overexpression versus CBFβ knockdown comparison (Figure 4.9). This lack of 
correlation indicates that CBFβ function is driven by the genetic landscape of individual 
breast cancers and highlights the heterogeneity of breast cancer, which ultimately 
contributes to the poor prognosis associated with certain tumour types. 
These comparisons show that, whilst CBFβ is clearly regulating breast cancer at the 
gene level, the minimal correlation between experimental groups indicate that it is 
necessary to investigate the changes occurring at the gene-set level in order to fully 
elucidate how CBFβ affects breast carcinogenesis and metastasis. 
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Fig. 4.8.  List of genes most significantly regulated by CBFβ  
Microarrays performed on human breast cancer cells with altered levels of CBFβ demonstrated that 
CBFβ regulates genes involved in normal breast development and breast cancer. A) The top 50 most 
significantly differentially regulated genes in response to CBFβ expression in Hs578T cells. B) The top 
50 most significantly differentially regulated genes in response to CBFβ down regulation in MDA-MB-
231 cells. 
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Fig. 4.9.  Comparison between the number of differentially expressed genes in relation to 
CBFβ  and Runx2 expression. 
A summary of the number of genes differentially regulated by Runx2 and CFBβ, showing that there is 
little correlation between the different experimental conditions at the gene level.  
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CBFβ  regulated expression of genes set involved in breast cancer formation, 
progression and metastasis 
At the gene level, there does not appear to be significant correlation of differentially 
regulated genes in response to CBFβ knock down, overexpression or Runx2 
overexpression in regards to breast cancer. In order to further elucidate the role of CBFβ 
in the regulation of breast cancer cell fate we analysed the effects of altering CBFβ 
expression in human breast cancer cells at the gene set level.  
Gene Set Enrichment Analysis (GSEA) was used to compare the molecular profiles 
of the sample data with published gene set databases in order to determine which gene 
sets were enriched in response to either CBFβ over expression or down regulation. For 
the purpose of this thesis, the sample data was compared to the “c2: curated gene sets”, 
which encompass published gene sets from pathway databases.  
A comparison of the differentially regulated genes sets found as a result of either 
CBFβ down regulation or overexpression can be seen in the Cytoscape maps in Figure 
4.10. In these maps, the outer circles represent CBFβ knockdown in MDA-MB-231 
samples and the inner circles represent CBFβ overexpression in Hs578T cells. Each 
circle represents a different gene set, those in red are significantly upregulated and those 
in blue are significantly down regulated.  
An overview of gene set expression can be seen in Figure 4.10.A, showing that 
between the two experimental conditions, CBFβ overexpression or down regulation, the 
majority of gene sets are oppositely regulated. Upon closer inspection of the Cytoscape 
maps, it is clear that, at the gene set level, CBFβ is involved in the regulation of several 
cancers, including numerous breast cancer-specific gene sets. In addition, it is clear that 
CBFβ is also involved in the regulation of many other gene sets that are essential to 
carcinogenesis and cancer progression, including; EMT pathways, ECM components, 
metastasis, integrin signalling, embryonic stem cells growth and cell cycle pathways 
(Fig. 4.10.B). This finding is highlighted in the GSEA plots in Figures 4.10.C & D, 
which also clearly show that reducing CBFβ expression in MDA-MB-231 cells let to an 
upregulation of these breast cancer gene sets whilst they were down regulated when 
CBFβ was overexpressed in Hs578T cells.  
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The opposite regulation of breast cancer, metastasis and cell cycle gene sets 
complements the functional assay data described and indicates a definite role for this 
transcription factor in breast cancer cell fate.  
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Fig. 4.10.  CBFβ  regulates gene sets that involved in breast development, carcinogenesis and 
metastasis. 
Several genes sets involved in the development and progression of breast cancer are regulated by CBFβ. 
A) A Cytoscape map showing an overview of the major gene sets that are significantly up (red) or down 
(blue) regulated in response to CBFβ expression. The size of the circle increases with the number of 
genes being differentially expressed in a particular gene set. B) Differentially expressed gene sets that are 
directly related to breast cancer, cell cycle, embryonic development, EMT and EMC pathways have to 
been highlighted to emphasis the wide-spread effects of CBFβ perturbation. C) GSEA plots showing 
upregulation of gene sets related to breast cancer when CBFβ expression is knocked down in MDA-MB-
231 cells. D) GSEA plots showing down regulation of gene sets related to breast cancer when CBFβ is 
overexpressed in Hs578T cells.   
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CBFβ  and Runx2 regulate genes involved in breast cancer and metastasis 
It is well established that the relationship between Runx2 and CBFβ is essential for 
the normal development of several systems and that the CBF transcriptional complex 
has been implicated in several diseases. To this effect, we compared the data from both 
the CBFβ microarrays and microarray data where Runx2 was overexpressed in MCF10a 
normal breast cells. Whilst we did not observe a significant amount of correlation at the 
gene level (Fig. 4.9), we see are marked increase in correlation between experimental 
groups when we interrogated that data at the gene set level.  
Separate comparisons were made between the MCF10a cells where Runx2 was 
overexpressed (inner circles) and either the MDA-MD-231 cells where CBFβ was 
knocked down (outer circles) (Fig.4.11.A) or the Hs578T cells where CBFβ was 
overexpressed (out circles) (Fig.4.11.B).  
The Cytoscape maps in Figure 4.11.A shows that the down regulation of CBFβ and 
the overexpression of Runx2 leads to opposite regulation of several gene sets involved 
in breast cancer. Interestingly, there are several instances where gene sets are only 
significantly differentially regulated in response to either CBFβ or Runx2 perturbation 
but not both conditions (white circles indicate no significant up or down regulation in 
response to the experimental condition). This supports the hypothesis that functions of 
CBFβ and Runx2 are not mutually exclusive.  
The effects of overexpressing CBFβ and Runx2 was also assessed and showed a 
greater degree of similarity in the expression pattern of the gene set. It can be seen in 
Figure 4.11.B that the expression of majority of gene sets, including those involved in 
breast cancer, are significantly down regulated. A major exception is the upregulation of 
two gene sets that are specific to invasive breast cancer, which is in alignment with the 
data from this thesis and published studies suggesting that both CBFβ and Runx2 play a 
role in driving aggressive and metastatic phenotypes in breast cancer cells (McDonald 
et al., 2014; Mendoza-Villanueva et al., 2010; Owens et al., 2014). 
Overall these comparisons highlight that Runx2 and CBFβ, both independently and 
in conjunction with each other, are involved in the regulation of genes essential for 
breast carcinogenesis, metastasis, cell cycle, EMT and multiple signalling pathways in 
the ECM.   
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Fig. 4.11.  CBFβ  and Runx2 regulate genes involved in breast cancer progression, cell fate 
and metastasis.  
A) Gene set comparisons between CBFβ knockdown and Runx2 overexpression show that a large subset 
of the gene sets involved in breast cancer are oppositely regulated as a result of these two experimental 
conditions. There are also a number of gene sets that are only significantly regulated by either Runx2 or 
CBFβ, indicating that their functions are not always mutually exclusive. The size of the circle increases 
with the number of genes being differentially expressed in a particular gene set. Red indicates up 
regulation and blue indicates down reagulation.   
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Discussion 
Transcriptional regulation of breast cancer cell fate has become an important aspect 
of breast cancer research and several important regulators of normal mammary gland 
development have been found to be implicated in cancer, including Elf5, ER, PR, WNT 
and Notch. Recent studies by our lab and others have now identified the osteogenic 
transcription factor Runx2 as being essential for mammary gland development during 
pregnancy (Owens et al., 2014) and its expression both correlates and contributes to 
invasive breast cancer cell phenotypes and tumourigenesis in vivo (McDonald et al., 
2014; Owens et al., 2014). There has been little investigation into the role of CBFβ in 
breast cancer and as such, this study provides one of the first in depth interrogations of 
the role of this non-DNA binding component of the CBF complex.  
Previous studies have identified increased CBFβ levels in the aggressive MDA-MB-
231 breast cancer cell line and have indicated that CBFβ may contribute to the invasive 
capacity of these cells (Mendoza-Villanueva et al., 2010). We have now shown that 
CBFβ is expressed in a wide range of human breast cancer cell lines from each of the 
major subtypes. Unlike Runx2, CBFβ expression does not correlate with a particular 
subtype, which was not unexpected given that CBFβ is generally more ubiquitously 
expressed than the Runx genes (Adya et al., 2000; Hajra & Collins, 1995; Ogawa et al., 
1993a; Wang et al., 1993).  
This study however, definitively shows that CBFβ is able to influence the ability of 
breast cancer cells to proliferate and migrate, two of the most common hallmarks of 
cancer (Hanahan & Weinberg, 2000). Previous studies have shown that CBFβ inhibition 
leads to reduced invasiveness in MDA-MB-231 cells (Mendoza-Villanueva et al., 
2010), but the effects of forced CBFβ expression have not been tested. This chapter 
addressed this issue and has now shown, using multiple cell lines, that knocking down 
CBFβ expression reduces the aggressive phenotypes of breast cancer cell lines and that 
the overexpression of CBFβ leads to an increase in both proliferation and migration. 
This data therefore suggests that CBFβ plays a role in controlling breast cancer cell fate. 
In order to begin to understand the mechanisms by which CBFβ is able to regulate 
the metastatic potential of breast cancer cells, microarrays were performed using the cell 
lines in which CBFβ levels were either increased or decreased. At the gene level, the 
data from these arrays show that CBFβ is influencing expression of several genes that 
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are involved in critical pathways such as WNT and Hedgehog signalling pathways. 
Both the WNT and Hedgehog signalling pathways play an important role in the normal 
breast development, from embryogenesis to adulthood, and have been implicated in 
several cancers, including breast cancer (Howe & Brown, 2004; Kasper et al., 2009). 
CBFβ mediated regulation of these critical signalling pathways may indicate a potential 
mechanisms by which CBFβ is able to drive mammary cell fate decisions.  
Furthermore, CBFβ was shown to regulate ECM proteins and growth factors that are 
required for normal mammary gland development and functionality have been 
implicated in breast cancer formation and progression including FGF12, IGFBP5, 
MEFG6 and CADM1. IGF and FGF signalling pathways in particular, are associated 
with the ability of breast cancer cells to colonise the bone function as a part of the 
“vicious cycle” of bone metastasis which also heavily relies on Runx2 expression 
(Roodman & Dougall, 2008; Steeg, 2006). The fact that CBFβ regulates members of 
these crucial signalling pathways may indicate it is acting independently or though 
Runx2 to promote breast cancer metastasis through regulation of IGF and FGF 
signalling. 
 This data provides further evidence that CBFβ is an important regulator of breast 
carcinogenesis and progression and that dysregulation of this transcription factor has 
severe implications on the genetic interactions of the breast. 
Whilst we were able to identify downstream target genes of CBFβ that are involved 
in breast cancer, there was minimal correlation at the gene level between CBFβ 
overexpression, CBFβ knockdown or following Runx2 overexpression. Breast cancers 
are grouped into subtypes that correlate to hormone receptor status and mutations in 
genes such as P53 and BRCA, which ultimately leads to differences in genetic 
landscapes of individual breast tumours. Therefore, the minimal correlation observed 
between breast cancer cells with altered CBFβ levels suggests that CBFβ function is 
influenced by the heterogeneity that exists in breast cancer.   
Therefore to further understand the influence of CBFβ control in the context of 
breast cancer, we interrogated the microarray data using Gene Set Enrichment analysis 
and Cytoscape software and found that a significant number of gene sets were 
oppositely regulated in response to CBFβ and Runx2 levels, including; Kegg Pathways 
in Cancer, Smid Breast Cancer Luminal A Up, Smid Breast Cancer Normal Like Up, 
Zhang Breast Cancer Progenitors, Biocarta ECM Pathway, Biocarta Met Pathway, Zhou 
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Cell Cycle and Pujana BrCa Centered Network. These gene sets identified as 
differentially regulated represent pathways and genes associated with multiple cancers, 
growth factors, stem cells, ECM components and cell cycle pathways. More 
importantly, a large number of these gene sets are specific to breast cancer formation, 
progression and metastasis. This analysis conclusively demonstrates that CBFβ is 
implicated in all aspects of breast cancer and an in depth analysis is required to 
determine the direct mechanism driving this regulation. 
A previous study has indicated a role for CBFβ and Runx2 in the ability of breast 
cancer cells to mediate osteoblast differentiation through regulation of the WNT-
antagonist sclerostin (Mendoza-Villanueva et al., 2011) and we have now confirmed 
through microarray analysis, that perturbation of CBFβ differentially regulates 
components of the WNT signalling pathway, such as β-catenin interacting protein 1. 
Together this data indicates that CBFβ may be regulating breast cancer cell fate through 
interactions with the WNT signalling cascade. Furthermore, a recent study in 
osteoblasts has shown that there is cross talk between WNT and TGFβ pathways that 
converges on Runx2 (McCarthy & Centrella, 2010), which is an interesting 
development as microarray analysis has also shown that CBFβ regulates several Smad 
proteins in breast cancer cells. Given our knowledge of Runx2 and CBFβ interactions, it 
is therefore possible that CBFβ is acting to stabilise and increase the DNA-binding 
affinity of Runx2 leading to transcriptional regulation of these crucial signalling 
pathways and subsequent dysregulation in the context of breast cancer.  
CBFβ may also be directing breast cancer cell fate through control of integrins and 
other ECM proteins as we observed differential expression of gene sets involved in 
integrin signalling and the FAK pathway. It has been previously shown that FAK 
interacts with MMP9 to promote cell migration and invasion (Das et al., 2009)and 
SMAD3 interacts with Runx2 in order to regulate TGFβ-mediated expression of 
MMP13 in human breast cancer cells (Selvamurugan et al., 2004). Therefore, as CBFβ 
is able to regulate FAK signalling and TFGβ signalling through control of Smad protein 
expression it is evident that CBFβ plays an important role in directing breast cancer cell 
fate. Further analysis is required to determine the precise mechanism through which 
downstream targets of CBFβ are directly and indirectly involve in breast cancer 
progression and metastasis. 
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Overall we have demonstrated a novel role for CBFβ in the control metastatic 
phenotypes in breast cancer an it is clear though functional assays and gene expression 
analysis that CBFβ is acting to regulate cell fate decisions in breast cancer. 
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5. CBFβ  is a key regulator of tumourigenesis and metastasis in the 
PyMT breast cancer model 
 
Introduction 
The data produced by this thesis has demonstrated exciting roles for CBFβ as a novel 
regulator of mammary gland development and breast cancer cell fate.  
 Over the last decade, a role for the Runx genes, specifically Runx2, has been 
established in mammary gland development (Blyth et al., 2005; Blyth et al., 2010; 
McDonald et al., 2014; Owens et al., 2014; Shore, 2005) and there is now mounting 
evidence suggesting that Runx2 is essential for the development and progression of 
metastatic breast cancer (McDonald et al., 2014; Mendoza-Villanueva et al., 2010; 
Owens et al., 2014) Runx2 has been found to be upregulated in all breast cancer 
subtypes but to a higher extent in the aggressive basal subtype, specifically the 
ER/PR/HER2 triple negative cancers (McDonald et al., 2014) indicating it may be 
crucial for regulating the metastatic potential of breast cancer cells.  
Our lab has shown that overexpressing Runx2 in the MCF10a normal breast cells 
results in the induction of epithelial to mesenchymal transition (EMT) whereby these 
cells undergo morphological and genetic modifications consistent with breast cancer. 
Similarly, overexpression of Runx2 in the HC11 mouse mammary epithelial cells leads 
to an increase in both the proliferative and migrational capacity of the cells, which are 
classic hallmarks of cancer (Owens et al., 2014). We and others have also shown that 
reducing Runx2 expression in the aggressive MDA-MB-231 breast cancer cell line 
leads to decreased ability of the cells to migrate and invade (Mendoza-Villanueva et al., 
2010; Mendoza-Villanueva et al., 2011; Owens et al., 2014). 
We have confirmed this role for Runx2 in breast cancer cell fate and progression in 
vivo by crossing the Runx2-/- mouse on to the luminal breast cancer PyMT mouse and 
performing mammary transplants. This resulted in a clear increase in both the tumour-
free survival and the overall survival rates of the Runx2 knock out mice as well as a 
significant decrease in the proliferation levels of hyperplastic regions of the Runx2-/- 
glands, as shown by reduced Cyclin D1 expression (Owens et al., 2014). This was the 
first in vivo study to show a clear role for Runx2 in breast tumourigenesis. These data 
are complemented by results from a separate study that demonstrated atypical pre-
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neoplastic and hyperplastic regions of the mammary epithelium in aged Runx2 
transgenic mice (McDonald et al., 2014). This study suggests that prolonged ectopic 
expression of Runx2 in the mammary gland leads to a re-structuring of tissue 
reminiscent of EMT-like changes (McDonald et al., 2014). 
CBFβ is the binding partner of all Runx genes and we have hypothesised that it plays 
an important role in mammary gland development, breast cancer and subsequent 
metastasis. We have now described a novel role for CBFβ in the regulation of 
mammary epithelial cell proliferation during ductal elongation gland in vivo and in 
addition, we have demonstrated that altering levels of CBFβ expression can either 
impair or accelerate migration and proliferation of human breast cancer cells, indicating 
a critical and novel role for CBFβ in mammopoiesis and breast cancer cell fate.  
The CBF complex is known to be important for development, stem cell homeostasis 
and also in human disease, particularly in leukaemias (Davis et al., 2010; Kurosaka et 
al., 2011). In the last three years there has been growing interest in the role of CBFβ in 
solid tumours, a role that is yet to be elucidated. It has now been shown that CBFβ may 
be involved in the malignancy of both ovarian and prostate cancers (Davis et al., 2010) 
and that it is may be required to support the invasive capacity of breast cancer cells in 
vitro (Mendoza-Villanueva et al., 2011). 
Breast cancer is one of the most common cancers amongst women and whilst the 
prognosis for primary breast cancer has improved markedly over the last 20 years, the 
survival rate for patients with distal metastasis is less than 10% and it is this metastatic 
disease that contributes the mortality and morbidity of breast cancer. Therefore it is 
imperative to determine key players that are involved in the process by which breast 
cancer is able to spread and CBFβ is becoming an increasingly plausible candidate. 
In order to extend upon the in vitro data already described in this thesis and by 
others, we generated a tumourigenic mouse model in which CBFβ was deleted solely in 
the mammary gland, resulting in the first in vivo study investigating the role of CBFβ in 
breast cancer progression. 
This chapter aims to explore the potential role CBFβ in breast cancer cell fate in the 
context of tumour latency, overall survival and distal metastasis through the use of an in 
vivo breast cancer model.   
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Results 
CBFβ  deletion in the mammary gland leads to increase in breast tumour latency 
We have now demonstrated that CBFβ may regulate breast cancer progression, as 
shown through altered migration and proliferation of human breast cancer cells in 
response to CBFβ expression. In order to build on this in vitro data and to further 
investigate the role CBFβ plays in vivo, we generated a tumourigenic mouse model with 
mammary-specific CBFβ deletion of CBFβ. 
This model was generated by first crossing the previously described CBFβf/f; BLG-
Cretg/+ mice (Chapter 3) on to the PyMTtg/+ luminal breast cancer model (Lin et al., 
2003) resulting in CBFβf/+;BLG-Cretg/+;PyMT mice. The CBFβf/+;BLG-Cretg/+;PyMT 
mice were then backcrossed on to the CBFβf/f model in order to generate both 
CBFβf/fCretg/+PyMT and CBFβf/fCre+/+PyMT mice. 
 A longitudinal study was undertaken to compare the tumour-free survival time of 
CBFβf/fCre+/+PyMT mice compared to the CBFβf/fCretg/+PyMT mice. The mice were 
examined three times a week for signs of mammary tumour development. A mouse was 
considered as having undergone tumourigenesis at the first incidence of a palpable 
tumour. The results of this study showed a significant increase (p = 0.0002) in tumour 
latency in the CBFβf/fCretg/+PyMT mice (n=22), with an average tumour-free survival of 
83.8 days compared to only 68.7 days in the CBFβf/fCre+/+PyMT control mice (n=23) 
(Fig. 5.1.).  
This data demonstrates a novel role for CBFβ in the regulation of breast 
tumourigenesis in vivo.  
  
 130 
 
  
 
Fig. 5.1.  Deletion of CBFβ  in the mammary gland increases tumour latency in the 
tumourigenic CBFβPyMT mouse model.  
There is a significant increase in tumour latency in the CBFβf/fCretg/+PyMT mice when compared to the 
CBFβf/fCre+/+PyMT mice (p = 0.0002, Hazard Ratio = 0.25, Log-rank (Mantel Cox) test)  
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Deletion of CBFβ  in the mammary gland leads to increased overall survival within a 
tumourigenic population 
Deletion of CBFβ in the mammary gland leads to a significant increase in tumour 
latency in mice, indicating a role for CBFβ in the progression of breast tumourigenesis 
in vivo. We next sought to ascertain whether CBFβ deletion in the mammary gland has 
an effect on the overall survival in the CBFβf/fCretg/+PyMT tumourigenic population.  
Similar to the previous study; mice were examined for tumours and overall health 
three times a week. In addition, all palpable tumours were measured using digital 
calipers and these readings were used to calculate the total tumour burden of each 
mouse. Once a mouse had reached the ethical endpoint (a total tumour burden of 10% 
by weight) it was sacrificed and all tumours and organs of interest were harvested and 
processed for histological analysis. 
 The data demonstrated that CBFβ deletion resulted in significantly increased overall 
survival in the CBFβf/fCretg/+PyMT population when compared to the 
CBFβf/fCre+/+PyMT control mice (p <0.0001). CBFβf/fCretg/+PyMT mice (N=22) 
survived for an average of 162.9 days compared to the CBFβf/fCre+/+PyMT mice 
(N=34) that only lived to an average of 123.6 days. This was an increased survival of 
almost 5.5 weeks in the CBFβf/fCretg/+PyMT animals (Fig. 5.2.).  
We have now shown a novel role for CBFβ as a regulator of tumour progression and 
as a critical factor in the overall survival in mice with breast tumours. 
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Fig. 5.2.  Deletion of CBFβ  in the mammary gland increases overall survival in the 
tumourigenic CBFβPyMT mouse model. 
CBFβ deletion leads to a significant increase in overall survival in the CBFβf/fCretg/+PyMT mice when 
compared to the CBFβf/fCre+/+PyMT mice. (p <0.0001, Hazard Ratio = 0.16, Log-rank (Mantel Cox) test). 
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Characterisation of the CBFβ f/fCretg/+PyMT tumourigenic mouse model 
Through the use of the CBFβf/fCretg/+PyMT mouse model, we have demonstrated a 
new role for CBFβ in the regulation of tumour latency and breast cancer progression in 
a luminal breast cancer context. To confirm that the phenotypes described were due to 
deletion of CBFβ in the mammary gland, western blotting was performed for CBFβ on 
mammary glands harvested from CBFβf/fCretg/+PyMT and CBFβf/fCre+/+PyMT mice. 
The ensuing results show a clear deletion of CBFβ and activation of Cre in the 
CBFβf/fCretg/+PyMT animals (Fig.5.3.A). Furthermore, we have shown that Runx2 
expression is also down regulated in conjunction with CBFβ in these mice. 
 
CBFβ  regulates breast cancer progression  
We have now shown that deletion of CBFβ in the mammary gland increases both 
tumour latency and overall survival in mice with mammary tumours. To further 
characterise the effects of CBFβ deletion in a luminal breast cancer context, we 
performed cross-sectional analysis using a 14-week-old cohort of CBFβf/fCretg/+PyMT 
(N=8) and CBFβf/fCre+/+PyMT (N=10) mice. Mice were euthanised at 14 weeks of age 
and mammary glands were harvested for whole mount and histological analysis.   
Whole mount analysis of the mammary glands collected shows a clear reduction in 
the severity of tumourigenesis in the CBFβf/fCretg/+PyMT mammary glands to the 
CBFβf/fCre+/+PyMT control mice. These glands were subsequently processed and 
sectioned for histological analysis where haemotoxylin and eosin staining highlights the 
decreased amounts of hyperplasia in the CBFβf/fCretg/+PyMT glands compared to the 
CBFβf/fCre+/+PyMT glands (Fig. 5.3.C).  
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Fig. 5.3.  Deletion of CBFβ  in the mammary gland reduces the severity of breast 
tumourigenesis. 
In a cross-sectional analysis, CBFβf/fCretg/+PyMT mice show less hyperplasticity compared to 
CBFβf/fCre+/+PyMT animals due to deletion of CBFβ in the mammary gland. A) Western blot showing a 
reduction in CBFβ levels, decreased Runx2 levels and Cre activation in CBFβf/fCretg/+PyMT mammary 
glands from 14-week-old mice. CBFβ deletion has been targeted only in epithelial cells therefore may 
still be present in other cells types, explaining the presence of CBFβ bands in western blotting B) 
Representative whole mount mammary gland images depicting the differences in tumourigenesis between 
CBFβf/fCretg/+PyMT and CBFβf/fCre+/+PyMT mice at 14 weeks of age. C) Haematoxylin and eosin 
staining on mammary glands depicting the differences in tumourigenesis between CBFβf/fCretg/+PyMT 
and CBFβf/fCre+/+PyMT mice at 14 weeks of age (Representative images of N=4 mice for each genotype).   
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CBFβ  regulates cancer cell proliferation in the PyMT mammary tumour model 
We have previously shown that CBFβ regulates proliferation of both mammary 
epithelial cells and human breast cancer cells. Given that tumourigenesis is a process 
mediated by the ability of cells to proliferate, we investigated the affect of CBFβ 
deletion on the proliferation of mammary tumours in CBFβf/fCretg/+PyMT mice by IHC 
staining for the proliferative marker Ki-67 (Fig. 5.4.A).  
We observed a significant difference (p <0.0001) in the number of Ki-67 positive 
cells, with 31.5% (±3.2) of Ki-67 positive cells in the CBFβf/fCre+/+PyMT glands 
compared to only 4.4% (±1.7) of Ki67 positive cells in the CBFβf/fCretg/+PyMT glands 
(Figure 5.4.B).  
These results are similar to data observed in Chapter 4 where the rate of proliferation 
in human breast cancer cells was accelerated or reduced depending on CBFβ expression 
levels and indicates that CBFβ plays a key role in regulating breast cancer cell fate in 
vivo and in vitro.  
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Fig. 5.4.  CBFβ deletion leads to a reduction in proliferating mammary cells in PyMT 
induced tumours in vivo. 
This panel shows a significant reduction in proliferation in the mammary glands of the 
CBFβf/fCretg/+PyMT mice compared to the CBFβf/fCret++PyMT mice. A) Ki-67 IHC staining showing 
significantly less Ki-67 positive cells in the CBFβf/fCretg/+PyMT compared to the CBFβf/fCre+/+PyMT 
mammary glands from 14-week-old CBFβPyMT mice. B) A histogram quantitating the significant 
decrease of Ki-67 positive cells in the CBFβf/fCretg/+PyMT glands of 14-week-old CBFβPyMT mammary 
glands compared to the CBFβf/fCre+/+PyMT glands (p <0.0001, Student’s unpaired t-test). Error bars 
represent SEM (N=10).  
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Mammary specific CBFβ  deletion reduces both the incidence and severity of distal 
metastasis in the PyMT breast cancer model 
Proliferation and migration are two of the major hallmarks of cancer (Hanahan & 
Weinberg, 2000) and we have demonstrated that CBFβ regulates these two phenotypes 
in breast cancer cells in vivo.  
In order to determine whether CBFβ deletion affected on the metastatic potential of 
breast cancer in vivo, a post mortem was performed on the CBFβf/fCretg/+PyMT and 
CBFβf/fCre+/+PyMT mice in order to determine whether metastases had formed in any 
distal organs. The lungs are the most common sites of metastasis in the PyMT model 
but all major organs were examined including brain, liver and kidney. We found that 
only the lungs of these animals had been affected by metastatic disease and as such, 
were harvested for gross morphology and histological analysis.  
We saw no difference in the incidence of lung metastasis, irrespective of size or 
severity, in response to CBFβ deletion with 78.8% of CBFβf/fCre+/+PyMT mice (N=33) 
presenting with lung metastases versus 76.2% of CBFβf/fCretg/+PyMT mice (N=21) 
(Fig. 5.5.A). Whilst there was no difference observed in the incidence of lung mets, 
there was a significant decrease in the severity of metastatic lung disease in 
CBFβf/fCretg/+PyMT mice compared to the control population (Figure 5.5.B-E).  
Photographs of the affected lungs in Figure 5.5.B clearly show that in terms of gross 
morphology, the lungs of CBFβf/fCretg/+PyMT mice have substantially reduced 
metastatic disease than the CBFβf/fCre+/+PyMT mice. Both the size and number of the 
metastases are decreased in the CBFβf/fCretg/+PyMT mice. This phenotype was 
confirmed in Figure 5.5.C by haemotoxylin and eosin staining, confirming the decrease 
of the size and number of lung metastases in CBFβf/fCretg/+PyMT mice.  
In addition to histological analysis, the number of lung metastases on each pair of 
lungs was counted before histological processing. These counts showed that lungs from 
a CBFβf/fCretg/+PyMT mouse had an average of 48 metastases, which is significantly 
lower than the CBFβf/fCre+/+PyMT mice with an average of 92 (p = 0.04) (Figure 
5.5.E). 
This data demonstrates a novel and critical role for CBFβ in the progression of breast 
cancer metastasis. 
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Fig. 5.5.  Mammary specific deletion of CBFβ results in decreased incidence and severity of 
lung metastasis in mice. 
CBFβ deletion in the mammary gland leads to decreased severity of metastatic lung disease in 
CBFβf/fCretg/+PyMT animals. A) Table depicting the reduced incidence of secondary lung metastasis in 
CBFβf/fCretg/+PyMT animals compared to CBFβf/fCre+/+PyMT mice. B) Images showing the gross 
morphological differences between the lungs of CBFβf/fCretg/+PyMT animals compared to the 
CBFβf/fCretg/+PyMT animals. C) Haematoxylin and eosin staining of metastatic lungs show a decrease in 
the severity of metastasis in CBFβf/fCretg/+PyMT mice compared to CBFβf/fCre+/+PyMT mice. D) 
Histogram showing the severity of lung metastasis is significantly reduces in CBFβf/fCretg/+PyMT animals 
compared to CBFβf/fCre+/+PyMT animals (p = 0.04, Student’s unpaired t-test). Error bars represent SEM.  
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Discussion 
CBFβ has a well-defined role in haematopoietic cancers, primarily leukaemias but 
recent studies have begun to explore the role of CBFβ in solid tumours, where it 
appears to have an oncogenic function (Davis et al., 2010). The data described in this 
chapter shows that deletion of CBFβ leads to increased tumour latency and overall 
survival in a breast cancer context, further supporting the hypothesis that CBFβ 
functions as an oncogene in solid tumours.  
We have also demonstrated that expression of CBFβ is required for breast cancer 
progression and metastasis, as indicated by the decreased hyperplasticity and severity of 
metastasis observed in the CBFβf/fCretg/+PyMT mice. This data complements results 
from a Runx2 study undertaken by our lab that observed an increase in tumour latency 
and overall survival of mice when Runx2 is deleted in the mammary glands of PyMT 
mice (Owens et al., 2014).  
It was not unexpected to see that the phenotypes observed though deletion of Runx2 
or CBFβ were somewhat similar as they are binding partners and it is known that CBFβ 
acts to primarily stabilise Runx2 and increase the transcription efficiency of down 
stream targets (Ito, 2008; Qin et al., 2014; Yoshida, 2002). There was however a greater 
increase in the tumour latency period in the CBFβf/fCretg/+PyMT mice than in the 
Runx2-/- model. This may be due to the fact that deletion of CBFβ expression negates 
the functional redundancy that can exist between the Runx genes (Blyth et al., 2005), 
meaning that Runx1 and Runx3 are not able to compensate for the function of Runx2, 
which they are able to do in the Runx2-/- model.  
There is also the potential that CBFβ deletion is having a greater effect on tumour-
free and overall survival due to a Runx2-independent function. Recent studies have 
shown evidence that the functions of Runx2 and CBFβ are not always mutually 
exclusive and it has been suggested that the interaction between these two co-factors 
may be a potential target for therapeutics (Mendoza-Villanueva et al., 2010). 
Furthermore, it has been shown in both prostate and ovarian cancer, that knocking down 
CBFβ expression leads to dysregulation of cell signalling pathways that play a role in 
malignancy (Davis et al., 2010). It is therefore evident that CBFβ is able to regulate of 
tumourigenesis and progression in solid cancers, including breast cancer. 
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Previous studies reported that CBFβ might be necessary for breast cancer invasion in 
an in vitro context, indicating a role for CBFβ in the breast cancer metastasis (Mendoza-
Villanueva et al., 2010). We furthered this knowledge by generating the 
CBFβf/fCretg/+PyMT and observed a significant reduction in both the size and number of 
lung metastases in response to CBFβ deletion. This finding recapitulates the in vitro 
data described in Chapter 3 that demonstrated a novel role for CBFβ in breast cancer 
cell fate regulation and together, this study provides the first detailed description of the 
role of CBFβ in breast cancer. 
The only other link between CBFβ and breast cancer comes from three independent 
studies sequenced a large array of human breast tumours that identified CBFβ as one of 
the most frequently mutated genes in luminal breast cancer (Banerji et al., 2012; 
CGAN, 2012; Ellis et al., 2012). The implication of this data is clear, that further 
investigation into CBFβ is required in regards to its involvement in breast 
carcinogenesis. 
The data from this chapter describes a novel role for CBFβ in breast cancer 
tumourigenesis, progression and metastasis in an in vivo context. This is a pivotal 
discovery because up until this point there has been no in vivo data to recapitulate the 
limited data observed in breast cancer cell lines.  
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6. General Discussion 
Mammary gland development occurs in precise and unique stages in response to 
series of regulatory hormones and genes that act on a smaller subset of transcription 
factors, essential in the control of mammary cell fate (Hennighausen & Robinson, 
2005). Regulators of cell fate are crucial for normal developmental and offer potential 
targets for the management and treatment of breast cancer. The overarching aim of this 
thesis was to determine a novel regulator of mammary cell fate in the transcription 
factor CBFβ and to determine its implications in breast carcinogenesis and progression. 
We have now shown a definitive role for CBFβ in the regulation of mammary epithelial 
proliferation during ductal elongation and provided conclusive evidence that CBFβ 
controls breast cancer cell fate both in vitro and in vivo. Deletion of CBFβ in the mouse 
mammary gland leads to significant increase in tumour latency and overall survival 
whilst also leads to a reduction in the severity of metastasis. These results confirmed in 
vitro data that showed significant change in the ability of breast cancer cells to migrate 
and proliferate in response to CBFβ expression levels. 
Together these data provide the first insight into the role of CBFβ as a novel 
regulator of mammary gland development and breast cancer. 
 
CBFβ  regulates mammary epithelial cells during ductal elongation 
The development of the mammary gland, from in utero to adulthood, is dynamic and 
complex in regards to both structure and signalling pathways. Considerable 
advancement has been made in regards to our current knowledge of the signalling 
pathways involved in the mediation of the genes and hormones that control the cyclical 
changes in the mammary gland that occur during sexual development and reproduction. 
The role transcription factors play in mammopoiesis however, is still under 
investigation (Visvader & Lindeman, 2003).  
The foundations for this thesis were formed as a result of recent studies from our lab 
describing a novel role for Runx2 in regulation of luminal mammary progenitors, 
specifically during lobuloalveolar development (Owens et al., 2014). Runx2 represents 
one half of the CBF complex, which is an essential activator or repressor of 
transcription in both developmental systems and cancer, depending on the context 
(Tanaka et al., 1995). CBFβ constitutes the non-DNA binding element of this complex 
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and binding to CBFβ is compulsory for all three Runx proteins for efficient 
transcription of downstream targets (Ito, 2008). The original aim of this study was to 
exploit the common requirement for CBFβ by the Runx proteins in order to remove the 
element of redundancy between these transcription factors and therefore gain a better 
understanding of the role of Runx2 in the mammary gland. This thesis has instead 
elucidated an exciting and novel role for CBFβ in the mammary gland, independent of 
Runx2. 
 Whilst CBFβ expression is generally ubiquitous, Runx protein expression is tissue-
specific (Adya et al., 2000; Hajra & Collins, 1995; Ogawa et al., 1993a; Wang et al., 
1993). This is the first study to demonstrate that CBFβ is expressed in the mammary 
gland, specifically in the epithelial compartment (Chapter 3). Furthermore, it is now 
clear that CBFβ is developmentally regulated throughout mammopoiesis, exhibiting the 
same expression profile as Runx2 (Chapter3), providing the first evidence that CBFβ is 
involved in mammary gland development. Expression levels of CBFβ are highest 
during virgin development and relatively low during pregnancy and lactation, indicating 
the importance of CBFβ during development of the virgin gland. 
CBFβ is involved in controlling the expansion of the ductal network at the onset of 
post-natal mammopoiesis through regulation of mammary epithelial cell proliferation 
(Chapter 3). CBFβ has been shown to be an essential regulator of cell fate in other 
developmental systems, including haematopoiesis and osteogenesis (Coffman, 2003; 
Huang et al., 1999; Nagata et al., 1999). Interestingly, CBFβ also controls the 
proliferation and differentiation of stem cells within these systems (Kurosaka et al., 
2011), and may therefore be regulating mammary epithelial cell fate through a similar 
mechanism. This hypothesis is supported firstly by expression of CBFβ in the 
myoepithelial compartment of the mammary epithelium (Chapter 3), which is where 
mammary stem cells are derived (Kendrick et al., 2008). The strongest evidence 
supporting a role for CBFβ in mammary stem cell regulation is the difference in the 
phenotypes observed between the two CBFβ knockout mouse models used in this study. 
When CBFβ deletion was mediated by the BLG-Cre transgene, deletion occurred in 
more differentiated cells and no developmental defects were observed. In the inducible 
transplantation model where CBFβ deletion was driven by CreERT2, every mammary 
cell was targeted, including the stem/progenitor populations and as such a delay in 
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ductal elongation was observed, indicating that CBFβ may regulate the specification of 
the stem/progenitor cell populations. Furthermore, our lab has recently shown that 
Runx2 is required for the regulation of luminal progenitor populations throughout 
lobuloalveolar development (Owens et al., 2014) so it is clear that there is mounting 
evidence to suggest that the CBF complex as a whole, is crucial for stem/progenitor cell 
fate regulation in the mammary gland. 
Interestingly, microarray analysis of CBFβ perturbation in breast cancer cells 
showed that CBFβ (Chapter 4) regulates the expression of several gene sets that 
encompass crucial signalling pathways associated with several aspects of mammary 
gland development and the regulation of stem/progenitor cells. Some of the major 
signalling pathways identified as differentially expressed in the microarray analysis 
include Hedgehog, WNT and FGF pathways, all of which are essential in mammary 
gland development breast cancer formation and progression. It has been shown 
previously that CBFβ functions to maintain stem cell populations and drives cell 
proliferation in tooth development through regulation of Fgf9 and Shh (Kurosaka et al., 
2011) and it may therefore have a similar function in the mammary gland.  
In order to fully elucidate if CBFβ is regulating mammary gland development 
through a stem cell mechanism it would be interesting to perform additional transplants, 
and then use mammary epithelium from these recipients in serial transplantation 
experiments. Serial transplants would allow us to determine whether or not the 
proliferative defect we believe exists in the mammary stem cells of CBFβ-/- glands, 
becomes compounded over time and would finally result in complete failure of ductal 
elongation. 
The identification of a role for CBFβ in the regulation of ductal extension of the 
mammary epithelium provides further insight into how this crucial phase of 
mammopoiesis is regulated. The importance of fully understanding the mechanisms 
behind ductal extension and branching morphogenesis is highlight by the statistics that 
show almost 90% of human breast cancers originating in the ductal cells of the 
mammary epithelium. CBFβ and its downstream targets may therefore provide potential 
therapeutic targets, which would ultimately increase the prognosis and outcome for 
breast cancer patients. 
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A role for CBFβ  in in the regulation of breast cancer cell fate 
Breast cancer is highly prevalent in society and whilst the statistics and prognosis are 
relative positive for those diagnosed at the primary stage, there is still a very high 
mortality and morbidity rate for those patients who present with distal metastases, 
indicating that further investigation into the mechanisms behind how these tumour cells 
are able to escape the mammary gland and colonise areas such as the brain, lungs and 
the bone.  
Breast cancer is a heterogeneous disease and therefore individual tumours, even 
within the same patient, can be under the regulation of multiple hormones, oncogenes 
and transcription factors. The key to increasing the long-term survival rates of breast 
cancer lies in identifying these regulatory pathways and the factors that control them.  
This thesis has aimed to identify a novel regulator of breast cancer cell fate by 
investigating the role of CBFβ, a transcription factor we have now shown to be essential 
for both the developing mammary gland and also breast tumourigenesis and progression 
both in vitro and in vivo. This is an exciting development as there has been little data 
linking CBFβ to breast cancer and only in an in vitro context. 
CBFβ has been primarily known for its role in leukaemias, where it has been shown 
to be involved in translocation, dominant negatives events and formation of fusion 
proteins in conjunction primarily with Runx1 (Adya et al., 1998; Look, 1997; 
Lutterbach et al., 1999). There is also evidence that CBFβ is down regulated in gastric 
cancers along with Runx1 and 3 (Sakakura et al., 2005), indicating, a possible tumour-
suppressor role for CBFβ in these cancers. However, one of the hallmarks of the CBF 
complex is that these transcription factors can act as both tumour-suppressors and 
oncogenes through the repression or activation of down stream targets depending on the 
context (Blyth et al., 2005). 
Whilst there is almost a complete lack of data at present that describes a role for 
CBFβ in solid tumours, the evidence that does exist is indicative of an oncogenic 
function. It has been shown that knocking down CBFβ in prostate and ovarian cancer 
cell lines leads to inhibition of tumour growth when the cells are xenografted into mice 
(Davis et al., 2010). Furthermore, it has been shown through gene expression profiling, 
that several developmental and cell signaling pathways associated with malignancy are 
perturbed in these cells, indicating that CBFβ is potentially required for tumourigenesis 
in certain solid tumours (Davis et al., 2010). The data in this thesis also suggests an 
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oncogenic function for CBFβ as breast tumourigenesis was significantly delayed as a 
result of CBFβ deletion. 
A previous study examining the role of Runx2 in breast cancer indicated that CBFβ 
might play a role in the invasive potential of breast cancer cells in vitro (Mendoza-
Villanueva et al., 2010). We have extended upon this data and have now demonstrated 
that CBFβ is able to regulate the ability of breast cancer cells to proliferate and migrate 
in vitro (Chapter 4) and controls tumourigenesis and proliferation in vivo (Chapter 5). In 
addition, deletion of CBFβ leads to a significant reduction in the severity of lung 
metastasis in PyMT mice, demonstrating that CBFβ can also influence breast cancer 
progression (Chapter 5). This is the first study to investigate the role of CBFβ in an in 
vivo breast cancer model and clearly demonstrates that CBFβ regulates essential aspects 
of cell fate that drive aggressive and metastatic phenotypes that are attributed to poor 
prognosis in beast cancer. 
In order to deduce the potential mechanism behind CBFβ mediated regulation of 
breast cancer cell fate, we performed microarrays and subsequent differential gene and 
GSEA analysis on breast cancer cells where CBFβ expression was perturbed (Chapter 
4). These analyses showed that CBFβ significantly regulates genes involved in the 
essential WNT and Hedgehog signalling pathways, which have well-documented roles 
in both mammary gland development and also breast cancer (Howe & Brown, 2004; 
Kasper et al., 2009). GSEA analysis showed that perturbed CBFβ expression correlated 
with the expression of numerous breast cancer specific gene sets including Smid Breast 
Cancer Luminal A Up, Smid Breast Cancer Normal Like Up, Zhang Breast Cancer 
Progenitors, Biocarta ECM Pathway, Biocarta Met Pathway, Zhou Cell Cycle and 
Pujana BrCa Centered Network. Within these gene sets, there are multiple genes 
significantly regulated by CBFβ that are components of signalling pathways involved in 
mammary gland development and breast cancer, including; Brca1 and 2, Smad1, 2,4 
and 5, Ihh and β-catenin interacting protein 1. The signalling pathways represented here 
are Hedgehog, WNT and TGFβ, which have proven roles in mammary gland 
development and have been implicated in breast cancer and suggest that CBFβ regulates 
breast cancer cell phenotype potentially through these pathways. 
In regards to CBFβ and WNT signalling, a previous study has shown that CBFβ 
regulates expression on the WNT-antagonist, Sclerostin, which may play a role in the 
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ability of breast cancer cells to mediated osteoblast differentiation and ultimately the 
spread of breast cancer to the bone (Mendoza-Villanueva et al., 2011). Furthermore, 
there is evidence of Runx2 dependent cross talk between WNT and TGFβ signalling 
pathways in osteoblasts (McCarthy & Centrella, 2010). The fact that CBFβ has now 
been shown to regulate several Smad proteins, it is possible that CBFβ also plays a role 
in the cross talk occurring between these pathways. 
In addition, it has been shown that TGFβ is able to regulate expression of MMP9 in a 
Smad dependent manner in order to regulate breast cancer cell invasion (Wiercinska et 
al., 2011). The significance of this is that our lab has previously found MMP9 to be 
significantly regulated by Runx2 and although we did not observe any significant 
change in response to CBFβ expression, we do know that CBFβ increases the stability 
and DNA-binding affinity of Runx2. Therefore, it is possible that CBFβ is playing 
either a supportive role in this interaction through Runx2 binding or it is acting on the 
Smad proteins in a more direct manner. 
As stated previously, the primary aim of this thesis was to identify novel regulators 
of mammary gland development and cell fate as it is a well-accepted paradigm that 
these factors are often perturbed in cancer. In order to fully understand and better treat 
breast cancer it is essential to understand its origins, a task made difficult due to the 
heterogeneity of this disease. We have now shown, for the first time that CBFβ 
transcriptionally regulates ductal extension in the mammary gland through controlling 
the proliferation of mammary epithelial cells and potentially, mammary stem cells. 
Furthermore, CBFβ has now been shown to control breast cancer cell fate both in vitro 
and in vivo, whilst differentially regulating several genes, gene sets and signalling 
pathways that have been implicated in breast cancer. Two of these pathways, WNT and 
Hedgehog, have been shown to regulate the existence of both multipotent mammary 
stem cells and luminal stem/progenitor cells respectively, the dysregulation of which 
has been shown to lead to breast cancer formation. It is therefore possible that CBFβ is 
acting to control mammary stem cell fate through cross talk between these pathways.  
Whilst the exact mechanisms by which CBFβ regulates mammary gland 
development and breast cancer remains to be determined, the data produced in this 
thesis has conclusively shown a novel for CBFβ as a new regulator of mammary gland 
development and breast cancer cell phenotype.   
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Future Directions 
This thesis has described several novel roles for CBFβ in the regulation of cell fate in 
both mammary gland development and breast cancer, however the mechanism behind 
this control is yet to be fully elucidated.  
It is clear that CBFβ is acting to regulate the process of ductal extension in early 
mammary gland development through controlling the proliferation of mammary 
epithelial cells. The in vivo data and microarray data described in this thesis indicate 
that CBFβ may be involved in the regulation of mammary stem/progenitor cell 
populations and as mentioned previously, serial transplantation experiments would 
assist in confirming this hypothesis. Furthermore, it would be interesting to harvest cells 
from the CBFβ-/- transplants and assess the populations of stem and progenitor cell 
lineages using FACS sorting based on specific markers for these populations.  
This method would allow further interrogation of the mammary cell populations that are 
controlled by CBFβ. 
In regards to the role of CBFβ in the direction of breast cancer cell fate, it would be 
informative to examine the affects of perturbing CBFβ levels in additional breast cancer 
cells lines, representative of all major subtypes, to confirm the phenotypes seen in this 
thesis. It would also be interesting to assess the ability of CBFβ to control the formation 
of tumour spheres in culture, an assay that would complement the proliferation and 
migration data described. 
We have shown that CBFβ deletion is able to increase tumour latency and overall 
survival in mice with mammary tumours and that it also leads to a decrease in the 
severity of metastasis. In order to build on this data, it would be informative to use 
xenografting techniques to inject breast cancer cells with altered CBFβ levels into mice, 
either through the nipple or tail vein, in order to assess the ability of these cells to 
metastasise. Given the mounting evidence that the Runx2/CBFβ complex may be 
regulating the progression and colonisation of breast cancer cells to the bone, it would 
be advisable to use cell lines that are known to target the bone, such as MDA-MB-231 
or 4T1.2 cells. These experiments would confirm that CBFβ is able to reprogramme 
breast cancer cell fate and regulate metastasis. 
In Chapter 4 we show preliminary data showing the first evidence that CBFβ is 
expressed in human breast tumour. Further analysis should be performed using this 
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cohort of human breast tumors in order to ascertain whether CBFβ expression correlates 
with the size, stage and subtype of breast tumours as well as with diagnostic molecular 
markers such as ER, PR and HER2. This would allow insight into whether CBFβ can 
function as a diagnostic or prognostic marker for breast cancer patients and could 
potentially leads to the development of new treatments and targets. 
Finally, additional analysis needs to be performed on the data produced by the 
microarrays performed on human breast cancer cell lines with perturbed CBFβ 
expression. The data so far confirms that CBFβ regulated numerous gene sets that are 
involved in many aspects of both mammary gland development and breast 
carcinogenesis and metastasis. There was minimal correlation at the gene level 
however, and further analysis is required to determine direct downstream targets of 
CBFβ, the validity of which could then be assessed by RT-qPCR and functional in vitro 
assays. 
The principal paradigm behind this thesis is that many of the genes implicated in 
breast cancer have been shown to play important roles in the development of the 
mammary gland. In recent years, the transcriptional regulators of mammary cell fate 
have shown to play essential roles in the ability of breast cancer cells to proliferate, 
migrate, invade and colonise secondary sites, ultimately resulting in the poor prognosis 
for metastatic breast cancer. It is therefore essential that we continue to explore the 
factors that control cell fate decisions in mammary gland development in order to better 
treat and potentially find a cure for breast cancer. 
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